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ABSTRACT 
 The enantioselective total syntheses and absolute configuration assignments of 
(+)-ponapensin and (+)-elliptifoline have been achieved via enantioselective [3+2] 
photocycloaddition between 3-hydroxyflavone and methyl cinnamate. The resulting 
cyclopenta[b,c]benzopyran was reduced through a reagent-controlled, diastereoselective 
reduction. Amidation was accomplished through direct ester-amide exchange mediated 
by trimethylaluminum, and diastereoselective N-acyliminium cyclization was observed 
likely due to stereoelectronic stabilization of one face of the N-acyliminium. The total 
syntheses revealed the absolute configuration to be opposite of what was hypothesized. 
These observations led to an interesting biosynthetic hypothesis in which a kinetic 
resolution/parallel kinetic resolution may be taking place. Through testing this conjecture, 
an asymmetric transfer hydrogenation kinetic resolution methodology was developed and 
applied to the first enantioselective total syntheses of (+)-aglaiastatin and (–)-aglaroxin C. 
The total syntheses confirmed the absolute configuration of these metabolites, and the 
natural enantiomers were found to be the most biologically active. 
 xi 
 Chiral urea, thiourea, trifluoroethanols, and TADDOLs have been evaluated as 
catalysts in the asymmetric [3+2] photocycloaddition between 3-hydroxyflavone and 
methyl cinnamate. Chiral trifluoroethanols such as Pirkle’s alcohol promoted [3+2] 
photocycloaddition between 3-hydroxyflavone and methyl cinnamate with 
enantioselectivities up to 40% ee with 20 mol% loading. These additives may be 
interacting with 3-hydroxyflavone through an excited state double proton transfer 
mechanism. 
 The synthesis, unexpected light-driven di-epimerization, and biological evaluation 
of a novel rocaglate-derived β-lactone and β-lactone analogs have been achieved. In 
addition to in vitro inhibition of the serine hydrolases ABHD10 and ACOT1/2, the most 
potent β-lactone enantiomer was found to inhibit ABHD10 in PC3 cells, suggesting that 
derivatives of this β-lactone may serve as valuable chemical probes. The mechanism of 
the photochemical di-epimerization was investigated and may be occurring through 
photochemical electron transfer. Biotinylated rocaglate derivatives have been synthesized 
and evaluated in a streptavidin pull down assay to determine the molecular target of 
rocaglates. eIF4G was pulled down as the molecular target for one of the biotinylated 
analogs, but eIF4A was not pulled down by any of the biotinylated analogs. 
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Bioactive Flavagline Natural Products and Previous Synthetic Studies 
 
1.1 Flavagline Natural Products and Their Biological Activities 
 The plant genus Aglaia (family Meliaceae, order Sapindales) consists of 
approximately 120 species ranging from small shrubs to large mahogany trees.1 Over 
thirty of these species produce secondary metabolites known as flavaglines, many of 
which exhibit insecticidal and anticancer activities (Figure 1.1). The first flavagline 
isolated was the cyclopenta[b]benzofuran (rocaglamides/rocaglates) (–)-rocaglamide (1) 
from the plant A. elliptifolia.2 Since then, other rocaglate congeners have been isolated, 
including (–)-methyl rocaglate (2),3,4 (–)-rocagloic acid (3),5 (–)-rocaglaol (4),4 (+)-
aglaiastatin (5), 6  and the complex rocaglate, (–)-silvestrol (6). 7  In their respective 
isolation reports, (–)-rocaglamide (1) and (–)-silvestrol (6) exhibited potent antileukemic 
activity against P388 leukemia cells in CDF1 mice. The structures of these metabolites 
were unambiguously determined by X-ray analysis; absolute stereochemistry was 
determined for silvestrol by X-ray analysis and relative configuration was determined for 
rocaglamide, while the absolute stereochemistry of (–)-rocaglamide (1) was determined 
via total synthesis by Trost and coworkers.8 The absolute configurations of (–)-methyl 
rocaglate (2), (–)-rocagloic acid (3), and (–)-rocaglaol (4) were confirmed through 
asymmetric synthesis by Dr. Baudouin Gerard of the Porco laboratory.9 
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Cyclopenta[bc]benzopyrans (aglains) and benzo[b]oxepines (forbaglins, also 
called forbaglines) are two other classes of flavaglines shown in Figure 1.1. Like their 
rocaglamide counterparts, these polyketide structures feature contiguous stereocenters 
with alcohol, amide, or ester functional groups.  The hemiaminal-containing (–)-
ponapensin (7) was found to potently inhibit NF-κB, a protein linked to cancer, 
Figure 1.1 Rocaglates, Aglains, and Forbaglins from Aglaia 
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inflammatory, and autoimmune diseases.10 A similar aminal-containing compound (–)-
elliptifoline (8), isolated from the same species as (–)-rocaglamide (1) and (–)-rocagloic 
acid (3), was proposed to have the opposite configuration at C13.5 Furthermore, 
elliptifoline (8) was found to be moderately potent against the P388 leukemia cell line. 
The relative configurations of these metabolites were both proposed through nOe 
experiments. (–)-Foveoglin A (9)11 is a constitutional isomer of desacetylpyramidaglains 
A and C (10 and 11),12 featuring switched amide and aryl substituents at C3 and C4. Like 
(–)-ponapensin (7), (–)-foveoglin A (9) was found to have NF-κB inhibitory activity, but 
no direct molecular targets were determined. 
(+)-Forbaglins A (9) and B (10)13 have opposite stereochemistry at C13 and have 
similar pyrrolidine amides like (–)-ponapensin (7) and (–)-elliptifoline (8). Relative 
configurations were assigned through nOe experiments and were confirmed through X-
ray crystal structure analysis. Unlike the rocaglates, the absolute configuration 
assignments of aglain and forbaglin derivatives were not assigned in their respective 
isolation reports or through total synthesis efforts. Therefore, the synthesis of these 
metabolites can serve to assign absolute configuration and provide material for further 
biological evaluation. 
In addition to biological activities previously mentioned, rocaglamides have been 
shown to be potent insecticides. This was first observed by insecticidal activity of 
extracts from A. odorata and later demonstrated directly using rocaglamide (1) and 
congeners.4 Furthermore, rocaglamides have also exhibited anti-inflammatory, 14 
neuroprotective,15 and cardioprotective effects.16 As anti-cancer agents, rocaglates such 
4 
as silvestrol (6) were shown to inhibit cell proliferation through inhibition of protein 
translation by interfering with the RNA helicase eIF4A.17 Section 1.4 will discuss 
synthetic rocaglamides as eIF4A inhibitors and anticancer agents. 
 
1.2 Proposed Biosynthesis of Aglains, Rocaglamides and Forbaglins 
 
 The rocaglamides, aglains, and forbaglins have only been isolated from the genus 
Aglaia, and have been given the collective name “flavagline” because their mutual 
biosynthetic origin has been proposed to arise from structurally related precursors.18 The 
biosynthesis of flavaglines proposed by Proksch and coworkers19 involves formal [3+2] 
cycloaddition between 3-hydroxyflavone (3-HF) 14 and cinnamic amides 15 via a 
Michael addition/aldol reaction sequence (Figure 1.2). The resulting aglain ketone 16 
Figure 1.2 Proksch and Coworkers’ Proposed Biosynthesis of Flavaglines 
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subsequently can be: a) rearranged then reduced, affording rocaglamide natural products 
(17); b) reduced to provide aglain natural products (18); or c) oxidatively rearranged (i.e. 
oxidative cleavage of the C5-C10 bond) to form forbaglin derivatives (19).  
  
Staunton and coworkers proposed rocaglamides could be derived from 5,7,4’-
trimethylapigenin (20) and cinnamic amide 21 through a photochemical [2+2], followed 
by rearrangement and hydration (Figure 1.3).20 An alternative biosynthesis has been 
proposed by Dumontet and coworkers in which aglain and forbaglin derivatives are 
derived from the cycloaddition of flavylium 24 and odorine 25 (also isolated from Aglaia 
forbesii bark extract) to provide aglain natural products such as aglaforbesin A (26) 
(Figure 1.4).13 In the latter report, the authors propose that other regioisomers of 
cycloadduct 27 are generated to give rise to forbaglin structures and other aglains after 
further oxidation and reduction steps. 
 




1.3 Previous Synthetic Approaches to the Rocaglamides 
The rocaglates, aglains, and forbaglins pose intriguing synthetic challenges: 
multiple functionalities, highly substituted skeletons, and in many cases, up to five 
contiguous stereocenters present. These compounds also possess a variety of 
pharmacological activities, making flavaglines attractive synthetic targets. Furthermore, 
to the best of our knowledge, total syntheses of aglain and forbaglin natural products 
have not been reported. The following syntheses, presented largely in chronological 
order, are significant because of the differing approaches towards the 









1.3.1 First Approaches to the Synthesis of Rocaglamide 
 Before (−)-rocaglamide was synthesized, there were two significant approaches 
published.  In 1987, Taylor and coworkers first accessed the tricyclic rocaglate core 
employing benzofuranone starting material 28 (Scheme 1.1).21  Alkylation with alkyl 
iodide 29 provided benzofuranone 30 which was then treated with n-butyllithium to 
assemble the cyclopenta[b]benzofuran core of 31.  Unfortunately, the 1,3-dithiane group 
of 31 proved difficult to remove.  Later syntheses, including Taylor’s total synthesis, 
have employed key intermediate 28 as starting material.
 




Taylor’s work towards the rocaglate skeleton was then followed by Kraus and 
coworkers’ synthesis of the di-epi-analog of rocaglamide (Scheme 1.2).22  Like Taylor’s 
approach, the investigators began their synthesis with known benzofuranone 28.  Kraus’ 
synthesis was the first approach involving a Michael addition of acrylonitrile (32) with 
benzofuranone 28.  Next, a samarium-mediated reductive cyclization was performed to 
afford rocaglate skeleton 34.  Later in the synthesis, a cuprate addition was conducted on 
unsaturated thioester 35 to provide enol intermediate 36 which through X-ray crystal 
structure analysis was shown to have trans aryl substituents. Accordingly, the cuprate had 
added unexpectedly to the concave face of the bicyclic ring system, possibly due to the 
adjacent para-methoxyphenyl ring blocking the cuprate from the convex face.  
Subsequent amidation and reduction of thioester 36 yielded rocaglamide isomer 37 that 
did not possess the same NMR spectra as natural rocaglamide (1).  Although the natural 
product was not synthesized, Kraus established two key steps (i.e. the Michael addition of 
acrylonitrile and the reductive cyclization using SmI2) that paved the way for future 
investigations in the field.  
Scheme 1.2 Kraus’Synthesis of Di-epi-Rocaglamide 
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1.3.2 The First Total Synthesis of Rocaglamide and Absolute 
 Configuration Assignment 
 The first total synthesis of rocaglamide (1) was accomplished by Professor Barry 
Trost and coworkers (Scheme 1.3). Asymmetric [3+2] cycloaddition of 
trimethylsilylmethyl precursor 38 and chiral, enantiopure oxazepinedione 39 afforded 
cyclopentene 40, a transformation which established the absolute configuration at C4.  
Following removal of the chiral auxiliary and ozonolysis (not shown), cyclopentanone 41 
was next condensed with dimethylphloroglucinol 42 to afford cyclopentene 43.  
Regioselective transesterification of 43 with benzyl alcohol was then performed which 
was followed by oxidative cyclization with DDQ to afford benzofuran 44.  With the 
rocaglate skeleton in hand, several reactions were performed to fully functionalize 44 and 
also invert stereochemistry at C3. The synthesis was completed in 16 steps and fully 
established the absolute configuration of the natural product as shown in Scheme 1.3. 
10 
 
Shortly after Trost’s synthesis, Taylor and coworkers reported their synthesis of 
(±)-rocaglamide (1) in eight steps from benzofuranone intermediate 28 (Scheme 1.4).23 
The key steps utilized were (1) Michael addition of trans-cinnamaldehyde (45) with 
benzofuranone 28 (1:1 dr), and (2) intramolecular, pinacolic coupling mediated by SmI2. 
This step afforded the product with high diastereoselectivity (6:1 dr) in constructing the 
rocaglate core. Diol 47 was oxidized and the resulting ketone 48 was transformed into 
methyl ester 49 in three steps. β-Ketoester 49 was then transformed directly to 
dimethylamide 50. The synthesis was completed with a hydroxyl-directed, 
diastereoselective reduction of α-hydroxy ketone 50 using tetramethylammonium 
triacetoxyborohydride to afford (±)-rocaglamide (1). Shortly after, Taylor and coworkers 
Scheme 1.3 Trost’s Synthesis of (–)-Rocaglamide 
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published a full account of the rocaglamide synthesis, highlighting hydrolysis of the 
dithiane group from his first approach and improved diastereoselectivity of the Michael 
addition used in his second approach.24 
 
1.3.3 Total Synthesis of (±)-Aglaiastatin 
 Inspired by the approaches of Kraus, Taylor, and Trost, Watanabe and coworkers 
achieved the racemic synthesis of aglaiastatin (5).25 As the synthesis of the ABC ring 
system had already been developed by Taylor, Watanabe began with advanced 
intermediate 51 previously reported by Taylor and coworkers.24 Carboxylic acid 51 was 
coupled with 4,4-diethoxybutanamine to form amide 52. After the secondary alcohol was 
oxidized using Parikh–Doering conditions, HCl was used to hydrolyze the acetal which 
Scheme 1.4 Taylor’s Racemic Synthesis of Rocaglamide (1) 
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was followed by treatment with formic acid and excess ammonium formate to provide 
(±)-aglaiastatin (5) in 2:1 dr through an N-acyliminium cyclization.26 
 
1.3.4 Biomimetic Approach to Rocaglamides and Congeners 
Proksch and coworkers proposed that rocaglamides may be biosynthetically 
derived from 3-hydroxyflavones (3-HFs) and cinnamide derivatives to form aglain 
intermediates which undergo skeletal rearrangements to rocaglates and forbaglins (cf. 
Figure 1.2).19 Based on this proposal, Porco and coworkers developed a unified 
apporoach to rocaglamide, aglain, and forbaglin cores employing biomimetic [3+2] 
photocycloaddition to afford the aglain scaffold (Scheme 1.6a).27 Upon irradiation of 3-
HF 53, an oxidopyrylium species (dipole) derived from excited-state intramolecular 
proton transfer (ESIPT)28  could be trapped with a dipolarophile (e.g. trans-methyl 
cinnamate 54), resulting in an overall [3+2] photocycloaddition to afford aglain 
intermediate 55. Forbaglin natural products, represented by analog 56, were accessed 
through oxidative cleavage of aglain intermediate 55, while rocaglamide and related 
Scheme 1.5 Total Synthesis of Aglaiastatin (5) 
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natural products (represented by analog 57) were obtained through an α-ketol shift, 
followed by hydroxyl-directed reduction of the α-hydroxy ketone 58. 
 
The methodology was subsequently used to synthesize (±)-methyl rocaglate (2) 
(Scheme 1.6b). Photocycloaddition of 3-hydroxyflavone 59 and methyl cinnamate (54) 
afforded aglain 60 as well as benzo[b]cyclobutapyran-8-one 61. Both 60 and 61 were 
then subjected to basic conditions and converged to provide α-ketol rarrangement 
product 62. Hydroxyl-directed reduction of α-hydroxyketone 62 yielded (±)-methyl 
rocaglate (2). This approach was a significant advance towards the synthesis of 
Scheme 1.6 Porco’s Unified Approach Toward Flavagline Natural Products and 
Total Synthesis of Methyl Rocaglate (2) 
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flavaglines, as Porco and coworkers’ method provided a direct and efficient method 
towards the rocaglamides, aglains, and forbaglins. 
 
To further improve this methodology, Porco and coworkers developed an 
enantioselective [3+2] photocycloaddition that was used to synthesize (–)-methyl 
rocaglate (2), (–)-rocaglamide (1), (–)-rocagloic acid (3), and (–)-rocaglaol (4) (Scheme 
1.7).9 Using TADDOL29 derivatives, an enantioselective [3+2] photocycloaddition was 
achieved in 86% ee. Recrystallization of methyl rocaglate (2) enhanced the ee to 94%, 
with 86% recovery of (−)-methyl rocaglate (2) from the mother liquor. (–)-Rocaglaol (4) 
was obtained through Krapcho decarboxylation of β-ketoester 62, followed by reduction. 
Recrystallization enhanced the ee to 96%. (–)-Rocaglamide (1) was synthesized from (–)-
methyl rocaglate (2) through saponification to (–)-rocagloic acid (3), and subsequent 
Scheme 1.7 Enantioselective Syntheses of (–)-Rocaglamide and Congeners 
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amide coupling with dimethylamine. Not only had Porco and coworkers advanced the 
field of enantioselective photochemistry30 with their studies, but they also confirmed the 
absolute configurations of (–)-methyl rocaglate (2), (–)-rocagloic acid (3), and (–)-
rocaglaol (4), which had previously been tentatively assigned through circular dichroism 
experiments.4 
 
The enantioselective synthesis of the complex rocaglate (–)-silvestrol (6) was 
reported by Porco and coworkers 31  and by Rizzacasa and coworkers 32  utilizing 
convergent strategies which connected the dioxanyloxy fragment to the fully elaborated 
rocaglate. Porco’s synthesis (Scheme 1.8) features enantioselective [3+2] 
photocycloaddition mediated by TADDOL 63, between 7-MOM protected 3-HF 64 and 
Scheme 1.8 Porco’s Enantioselective Synthesis of (–)-Silvestrol 
 
F-PPh3 = Ph2PC6H4-4-(CH2CH2C8F17) 
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methyl cinnamate (54). Ketol rearrangement, reduction, and deprotection of the MOM 
ether provided phenolic rocaglate 65, which was recrystallized and isolated in 87% ee. 
Diol 66, derived from D-dimethyl tartrate, was used to form an O-stannylene acetal, 
which was then combined with 2-bromo-2-methoxy acetate to afford a dioxanylone 
intermediate. Reduction of the dioxanylone intermediate with DIBAL-H afforded key 
dioxanyloxy fragment 67 to be used in the coupling reaction. Using Mitsunobu 
conditions, fragments 65 and 67 were successfully coupled, and the penultimate 
intermediate was subjected to hydrogenolysis to provide (–)-silvestrol (6). Rizzacasa and 
coworkers synthesized (–)-silvestrol employing a strategy similar to Porco’s (Scheme 
1.9). Using di-TBS protected dioxanyloxy fragment 68 (6:1 ratio of epimers), Rizzacasa 
accessed (–)-epi-silvestrol (69) first via Mitsunobu coupling with racemic phenolic 
rocaglate 65 (obtained using [3+2] photocycloaddition developed by Porco) and 
subsequent TBS removal with TBAF. (–)-Silvestrol (6) was then synthesized through a 
selective Mitsunobu reaction of (–)-epi-silvestrol (69). 
17 
 
1.3.5 Magnus’ and Frontier’s Approaches via Nazarov Cyclization 
 Control of stereochemistry of the adjacent phenyl and para-methoxyphenyl 
groups is one of the challenges frequently encountered in the synthesis of rocaglates and 
analogs (cf. Scheme 1.2 and Scheme 1.3). Philip Magnus and coworkers synthesized (±)-
1,2-anhydro methyl rocaglate 70 stereospecifically in which stereocontrol was generated 
through Nazarov33 cyclization/Isler−Mukiayama aldol reaction34 (Scheme 1.10).35 The 
synthesis commenced with Sonogashira coupling between 2,4,6-trimethoxyiodobenzene 
and 4-methoxyphenylacetylene to afford alkyne 71. Next, oxidation was carried out with 
catalytic ruthenium chloride/sodium periodate to provide dione 72, which was then 
treated with boron trichloride to selectively demethylate with simultaneous hemiketal 
formation. Methylation of the hemiketal intermediate provided benzofuranone 73 which 
was alkylated to provide β-hydroxyketone 74. Exposure of 74 to Amberlyst® 15 ion-
exchange resin afforded α,β-unsaturated ketone 75, and treatment with NaH/TIPSCl 
Scheme 1.9 Rizzacasa’s Syntheses of (–)-Epi-silvestrol and (–)-Silvestrol 
 
PNBA = p-nitrobenzoic acid 
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provided Nazarov cyclization precursor 76. Nazarov cyclization, mediated by tin 
tetrachloride, provided cyclopenta[b]benzofuran-2-one 77 stereospecifically, which was 
further transformed to 1,2-anhydro methyl rocaglate 70. 
 




The most recent synthesis of rocaglamide was accomplished by Frontier and 
coworkers.38 Benzofuranone 28 was first alkylated with vinyl magnesium bromide and 
then oxidized to form aldehyde 78 (Scheme 1.11). Subsequent alkylation with 
phenylacetylene and protection of the propargyl alcohol afforded propargyl ether 79. 
Next, 79 was deprotonated with tert-butylithium and the resulting allenyl anion was 
trapped with tri-n-butyltin chloride to afford stannyl alkoxyallene 80. In the key step of 
the synthesis, the allenol ether was oxidized with m-CPBA forming epoxide intermediate 
81, which opened to form putative pentadienyl cation 82 which undergoes Nazarov 
cyclization. Treatment of resulting cyclopenta[b]benzofuran 83 with excess DDQ and 




water produced a diosphenol intermediate which was then triflated, and carbonylated to 
form α,β-unsaturated ketone 84. Hydrogenolysis of 84 provided a keto-rocaglate 
intermediate as a single diastereomer, and hydroxyl-directed reduction with sodium 
triacetoxyborohydride provided (±)-methyl rocaglate (2). Saponification and amide 
coupling of rocagloic acid (3) with dimethylamine afforded (±)-rocaglamide (1). 
 
 
Recently, Magnus and coworkers reported a formal synthesis of (±)-methyl 
rocaglate (2) via Nazarov cyclization mediated by acetyl bromide (Scheme 1.11).36 
Starting with alkyne 85, palladium (II) catalyzed cyclization/carbonylation provided 
benzofuran 86 which was converted to β-keto phosphonate 87. Using Masamune–Roush 
conditions,37 87 was treated with benzaldehyde to form Nazarov substrate 88. Treatment 
Scheme 1.12 Magnus’ Formal Synthesis of (±)-Methyl Rocaglate 
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with acetyl bromide provided the Nazarov 4π-electrocyclization product 89 in 81% yield, 
installing the rocaglate core.  Cyclopenta[b]benzofuran 82 was then further 
functionalized in five steps to α,β-unsaturated ketoester 83 which has been previously 
converted to methyl rocaglate (cf. Scheme 1.11).38 
 
1.4 Development of Rocaglamides and Analogs as Anticancer 
Therapeutic Agents 
1.4.1 eIF4A RNA Helicase 
 Eukaryotic initiation factor 4A is an integral protein involved in the initiation of 
protein translation.39 It serves as an RNA helicase (i.e. a protein that unwinds double 
stranded RNA), and is bound to eIFG in the eIF4F complex (Figure 1.5). When bound to 
eIF4G, eIF4A is locked in a conformation that has high RNA binding affinity which 
facilitates binding of eIF4A with the mRNA template. Since overall inhibition of the 
eIF4F complex is desirable as an anticancer therapy, targeting the catalytic subunit of 
eIF4A is highly beneficial. Detailed analysis of more than 25 different cancer types 
revealed that four known eIF4F transcripts (MYC, MCL1, BCL-XL, and CCND1) to be 
among the most amplified genes.40 Since these proteins are ubiquitous in cancer cells and 
play key roles in tumor cell maintenance, inhibiting the production of these proteins is 
expected to have significant consequences on tumor cell maintenance. 
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1.4.2 Désaubry’s Medicinal Chemistry Efforts Around Rocaglaol 
Analogs As previously mentioned, rocaglamide (1) and related natural products 
have been shown to be potent insecticides and anti-proliferative agents. Désaubry and 
coworkers were the first group to discover a synthetic rocaglamide-type compound that 
inhibits cell proliferation at lower doses than rocaglaol (4) (Scheme 1.13).41 Using 
Dobler’s methods 42  for the preparation of rocaglamides, the synthesis of racemic 
rocaglaol (4) and derivatives 90, 91, and 92 were achieved. These compounds were tested 
on a variety of human cancer cell lines. In all cases, 4’-bromo rocaglaol 91 was the most 
potent, having IC50 values lower than 1 nM for KB (nasopharynx), MCF7R (breast), 
HCT116 (colon), and HL60 (neutrophil) human cancer cell lines. Removal of the 
substituents on the D ring decreased potency, while rocagaol derivative 92 was inactive 
(4”-OMe substitution). Fluorescent probe 93 was synthesized from an amide coupling 
between fluorescent coumarin intermediate 94 and rocagloic acid analog 95 (derived 
from [3+2] photocycloaddition and subsequent transformations9). The synthesis of 
affinity ligand 96 was initiated by amide coupling between fragments 97 and 98 to afford 
azide 99, which was converted to amine 100 using SnCl2 and thiophenol. Amine 100 was 
conjugated to Affi-Gel 10 to afford the affinitity ligand 96 used in pull down experiments 
Figure 1.5 The eIF4F Complex 
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that surprisingly did not reveal any interaction between 96 and eIF4A. Fluorescent probe 
93 was shown to accumulate in the endoplasmic reticulum (ER), implying that 
rocaglamides bind to their target in the ER, inducing the death of cancer cells via 
activation of the AIF and caspase-12 pathways which lead to an inhibition of eIF4A. 
 




Scheme 1.14 Désaubry’s Second Generation Analogs 
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 With knowledge that 4’-bromo substituted rocaglaol 91 was the most potent of all 
rocaglaol analogs synthesized, Désaubry and coworkers studied structure activity 
relationships (SAR) by varying C1, C2, and C8 substitutions.43 The rocaglamide core was 
constructed through Porco’s [3+2] photocycloaddition, followed by acyloin 
rearrangement (Scheme 1.14). Rocaglaol 101 was prepared through Krapcho 
decarboxylation of a ketorocaglate intermediate and subsequent reduction. Methyl 
rocaglate analogs 102a-c were tested and 102a was used to make rocaglamide analogs 
103a and 103b. Primary amides 104a and 104b were also prepared. Using modified 3-HF 
105 and cinnamic amide 106, synthetic rocaglamide 107 was efficiently prepared using 
[3+2] photocycloaddition, ketol rearrangement, and subsequent reduction. With C2 
analogs in hand, C1 analogues were constructed from α-hydroxyketone 108. Reduction 
with tetramethylammonium triacetoxyborohydride afforded rocaglaol analog 109, which 
was esterified to afford analogs 110, 111, and 112. When α-hydroxyketone 108 was 
treated with sodium borohydride, Désaubry and coworkers observed opposite selectivity 
from tetramethylammonium triacetoxyborohydride, forming cis-diol 113. Although the 
authors do not explain why concave addition is favored, it is possible that the cis-aryl 
rings of 108 prohibit Bürgi−Dunitz delivery44 of the hydride from the typically favored 
convex face (Scheme 1.14, inset).  Cis-diol 113 was then esterified to afford formate 
114. Oxime methyl ether 115 (derived from ketone 108) was reduced using borane to 
give two epimers 116 and 117, which were then acylated to give corresponding esters and 
sulfonic esters. 
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 A SAR investigation tested cytotoxic activity of these novel analogs against a 
variety of human cancer cell lines, and found that 8-desmethoxy compounds 101, 103b, 
103c, 104b, and 107 were less active than their 8-methoxy counterparts, suggesting a 
necessity of a methoxy group for cytotoxicity. It was also determined that having an 
amide or ester substituent at C2 was detrimental to activity against HL60R cells, 
suggesting a greater likelihood of multidrug resistance as well. Although configuration of 
the hydroxyl at C1 was not crucial for activity, formamide analog 121 had better activity 
in comparison to epimer 118. Compound 121 also proved to be the best therapeutic 
candidate from in vitro studies. In vivo studies were then performed on mice with 
xenografted 3LL tumors using 121 which reduced the growth of the tumor by 65% 
without any visible toxicity in the mice. 
 
1.4.3 Porco’s Medicinal Chemistry: Hydroxamate Rocaglamide Analogs 
 Porco and coworkers, using optimized reaction conditions and sequences, 
displayed the broad scope of their photocycloaddition methodology in the syntheses of 
rocaglate analogs (Scheme 1.15).45 Using a variety of dipolarophiles, novel cycloadducts 
were obtained including thioester 122a, Weinreb amide 122b, and amide 122c. The 
aglain intermediates were then converted to cyclopenta[b]benzofurans using two 
methods. Cycloadducts bearing ester moieties were readily converted to rocaglate 
isomers, but in many cases, a TMSOTf-mediated ketol rearrangement was found to be 
necessary due to sensitivity of certain moieties to methoxide (e.g. thioester). Of the 25 
compounds synthesized, six compounds had IC50 values lower than 10 µM in an eIF4A 
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inhibition in vitro assay done by Jerry Pelletier at McGill University. Compounds 122b 
and 122c were found to be the most potent with IC50 values of 300-400 nM. The positive 
control, (−)-silvestrol (6), had an IC50 of 100 nM in the same assay, demonstrating 
excellent potency from the synthetic analogs. When tested in vivo, hydroxamate 122b 
was the most potent, inhibiting 85% of protein synthesis over the course of an hour, 
similar to (−)-silvestrol (6) (tested by Prof. Jerry Pelletier at McGill University). 
Furthermore, rocaglamide 122b was also identified as a potent inhibitor of heat shock 
factor 1 (HSF1), a transcriptional regulator of tumorigenesis and other cellular processes, 
and doses of rocaglamide 122b at 1mg/kg significantly reduced tumor masses in mouse 
xenograft models (5e7 M0-91 cells). 46  The reaction scope of the [3+2] 
photocycloaddition that was conducted in this paper will be further discussed in Chapter 
3.  
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 Equipped with the knowledge that hydroxamate rocaglamide 122b was most 
potent of the synthetic analogs generated, Porco and coworkers synthesized additional C2 
substituted hydroxamate analogs (Scheme 1.16) using [3+2] photocycloaddition to 
rapidly access methyl rocaglate (2), and saponification/amide coupling to generate 
analogs 123a-g in a divergent manner.47 Hydroxamate 123b was identified as the most 




potent analog in an in vitro translation inhibition assay done by Prof. Jerry Pelletier at 
McGill University. With the most potent C2 hydroxamate substitiution determined, 
halogenation and nitration of the A ring was also explored. Unfortunately, analogs 124a-j 
exhibited less in vitro translation inhibition than 123b. To further test their hypothesis 
that a hydrogen bond acceptor/metal chelating moiety at C2 may be necessary to retain 
potency similar to that of silvestrol (6), Porco and coworkers also generated C2 
substituted aromatic heterocycle ketones which possessed modest activity. Lastly, using a 
resolution via menthol esters of rocagloic acid (3), Porco and coworkers synthesized (–)-
123b (Scheme 1.16, inset) and (+)-123b and found (–)-123b and (–)-silvestrol to be 
equipotent in translation inhibition in vitro assays as well as in vivo. When (–)-123b was 
used in conjunction with doxorubicin,48  drug-resistant lymphomas in mice became 
sensitized to doxorubicin again, with efficacy similar to (–)-silvestrol (6)/doxorubicin. 
Interestingly, the enantiomer (+)-123b was found to be inactive. Rocaglate hydroxamates 
like 123b have also been found to be effective in breast cancer,49 can block translation of 
the MUC1-C oncoprotein,50 and can block elevated MYC in pre-malignant preB/B 
cells.51 
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1.4.4 Infinity Pharmaceuticals’ Silvestrol Analogs 
 Most recently, Infinity Pharmaceuticals published a study involving the synthesis 
and evaluation of silvestrol analogs.52 Using [3+2] photocycloaddition developed by the 
Porco laboratory,27 scientists at Infinity rapidly generated analogs of silvestrol (6) which 
were much less complex, had similar potencies, and had better physicochemical 
Scheme 1.16 Porco’s Second Generation Hydroxamate Analogs 
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properties such as a lower efflux ratio (i.e. how fast a compound is pumped out of cells) 
and higher exposure (i.e. how much drug is orally bioavailable, and how quickly the drug 
is metabolized or cleared from the blood serum) (Figure 1.6). Rocaglamide 4’-cyano 
analog (–)-125 was identified as their best lead, although the study concluded that eIF4A 
inhibitors like 125 and silvestrol (6) may have limited therapeutic windows due to poor in 
vivo efficacy of these two compounds in L3.6pl and RPMI-8226 tumor xenografts despite 
their excellent performances in the same cell line based assays. This inconsistency could 
not be explained by the study, although they concluded that rocaglamide analogs were 
still worthy of further investigation. 
 
1.5 Conclusion 
 In summary, many approaches towards rocaglamides have been reported, 
including asymmetric syntheses by the Trost and Porco laboratories. While much is 
known about the biological activity and absolute configurations of rocaglamides, the 
absolute configurations of aglain and forbaglin structures are unknown. To the best of our 
knowledge, no syntheses of aglain or forbaglin natural products were reported at the 
Figure 1.6 Simplified Silvestrol Analog with Improved Physicochemical Properties 
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outset of my Ph.D. studies. We will next describe our efforts towards the aglain natural 
products (–)-ponapensin (7), (–)-elliptifoline (8), and the alkaloidal rocaglamides (+)-
aglaiastatin (5) and (–)-aglaroxin C which have unknown absolute configurations 
(Chapter 2). Then, we will disclose our studies towards a catalytic, enantioselective [3+2] 
photocycloaddition (Chapter 3). Lastly, our [3+2] photocycloaddition methodology will 
be applied to make novel chemical entities and bioconjugates for chemical biology 
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A Biomimetic Approach to the Aglains (−)-Ponapensin and (−)-
Elliptifoline and the Alkaloidal Rocaglamides (+)-Aglaiastatin and (−)-
Aglaroxin C 
 
2.1 Synthetic Approach Towards Aglain Natural Products 
 Based on the pioneering work done by Prof. Porco and Dr. Baudouin Gerard,9 and 
the biosynthetic hypothesis that aglains and rocaglamides shared common precursors,18 
we planned the retrosynthesis outlined in Scheme 2.1. We proposed that (−)-ponapensin 
(1)10 and (−)-elliptifoline (2)5 could be formed through a Lewis or Brønsted acid 
catalyzed cyclization of amide-acetal 3 with nucleophilic addition to an N-acyliminium 
species26 to install the C13 aminal center of (–)-elliptifoline (2). Tethered amide-acetal 3 
could arise from diastereoselective reduction of the C10 ketone of aglain 4a and 
subsequent amidation of the methyl ester. Previously, our laboratory developed an 
enantioselective [3+2] photocycloaddition between 3-hydroxyflavone (3-HF) 5 and 
methyl cinnamate 6 through host-guest complexation with TADDOL29 (+)-79 providing 
aglain ketone 4 in 71% ee. The absolute configuration of ketone 4a was confirmed 
through the total synthesis of (–)-methyl rocaglate (8), which was transformed to (–)-
rocaglamide (9) in two steps (Scheme 2.2). The absolute configuration of (–)-
 37 
rocaglamide (9) was previously determined through Trost’s total synthesis (cf. Scheme 
1.3). Thus, we hypothesized that the absolute configurations of (–)-ponapensin (1) and (–
)-elliptifoline (2) are the same as the structures drawn in Scheme 2.1. 
 
 
 Before proceeding with experiments testing our retrosynthetic hypothesis, it is 
important to highlight relevant literature describing oxidopyrylium cycloaddition or 
Scheme 2.1 Retrosynthetic Analysis of (–)-Ponapensin and (–)-Elliptifoline 
 




ESIPT to generate complex molecules. Wender’s [5+2] cycloaddition of an 
oxidopyrylium employed in the total synthesis of phorbol is a classic example (Scheme 
2.3).53 Oxidopyrylium 11 was generated from pyrone 12 using DBU in nonpolar solvent, 
which was then trapped with its pendant primary alkene. This was the key step of the 
synthesis that rapidly generated four contiguous stereocenters and the tricyclic skeleton 
of 13. 
 
 Other than the syntheses outlined in Chapter 1, there are very few examples of 
excited state intramolecular proton transfer (ESIPT)28 being used in synthetic efforts. 
Recently, Kutateladze and coworkers have disclosed ESIPT-mediated intramolecular 
cycloadditions of aromatic o-amidoketones (e.g. 14) with a tethered pyrrole (Scheme 2.4) 
to provide polyheterocyclic cores.54 They have also shown this ESIPT method to work 
with aromatic o-amidoaldehydes with tethered furan pendants to provide [4+2] and [4+4] 
products.55 Wan and coworkers have investigated ESIPT of isomeric phenyl naphthols 
and naphthyl phenols through preparative photolyses in CH3CN−D2O, fluorescence 
spectroscopy, laser flash photolysis, and ab initio calculations.56 This form of ESIPT is 
distinct from others as it involves proton transfer from oxygen to carbon. Another recent 
example of this type of ESIPT has been described by Freccero and coworkers observing 
ESIPT of 2-alkynylphenols. 57  After irradiation, the authors observed formation of 
Scheme 2.3 Wender’s Oxidopyrylium Cycloaddition Toward Phorbol 
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vinylidene-quinone methides (QMs), which were detected by laser flash photolysis in 
organic solvents and aqueous acetonitrile. 
 
Before embarking on the enantioselective total syntheses of (–)-ponapensin (1) 
and (–)-elliptifoline (2), we first aimed to synthesize these natural products in racemic 
fashion. To assist with reaction screening, we planned to make cycloadduct 4a in a large 
scale. This, however, was found to be challenging in the past as cycloadduct 4a has 
proven difficult to isolate cleanly.9,45 Previously, Dr. Gerard measured the enantiomeric 
excess on rocaglate derivatives of 4a because the endo 4a and exo diasteromer 18 of the 
cycloaddition were inseparable (Scheme 2.5a). Furthermore, strong evidence was 
provided that a similar compound, desmethoxy aglain 19, could rearrange in the presence 
of a Brønsted acid such as silica gel (Scheme 2.5b).27 The direct formation of aglain 19 
(derived from cycloaddition of 3-HF 20 and methyl cinnamate) in the reaction was 
monitored by 1H NMR. Furthermore, when purifying by column chromatography, an 
equilibrium between aglain 19 and benzo[b]cyclobutapyranone 21 was observed and 21 
could be converted to aglain 19 via thermolysis in ethyl acetate. From these accounts, it 
became clear that clean isolation of aglain 4a would be necessary to properly evaluate 
reduction conditions by avoiding formation of complex mixtures. 




2.2 Reagent-Controlled, Diastereoselective Reduction of a Bridge 
Ketone 
 
Scheme 2.5 Problems Previously Encountered in the Isolation of Aglain 
Ketones 
 
Scheme 2.6 Gram Scale [3+2] Photocycloaddition Between 3-HF 5 and Methyl 
Cinnamate 6 and Recrystallization of Aglain Hydrate 4b 
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With this knowledge in hand, [3+2] photocycloaddition between 3-HF 5 and 
methyl cinnamate 6 with optimized conditions previously reported45 were applied on a 
gram scale (Scheme 2.6). After chromatography, a 61% yield of 4a and 18 were isolated 
(61% yield, 3:1 ratio). Gratifyingly, the endo hydrate 4b was isolated in 26% yield as a 
pure compound from recrystallization in acetonitrile after a thorough screen of 
crystallization conditions. Before examining reduction conditions, we evaluated the 
formation of the ketone 4a from hydrate 4b. Indeed, treatment of 4b with 4 Å molecular 
sieves resulted in quantitative formation of ketone 4a which was characterized by 13C 
(C10, δ 205.5 ppm) and 1H NMR spectroscopy. From 1H NMR analysis of the reaction, 
we determined that ketone 4a was being formed directly, and introduction of water from 
silica chromatography formed hydrate 4b. Figure 2.1 shows overlayed 1H NMR spectra 
of ketone 4a and hydrate 4b. 
With adequate quantities of aglain 4b in hand, we next examined the reduction of 
the bridge ketone. We first attempted biomimetic reductions using Hantszch ester, acting 
as an NADH mimic.58 These reactions did not lead to the desired product. Next, we 
examined more common reducing agents, such as DIBAL-H, L-Selectride, and aluminum 
isopropoxide, all of which did not lead to significant amounts of the desired reduction 
product. Later, we determined that the products forming under these conditions were 
primarily the 10R reduction product ((±)-22, cf. Table 2.1). 
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 When we first used sodium borohydride, we did not observe any reaction with 
hydrate (±)-4b when methanol was used as solvent (Table 2.1, entry 1). We found 
success using other solvents like THF which better solubilized hydrate (±)-4b and 
afforded reduced products (±)-22 and (±)-23 in a 5:1 ratio (entry 2). Interestingly, the 
same diastereoselectivity was observed using tetrabutylammonium borohydride 
(Bu4NBH4)59 which afforded reduced aglain 22 as the major product (dr = 5:1) in 98% 
yield (entry 3). Fortunately, treatment of 4b with tetramethylammonium 
triacetoxyborohydride60 in benzene (entry 4) afforded reduction product 23 which has the 
Figure 2.1 Stacked 1H NMR Spectra of Ketone 4a and Hydrate 4b 
 
Top: ketone 4a, 400 MHz, CDCl3; bottom: hydrate 4b, 400 MHz, CDCl3. 
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crucial 10S configuration required for the synthesis of both ponapensin (1) and 
elliptifoline (2). The relative configuration assignment of C10 was determined via nOe 
correlation observed between H4/H10 of aglain 22 and an absence of this correlation in 
its epimer 23. 
 After evaluation of nonpolar solvents (entries 5 through 7), we found that 2,2,2-
trifluoromethylbenzene (PhCF3) was an optimal solvent for hydroxyl-directed reduction 
of aglain (±)-4b to afford (±)-13 in 5:1 dr (entry 7). The counterion size of the 
triacetoxyborohydride appears to be significant in enhancing the diastereoselectivity of 
the reduction, as NaBH(OAc)361 provided the 10S diastereomer (±)-23 in 10:1 dr (entry 
8). When ketone (±)-4a was used as a substrate in this reaction (cf. Scheme 2.6), full 
conversion of (±)-4a in shorter time (2 h vs. 16 h for (±)-4b) without loss of 
diastereoselectivity was observed. 
Table 2.1 Diastereoselective Reduction of Aglain 4b 
 
entry reagent solvent 23:22a yield (%) b 
1 NaBH4 MeOH - 0 
2 NaBH4 THF 1:5 88 
3 Bu4NBH4 THF 1:5 98 
4 Me4NBH(OAc)3 benzene 3:1 95 
5 Me4NBH(OAc)3 CH2Cl2 4:1 95 
6 Me4NBH(OAc)3 PhMe 4:1 95 
7 Me4NBH(OAc)3 PhCF3 5:1 95 
8 NaBH(OAc)3 PhCF3 10:1 95 





 A rationale for reagent-controlled, diastereoselective reduction of bridged ketone 
4a is shown in Figure 2.2. When using a borohydride reducing agent (e.g. NaBH4, 
Bu4NBH4), the bridged ketone may be preferentially attacked on the si face due to larger 
dihedral angles for O-C10-C5-C4 and O-C10-C2-C3 (134° and 138°, respectively) vs. the 
smaller dihedral angles of O-C10-C5-C5a and O-C10-C2-O (113° and 102°, 
respectively), thereby allowing more optimal orbital alignment for hydride addition to the 
bridged carbonyl. 62  When a triacetoxyborohydride reducing agent was used (e.g. 
NaBH(OAc)3), the hydride attacks the re face of the carbonyl for reasons that are not 
clear. We considered that the oxygen lone pair of the 6-methoxy group may be 
coordinating the borate derived from exchange of the 5-OH with BH(OAc)3 to further 
direct the reduction to the re face. This issue was examined using model aglain 1927 (cf. 
Scheme 2.2b) which lacks a methoxy at C6. Sodium triacetoxyborohydride reduction of 
aglain 19 furnished reduced aglain 24 in 8:1 dr (Scheme 2.7) which was not signicantly 
different from the corresponding reduction of aglain 4b (10:1 dr, cf. Table 2.1, entry 8). 
Figure 2.2 Proposed Model for Diastereoselective Reduction of Aglain 4a with 
NaBH4 
 
PMP = para-methoxyphenyl. 
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Therefore, the methoxy coordination is most likely not a significant factor to the 
diastereoselectivity for the reduction. Furthermore, reduction of ketone 19 with Bu4NBH4 
yielded the reduced aglain 24 in 7:1 dr, which is comparable to the diastereoselectivity 
observed in the Bu4NBH4 reduction of aglain 4b (5:1 dr). Relative configurations of 23 
and 24 were determined by NOESY NMR spectroscopy. 
2.3 Further Elaboration of the Aglain Core 
 With reduced aglain (±)-23 in hand, conditions to saponify the methyl ester for 
subsequent amide coupling were examined (Scheme 2.8). Unfortunately, hydrolysis 
conditions using base (e.g. LiOH, KOH, NaOH) and water resulted in decomposition. 
Lithium and magnesium halides (e.g. LiBr, LiI, MgI2) did not effect a reaction. 
Interestingly, saponification of epimer (±)-22 proceeded with quantitative yield (Scheme 
Scheme 2.7 Reductions of Desmethoxy Aglain 19 
 
Scheme 2.8 Attempted Hydrolysis of Aglain 23 
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2.6) which suggests the decomposition of 23 is related to the relative configuration of 
C10. 
While attempting hydrolysis conditions on (±)-23, benzyl ester 27 was prepared 
using [3+2] photocycloaddition of 3-HF 5 and benzyl cinnamate 28 (Scheme 2.9). 
Cycloadduct 29 was provided in 60% yield (3:1 ratio of 29:30), and was recrystallized 
from acetonitrile. Reduction of hydrate 29 with sodium triacetoxyborohydride afforded 
reduced aglain 27 in 10:1 dr. Benzyl ester 27 was hydrogenolyzed and the derived 
carboxylic acid 25 (cf. Scheme 2.10) was subsequently coupled with 4,4-dimethoxy-1-
butanamine 3125 to provide amide-acetal (±)-3 in 95% yield (two steps, Scheme 2.10). In 
an alternative pathway, trans-esterification of methyl ester (±)-23 was achieved using 
Otera’s distannoxane catalyst63 in benzyl alcohol as solvent to afford benzyl ester (±)-27 
in 63% yield (91% B.R.S.M., Scheme 2.10). Several reagents were evaluated in order to 
achieve direct ester-amide exchange of methyl ester (±)-23 including Otera’s catalyst, 
Sc(OTf)3, Zn4(OCOCF3)6O, Mg(OTf)2, and Zr(OtBu)4 as either catalysts or 
Scheme 2.9 [3+2] Photocycloaddition of 3-HF 5 and Benzyl Cinnamate 28 
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stoichiometric additives.64 Modest conversions of aglain (±)-23 to (±)-3 were observed 
using Otera’s catalyst and Mg(OTf)2. Interestingly, when using trimethylaluminum65 for 












Scheme 2.10 Routes to Penultimate Intermediate 3 from Methyl Ester 23 and 
Benzyl Ester 27 
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2.4 Final Cyclizations to Ponapensin and Elliptifoline 
 
 With penultimate intermediate (±)-3 in hand, we next examined its cyclization to 
the hemiaminal (±)-ponapensin (1) (Scheme 2.11).66 Treatment of amide-acetal (±)-3 
with (±)-CSA in EtOAc led to a mixture of products that were isolated after two 
purifications. The major product observed was (±)-ponapensin (1) in 30% yield as a 
single hemiaminal diastereomer. The other product isolated was the ethyl hemiaminal 
derivative of ponapensin, aglain (±)-32, isolated in 12% yield. The formation of this 
compound was due to trace ethanol present in the ethyl acetate. Cyclic intermediate (±)-
33 was also isolated in 2% yield, and its relative configuration was assigned via nOe 
correlation observed between H4 and H13 (Figure 2.3). 




Oxazinone67 (±)-33 provides important evidence for the intermediacy of N-
acyliminium 34 and accounts for formation of a single diastereomer of (±)-ponapensin 
(1). However, the tertiary hydroxyl may not be the only contributing factor to the 
diastereoselectivity. Figure 2.4 shows a Spartan ’10 model 68  of the ground state 
conformation (B3LYP/6-31G**) of N-acyliminium intermediate 34. Trans-acyliminium69 
34 may be formed to avoid unfavorable A(1,3) strain interactions70 leading to the 
conformer depicted in Figure 2.4. In this conformer, the oxygen of the 6-methoxy group 
is approximately 2.7 Å from C13 which bears a π* orbital.71 An n → π* interaction 
appears to stabilize this conformation and allows nucleophilic attack selectively from the 
opposite face of N-acyliminium 34. Furthermore, trace amounts of the dihydropyrrole 
derived from 34 and possible dimeric products from the reaction mixture were also 
isolated. Cyclizations were attempted in other solvents such as THF and 1,4-dioxane to 
avoid formation of 13-OEt derivative 32, however ponapensin was not produced cleanly 
in either case. After considerable optimization, we found that treatment of amide-acetal 
Figure 2.3 Ground State Conformer of Oxazinone 33 
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(±)-3 with (±)-CSA in THF containing methanol (15 equiv) led to the formation of (±)-
ponapensin (1) in 68% yield (Scheme 2.12) as a single diastereomer. When methanol 
was used as solvent, the reaction stopped at approximately 50% conversion to (±)-
ponapensin (1) suggesting that an equilibrium had been reached. In a similar manner, 
treatment of aglain (±)-3 with tiglic amide 35 (5 equiv) and CSA (50 mol%) in THF led 
to the isolation of (±)-elliptifoline (2) as a single diastereomer in 81% yield. 
 
Figure 2.4 Ground State Conformer of N-Acyliminium 34 and Stereoselective 




 The relative configurations at C13 of both 1 and 2 were confirmed via X-ray 
crystal analysis to be the same for ponapensin (1) and elliptifoline (2) (Figure 2.5). The 
X-ray structures show that the pyrrolidine amide moiety is folded in a trans-rotamer over 
the neighboring aromatic ring. A C−H−π interaction may also stabilize this conformation 
where the phenyl ring donates electron density to the electron-deficient C−H bonds of the 
13-OMe in ponapensin (1).69a Kinghorn and coworkers correctly predicted this 
conformation for ponapensin (1) using molecular modeling and observed the 1H NMR 
shielding of the C13 methoxy protons.10 It should be noted that synthetic elliptifoline (2) 
was determined to have the opposite configuration at C13 than reported by Duh and 
coworkers (cf. Scheme 2.12).5 The crucial nOe between H4 and H13 was observed in our 
hands as reported by Duh and coworkers. Regardless, it is difficult to determine the 
configuration of C13 without X-ray analysis since the H4/H13 nOe is meaningless 
without knowing which way the 13-tiglic-amide is oriented. Neither Duh and coworkers’ 
Scheme 2.12 Optimized Syntheses of Ponapensin and Elliptifoline 
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nor our attempts uncovered nOe correlations between 6-OMe/H22 or H22/H2” which 
would elucidate the relative configuration. Since the 1H and 13C NMR data match those 
reported by Duh and coworkers and given our X-ray crystal analysis of elliptifoline (2), 




Figure 2.5 X-ray Crystal Structures of Ponapensin and Elliptifoline 
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2.5 Enantioselective Syntheses of Ponapensin and Elliptifoline: Absolute 
Configuration Assignments 
 
With the racemic syntheses of ponapensin (1) and elliptifoline (2) optimized, we 
used modified conditions of the previously reported enantioselective [3+2] 
photocycloaddition between 3-HF 5 and methyl cinnamate 6, mediated by tetrakis-9-
phenanthrenyl TADDOL (+)-7 (Scheme 2.13) to access enantioenriched products. 
Methylene chloride was used as the solvent to improve both the solubility of 3-HF 5 and 
the yield of the cycloaddition. After reduction, we isolated reduced aglain (+)-23 in 47% 
yield and 71% ee. The ee of (+)-23 was enhanced to 92% after recrystallization from 
isopropanol, then to 98% ee after a second recrystallization from acetonitrile. Relative 
and absolute stereochemistries of enantiopure aglain (+)-23 were confirmed by X-ray 
Scheme 2.13 Enantioselective Total Syntheses of (+)-Ponapensin and (+)-
Elliptifoline, Enantiomers of the Natural Metabolites 
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analysis using Cu Kα radiation72 (Figure 2.6). Enantioenriched (+)-23 was transformed 
to amide-acetal (+)-3 via trimethylaluminum mediated ester-amide exchange, and the 
penultimate intermediate (+)-3 was converted to (+)-ponapensin (1) ([α]25D = +170° 
synthetic (c 0.2, CHCl3), [α]22D = –167º natural (c 0.4, CHCl3)) and (+)-elliptifoline (2) 
([α]25D = +172° synthetic (c 0.2, CHCl3), [α]22D = –88.9º natural (c 0.6, CHCl3)), which 
to our surprise were the enantiomers of the natural products. To further confirm the 
configuration assignments of (+)-ponapensin (1) and (+)-elliptifoline (2), intermediate 
(+)-4b was converted to (–)-methyl rocaglate (8) through ketol rearrangement and 
hydroxyl-directed reduction (Scheme 2.14). 
 
Figure 2.6 X-ray Structure of (+)-23 
 





From the X-ray structure of (+)-23 and the synthesis of (–)-methyl rocaglate (8) 
from common intermediate (+)-4b, the (+)-enantiomers of ponapensin (1) and 
elliptifoline (2) were assigned to be the structures drawn in Scheme 2.13. Figure 2.7 
shows the assigned absolute configurations of the natural products. From this finding, we 
propose that a kinetic resolution may occur in nature wherein (–)-aglain ketone core 
structures undergo reduction and (+)-aglains do not (Figure 2.8). Racemic bridged 
Scheme 2.14 Confirmation of the Absolute Stereochemistry of Aglain (+)-23 by 
Synthesis of (–)-Methyl Rocaglate (8) 
 
Figure 2.7 Absolute Stereochemical Assignments of (–)-Ponapensin and (–)-
Elliptifoline 
 
(–)-Elliptifoline (2) is drawn with its reassigned configuration at C13. 
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ketones have been utilized as substrates for kinetic resolution using either microbes such 
as C. lunata and R. rubra or ketoreductase/NADP.73 (+)-Aglains may then be converted 
to their (–)-rocaglate counterparts via a reductoisomerase/NADPH pathway (e.g. DXR, 
ketol-acid reductoisomerase). Keto-acid reductoisomerase is known to catalyze the 
conversion of 2-acetolactate to 2,3-dihydroxyisovalerate, and DXR (1-deoxy-D-xylulose-
5-phosphate reductoisomerase) is involved in terpenoid biosynthesis in E. coli. 74 
Furthermore, it is also possible that a parallel kinetic resolution (PKR)75 may occur where 
(+)-aglains selectively undergo ketol rearrangement/reduction, and (–)-aglains are 
reduced via reductoisomerase/NADPH leading to enantiopure (–)-rocaglates and (–)-
aglain scaffolds, respectively. 
 
 
Figure 2.8 Proposed Kinetic Resolution of Racemic Aglains 
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2.6 Biomimetic Kinetic Resolution of Racemic Aglains and Total 
Syntheses of (+)-Aglaiastatin and (–)-Aglaroxin C 
 
 Noyori and coworkers previously have used chiral ruthenium complexes in the 
kinetic resolution of racemic secondary alcohols.76 Recently, Metz and coworkers utilized 
Noyori reduction towards the kinetic resolution of racemic flavanone substrates (Figure 
2.9).77 Since flavanones are related compounds to aglains, we became interested in 
examining similar catalyst systems to develop a biomimetic kinetic resolution of aglain 
ketones (cf. Figure 2.8). In collaboration with Mr. Steven Stone (undergraduate, Boston 
University), an enantio- and diastereoselective hydrogenation of racemic aglain ketones 
was developed to accomplish a biomimetic kinetic resolution as depicted in Scheme 
2.15). Rhodium(III) chloride-Cp* dimer with (R,R)-diphenylethylenediamine as ligand 




was found to be an optimal catalyst, performing the hydrogenative kinetic resolution with 
isolation of (–)-23 in 45% yield and 96% ee, and recovery of enantiopure starting 
material in 42% yield. The ee of the starting material was determined by conversion to (–
)-methyl rocaglate (8) and chiral HPLC analysis. 
 
 What was perhaps more intriguing than the excellent enantioselectivity was the 
complete diastereoselectivity observed. Based on our previous reductions of ketone 4a 
and hydrate 4b (cf. Table 2.1) we predicted that reducing agents would preferably attack 
the in-situ generated ketone away from the phloroglucinol ring based on a preferred 
trajectory (cf. Figure 2.2). To our surprise, the hydride was delivered from the opposite 
face of the carbonyl with complete diastereoselectivity observed. For the rhodium 
catalyst system, we believe that there are stabilizing events that strongly prefer attack 
from the phloroglucinol face. In Metz’s kinetic resolution of flavanones through catalytic 
asymmetric transfer hydrogenation, the authors proposed a transition state for kinetic 
resolution of flavanones featuring stabilizing CH-π interactions78 between the methyl 
groups on the Cp* ligand and the aromatic substituent of the ketone (cf. Figure 2.9). 
Scheme 2.15 Biomimetic Kinetic Resolution: Enantio- and Diastereoselective 
Hydrogenation of Aglain (±)-4b 
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Figure 2.10 depicts molecular models generated using Spartan ‘1068 for both the favored 
and disfavored enantiomers of the aglain ketone substrates. In the case of the favored 
substrate/catalyst assembly (Figure 2.10A), we propose that, in addition to the stabilizing 
CH−π interaction, a hydrogen bond between the tertiary alcohol of (–)-4a and the 
sulfonyl oxygen of the catalyst helps direct the chiral reducing agent and lowers the 
energy of the transition state. In the case of the disfavored substrate/catalyst (Figure 
2.10B), this hydrogen bond interaction is not evident, which allows (–)-4a to be 
selectively reduced through assembly (A). 
 
Figure 2.10 Favored and Disfavored Assemblies for the Kinetic Resolution 
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 To demonstrate the utility of the kinetic resolution methodology, we planned to 
use it towards the asymmetric syntheses of the alkaloidal rocaglamide natural products 
(+)-aglaiastatin (36) and (–)-aglaroxin C (37). The absolute configuration of (+)-
aglaiastatin (36) has been proposed to be identical to other members of the rocaglate 
family and circular dichroism spectra support this notion.79 We intended to use our 
method to conclusively determine the absolute stereochemistry of 36 and to compare it to 
that of both (–)-ponapensin (1) and (–)-methyl rocaglate (8). The synthesis of aglaiastatin 
(36) (Scheme 2.16) involved ketol rearrangement of aglain (+)-4b to keto-rocaglate 10 
(cf. Scheme 2.1) followed by ester-amide exchange to afford butyramide dimethyl acetal 
38 which is similar to an intermediate employed by Watanabe and coworkers.25 Under 
acidic hydrolysis conditions, acetal 38 formed hemiaminal derivative 39 which was 
heated with ammonium acetate to form (+)-aglaiastatin (36) ([α]27D = +86.1° synthetic (c 
0.7, CHCl3), [a]20D = +45.7° natural (c 0.19, CHCl3)$) in 62% yield (10:1 dr, four steps). 
(–)-Aglaroxin C (37) (([α]27D = –49.2° synthetic (c 0.1, CHCl3), [α]20D = –50.1° natural (c 




 With (+)-aglaiastatin (36) obtained in a 10:1 ratio relative to its C5a”’ epimer 40 
(epi-aglaiastatin), various experiments were performed to rationalize the high 
diastereoselectivity observed for the N-acyliminium cyclization. When hemiaminal 39 
was heated at 60 C for 2 h in the presence of ammonium acetate, a 10:10:1 ratio of (±)-
aglaiastatin (36) : oxazinone (±)-41 : C5a”’ epimer (±)-40 (Scheme 2.17A) with 55% 
overall yield. On a side note, we found that (±)-41 could be synthesized directly by 
heating (±)-39 overnight in the presence of magnesium sulfate (Scheme 2.17B). The 
configuration at C5a’’’ was determined via X-ray crystal analysis of oxazinone (±)-41 
(Figure 2.11). When hemiaminal (±)-39 was treated with formic acid and ammonium 
formate at room temperature (conditions similar to that of Watanabe and coworkers25), 
we observed a 1.2:1.2:1 ratio of (±)-36 : (±)-41 : (±)-40 in 69% yield (Scheme 2.17C). 
This ratio of products seems to be controlled by the size of the N-acyliminium 
counterion, as heating (±)-39 in the presence of ammonium formate led to the same 
Scheme 2.16 Asymmetric Total Synthesis of (+)-Aglaiastatin and (–)-Aglaroxin C 
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distribution of products (Scheme 2.17D). The presence of formic acid does not affect the 
product ratios. With two reagents (ammonium acetate vs. ammonium formate) providing 
different ratios of (±)-aglaiastatin (36) and (±)-epi-$ aglaiastatin (40), we wanted to 
determine whether these reactions were controlled by kinetics or thermodynamics.  
 




 To support our observations, ground state computations of N-acyliminium 
rotamers 42a and 42b, aglaiastatin (36), and epi-aglaiastatin (40) were performed at the 
B3LYP/6-31G* level of theory in the gas phase (Figure 2.12).68 We first analyzed 
conformer distributions of the molecules using MMFF level of theory, then calculated 
their single point energies of these at the B3LYP/6-31G* level. We then took the lowest 
Scheme 2.17 Variations of Reaction Conditions to Provide Different Ratios of 36, 
40 and 41 
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energy structures of 36, 40, 42a, and 42b and calculated their equilibrium geometries at 
the B3LYP/6-31G* level of theory to determine the ground state conformers. 
 
Aglaiastatin (36) was calculated to be 0.7 kcal/mol lower in energy than epi-
aglaiastatin (40), and N-acyliminium rotamer 42a was found to be 0.3 kcal/mol lower in 
energy than rotamer 42b. If the preferred formation of aglaiastatin (36) over epi-
aglaiastatin (40) is under thermodynamic control, a 0.7 kcal/mol difference in energy 
(~2:1 ratio) should be reversible, and we should be able to convert epimer 40 to 
aglaiastatin (36). Interestingly, epimer (±)-40 could not be converted to (±)-aglaiastatin 
(36) when subjected to ammonium acetate/heat or ammonium formate/formic acid 
Figure 2.12 Reaction Coordinate of N-Acyliminium Cyclizations Forming 




(Scheme 2.18). Likewise, (±)-aglaiastatin (36) could not be converted to (±)-epi-
aglaiastatin 40 through treatment with ammonium formate/formic acid or ammonium 
formate/heat. Interestingly, oxazinone (±)-41 was converted to (±)-aglaiastatin (36) and 
(±)-epi-aglaiastatin 40 in a 2:1 ratio, 40% conversion, favoring (±)-23 when heated in the 
presence of ammonium acetate (Scheme 2.19). Since the minimum computed structures 
of aglaiastatin (36) and epi-aglaiastatin (40) differ by 0.7 kcal/mol and the formation of 
aglaiastatin (36) and epi-aglaiastatin (40) are irreversible using the previously mentioned 
reaction conditions, we concluded that the reactions are under kinetic control. 
 
 
Scheme 2.18 Evidence for Kinetic Control of Products 
 
Scheme 2.19 Conversion of Oxazinone 41 to Aglaiastatin and Epi-aglaiastatin 
 
 66 
Using PM3 level of theory in the gas phase, estimated transition states were 
calculated through bond profile analysis, and single point energies for these structures at 
the B3LYP/6-31G* level of theory were then performed. ΔΔG‡ was calculated to be 0.9 
kcal/mol (~4:1 ratio) (Figure 2.12, Figure 2.13). This analysis is in agreement with the 
diastereoselectivity observed in the reaction when ammonium acetate/heat mediate the 
cyclization. The energy difference between transition states results from the N-
acyliminium reaction center being underneath the concave face of the 
cyclopenta[b]benzofuran ring system in the course of 42b transforming to epimer 40. The 
transition state of 42a to aglaiastatin (36) features the N-acyliminium reaction center 
being above the convex face of the cyclopenta[b]benzofuran ring system, similar to what 




 With the natural products (enantiopure and racemic) and analogs in hand, we 
collaborated with Dr. Luke Whitesell (Whitehead Institute) who tested their potencies in 
whole cell assays reporting on several of the biological activities previously reported for 
this compound class: inihibition of the HSF1-dependent heat-shock response, 
cytotoxicity, and translation inhibition (Table 2.2). Additionally, we synthesized the 
unnatural enantiomers of aglaiastatin (36) and aglaroxin C (37) by using the (S,S) 
enantiomer of Rh(III) diphenylethylenediamine catalyst in the kinetic resolution of aglain 
Figure 2.13 Estimated Transition States for Aglaiastatin and Epi-aglaiastatin 
(PM3 Level of Theory) 
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(±)-4b (cf. Scheme 2.15), and tested (–)-aglaiastatin (36) and (+)-aglaroxin C (37) in the 
aforementioned assays. Table 2.2 summarizes the data. The natural enantiomer, (+)-
aglaiastatin (36) was found to be the most potent with single-digit nanomolar IC50 values 
obtained for both heat-shock reporter inhibition and cytotoxicity (entry 1).  Racemates of 
aglaiastatin ((±)-36, entry 2) and aglaroxin C ((±)-37, entry 6) were not as potent as their 
respective natural enantiomers (entries 1 and 3), and unnatural enantiomers (entries 7 and 
8) were significantly less potent. Interestingly, (+)-36 and (±)-36 (entries 1 and 2) were 
more potent than positive control rohinitib (RHT, entry 9), and natural aglaroxin C ((–)-
37, entry 3) was found to have similar potencies to RHT. In general, (±)-epi-aglaiastatin 
(40, entry 4) was more potent than (±)-aglaroxin C ((±)-37, entry 6), which was more 
potent than oxazinone (±)-41 (entry 5). Interestingly, the unnatural enantiomer of 
aglaiastatin (−)-36 was found to active in these assays. This is unusual, as rocaglates with 
the unnatural configuration have been inactive.47,52 Moreover, a concordance in potency 
was observed for all derivatives across the three bio-assays, suggesting there may be a 
single, conserved molecular target which is responsible for their activity, such as eIF4A 
as previously reported for hydroxamate rocaglamides such as RHT. 
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2.7 Summary and Outlook 
 In summary, we accomplished the enantioselective total syntheses and absolute 
configuration assignments of (+)-ponapensin and (+)-elliptifoline via enantioselective 
[3+2] photocycloaddition between 3-hydroxyflavone and methyl cinnamate. The 
Table 2.2 Concentration-dependent Biological Activities of Aglaiastatin and 













1 (+)-36 3.8 3.9 15.6 
2 (±)-36 5.2 7.1 26.0 
3 (–)-37 15.3 11.2 77.7 
4 (±)-40 23.8 21.7 117.6 
5 (±)-41 25.8 31.8 241.1 
6 (±)-37 37.7 26.1 210.7 
7 (–)-36 99.2 105.7 761.8 
8 (+)-37 >1000 >1000 >1000 
9 (±)-RHT 14.8 18.5 75.6 
a: 4-parameter  non-linear curve fit of dose-response data in whole cell assays, all determinations in 
quadruplicate.  R2 for all curve fits >0.95. b: Concentration  resulting in 50% reduction in heat-induced 
luciferase reporter activity. c: Concentration  resulting in 50% reduction in relative viable cell number. d: 
Concentration  resulting in half-maximal  inhibition of constitutive luciferase activity. 
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resulting aglain was reduced through a reagent-controlled, diastereoselective reduction. 
Amidation was accomplished through direct ester-amide exchange mediated by 
trimethylaluminum, and diastereoselective N-acyliminium cyclization was observed 
likely due to stereoelectronic stabilization of one face of the N-acyliminium. The total 
syntheses revealed the absolute configuration to be opposite of what we hypothesized. 
These observations led to an interesting biosynthetic hypothesis in which a kinetic 
resolution/parallel kinetic resolution may be taking place. Through testing this conjecture 
using synthetic chemistry, we developed an asymmetric transfer hydrogenation kinetic 
resolution methodology that was applied to the first enantioselective total syntheses of 
(+)-aglaiastatin and (–)-aglaroxin C. Diastereoselectivities of these N-acyliminium 
cyclizations were determined to be under kinetic control through computational and 
experimental data. The total syntheses confirmed the absolute configuration of these 




 Although we successfully synthesized the aglain metabolites ponapensin and 
elliptifoline, other aglain metabolites such as foveoglin A, and desacetylpyramidaglains 
A and C have yet to be synthesized (Figure 2.14). Foveoglin A features opposite 
regiochemistry of the desacetylpyramidaglains, and the absolute configuration of these 
metabolites are currently unknown. Furthermore, the forbaglins are also of unknown 
absolute configuration and biological activity, and total synthesis may provide ample 
material for determination of both. 
2.8 Experimental Section 
General Information: 1H NMR spectra were recorded at 300, 400, or 500 MHz at 
ambient temperature with CDCl3, CD3OD, DMSO-d6 or benzene-d6 (Cambridge Isotope 
Laboratories, Inc.) as solvents. Data for 1H NMR are reported as follows: chemical shift, 




integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet) and coupling constants in Hz. 13C NMR spectra were 
recorded at 75.0, 100.0, or 125 MHz at ambient temperature with the same solvents 
unless otherwise stated. Chemical shifts are reported in parts per million relative to the 
deuterated solvents. All 13C NMR spectra were recorded with complete proton 
decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
Chemical Instrumentation Center using a Waters Q-TOF API-US mass spectrometer. 
Melting points were recorded on a Mel-Temp apparatus (Laboratory Devices). Analytical 
LC-MS was performed on a Waters Acquity UPLC (Ultra Performance Liquid 
Chromatography (Waters MassLynx Version 4.1) with a Binary solvent manager, SQ 
mass spectrometer, Water 2996 PDA (PhotoDiode Array) detector, and ELSD 
(Evaporative Light Scattering Detector). An Acquity UPLC BEH C18 1.7 m column 
was used for analytical UPLC-MS. Optical rotations were recorded on an AUTOPOL III 
digital polarimeter at 589 nm, and specific rotations are given [α]D20 (concentration in 
grams/100 mL solvent). SFC analysis of enantioenriched compounds was performed on a 
Berger SFC (Waters) System with a diode array detector using a SFC Chiralcel®OD-H 
(Chiral Technologies Inc., 100 × 4.6 mm I.D., 5µm) column. CD spectra were measured 
on an AVIV Circular Dichroism Spectrometer, Model 62DS. Preparative HPLC was 
performed on a Gilson PLC2020 using a Waters SunFire™ Prep C18 OBD™ 5µm 
19X50 mm column. 
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Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-
F plates. Flash chromatography was performed using 200-400 mesh silica gel (Scientific 
Absorbents, Inc.). Yields refer to chromatographically and spectroscopically pure 
materials, unless otherwise stated. HPLC grade tetrahydrofuran, methylene chloride, 
diethyl ether, toluene, acetonitrile, and benzene were purchased from Fisher and VWR 
and were purified and dried by passing through a PURE SOLV® solvent purification 
system (Innovative Technology, Inc.). Other ACS grade solvents for chromatography 
were purchased from Clean Harbors.  
Select photochemistry experiments were performed using a Rayonet RPR-100 
photochemical reactor equipped with RPR-3500 irradiation lamps (UVA 315-400 nm). 
Photochemical reactions were performed in a photobox using a Hanovia 450 W medium 
pressure mercury lamp housed in a quartz immersion well, cooled with a Thermo Neslab-
ULT 80 system circulator. Pyrex test tubes (16 x 100 mm) were mounted on a support 
approximately 5.0 cm from the immersion well lamp. A uranium filter (hν > 350 nm) was 
obtained from James Glass (Hanover, MA). All other reactions were carried out in oven-
dried glassware under an argon atmosphere unless otherwise noted. 
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3-hydroxy-5,7-dimethoxy-2-(4-methoxyphenyl)-4H-chromen-4-one 5: 3-HF 5 was 
prepared from 3,5-dimethoxyphenol in 5 steps using methods previously disclosed by Dr. 
Baudouin Gerard as reported in his Ph.D. thesis.80 
 
Procedure for [3+2] photocycloaddition of 3-HF 5 and cinnamic esters (aglains 4b 
and 29): A 32 x 240 mm Pyrex test tube was charged with 3-HF 5 (1.0 g, 3.04 mmol, 1.0 
equiv), benzophenone (555 mg, 3.04 mmol, 1.0 equiv) and dipolarophile (methyl 
cinnamate 6/benzyl cinnamate 28) (15.2 mmol, 5.0 equiv) in CH2Cl2/2,2,2-
trifluoroethanol (7:3, 75 mL) as solvent. After degassing with argon for 10 min, the 
mixture was irradiated (Rayonet, λ > 315 nm) at 0 oC for 12 h. The crude material was 




Purification via flash chromatography using a gradient of hexanes/EtOAc afforded 
cyclopenta[bc]benzopyrans 4b and 29 as mixture of isomers (62% yield 4b, 60% 29). 
This mixture was recrystallized in acetonitrile to afford pure 4b and 29 (27% 4b, 24% 
29). Hydrate 4b was isolated as a white crystal, and was found to be identical to a 
previous report.43 
Benzyl (2R,3S,4S)-5,10,10-trihydroxy-6,8-dimethoxy-2-(4-methoxyphenyl)-3-phenyl-
2,3,4,5-tetrahydro-2,5-methanobenzo[b]oxepine-4-carboxylate 29: White solid;  Rf = 
0.44 (1:1 EtOAc/hexanes); m.p. 110-114 ºC; IR νmax (film): 3484, 3014, 2939, 2840, 
1731, 1618, 1590, 1517, 1490, 1456, 1252, 1217, 1148, 1094, 1003, 980, 831, 754 cm-1; 
1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 9.0 Hz, 2H), 7.33-7.30 (br dd, J = 6.5, 6.5 Hz, 
3H), 7.27-7.22 (overlapping m, 3H), 7.18 (d, J = 6.5 Hz, 2H), 7.05 (dd, J = 6.8, 6.8 Hz, 
2H), 7.01 (brt, J = 6.8 Hz, 1H), 6.65 (d, J = 9.0 Hz, 2H), 6.21 (d, J = 2.2 Hz, 1H), 6.03 (d, 
J = 2.2 Hz, 1H), 5.89 (s, 1H), 5.05 (d, J = 12.8 Hz, 1H), 4.94 (d, J = 12.8 Hz, 1H), 4.24 
(d, J = 9.2 Hz, 1H), 3.79 (d, J = 9.2 Hz, 1H), 3.77 (s, 3H), 3.70 (s, 3H), 3.57 (s, 3H), 3.18 
(s, 1H); 13C NMR (125 MHz, CD3Cl) δ 171.3, 161.5, 158.9, 158.6, 153.8, 140.0, 135.9, 
130.2 (2C), 130.0 (2C), 128.7 (2C), 128.2 (2C), 128.1 (2C), 127.7 (2C), 126.7, 112.9 
(2C), 103.7, 98.1, 94.7, 93.0, 88.0, 81.4, 66.7, 63.0, 55.8, 55.5, 55.2, 54.7; HR-MS: m/z 




2,3,4,5-tetrahydro-2,5-methanobenzo[b]oxepine-4-carboxylate 4a: A dry flask was 
charged with a stir bar, hydrated-aglain 4b (60 mg, 0.12 mmol, 1.0 equiv), and 4Å 
molecular sieves (750 mg) in CH2Cl2 (5 mL) under argon.  The mixture was stirred for 24 
h at room temperature, and formation of the ketone was monitored by 1H NMR.  The 
sieves were filtered using a plug of Celite, and the filtrate was concentrated in vacuo to 
afford the ketone 4a without any purification (58 mg, 0.12 mmol, 100%). White solid; Rf 
= 0.42 (3:2 EtOAc/hexanes); m.p. 88 ºC; IR νmax (film): 3496, 3018, 2952, 2840, 1784, 
1734, 1616, 1589, 1517, 1495, 1456, 1437, 1337, 1298, 1253, 1216, 1201, 1161, 1146, 
1092, 820, 748 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 9.2 Hz, 2H), 7.03 (br dd, 
J = 7.5, 6.5 Hz, 2H), 7.00 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 6.5 Hz, 2H), 6.64 (d, J = 9.2 
Hz, 2H), 6.19 (d, J = 2.5 Hz, 1H), 6.13 (d, J = 2.5 Hz, 1H), 5.80 (s, 1H), 4.50 (d, J = 9.0 
Hz, 1H), 3.85 (s, 3H), 3.77 (s, 3H), 3.67 (s, 3H), 3.64 (s, 3H), 3.59 (d, J = 9.0 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 205.5, 170.8, 162.1, 158.9, 158.2, 153.1, 138.3, 129.0 
(2C), 128.9 (2C), 128.3 (2C), 127.1, 125.7, 112.9 (2C), 105.0, 94.6, 93.7, 83.9, 81.0, 
57.7, 56.3, 55.6, 55.2, 53.5, 52.4; HR-MS: m/z Calcd for [C28H26O8+Na]+ 513.1525, 





phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[b]oxepine-4-carboxylate 23: A dry flask 
was charged with a stir bar, sodium triacetoxyborohydride (0.24 mmol, 6 equiv), acetic 
acid (13 µL, 0.24 mmol, 6 equiv.), and trifluorotoluene (1.5 mL) at rt under argon. The 
mixture was then sonicated briefly and stirred for 10 min. Aglain 4b (20 mg, 0.039 
mmol, 1.0 equiv) was then added in one portion under argon. The resulting mixture was 
then stirred for 18 h and was quenched with saturated ammonium chloride. The organic 
layer was separated, and the aqueous layer was extracted with CH2Cl2 (3 X 10 mL). The 
combined organic extracts were washed with saturated sodium bicarbonate, dried over 
sodium sulfate, and filtered. The filtrate was concentrated in vacuo and column 
chromatography was used to purify the compounds (23 eluted at 5:95 EtOAc/CH2Cl2, 22 
at 10:90 EtOAc/CH2Cl2, 95%). Compound 23 was isolated as a white solid; Rf = 0.88 
(1:9 EtOAc/CH2Cl2); m.p. 206-209 ºC; IR νmax (film): 3427, 2952, 1729, 1617, 1516, 
1456, 1250, 1214, 1186, 1148, 1120, 1079, 831, 752 cm-1;  1H NMR (400 MHz, CDCl3) 
δ 7.41 (d, J = 9.0 Hz, 2H), 7.23 (d, J = 6.8, 2H), 7.05 (dd, J = 6.8, 6.8 Hz, 2H), 7.01 (brt, 
J = 6.8 Hz, 1H), 6.67 (d, J = 9.0 Hz, 2H), 6.09 (d, J = 2.4 Hz, 1H), 6.07 (d, J = 2.4 Hz, 
1H), 5.63 (s, 1H), 4.78 (s, 1H), 4.37 (d, J = 9.2 Hz, 1H), 3.85 (s, 3H), 3.79 (d, J = 9.2 Hz, 
1H), 3.73 (s, 3H), 3.70 (s, 3H), 3.60 (s, 3H), 3.35 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 
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172.3, 161.3, 158.8, 157.9, 153.8, 141.6, 130.3 (2C), 130.2 (2C), 129.9, 128.1 (2C), 
126.3, 113.0 (2C), 104.7, 94.4, 92.5, 89.1, 80.5, 79.2, 65.2, 56.8, 56.0, 55.4, 55.2, 51.8; 
HR-MS: m/z Calcd for [C28H28O8+Na]+ 515.1682, found 515.1699 (+3.3 ppm). 
 Methyl (2R,3S,4S,10R)-5,10-dihydroxy-6,8-dimethoxy-2-(4-methoxyphenyl)-3-
phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[b]oxepine-4-carboxylate 22: A dry flask 
was charged with a stir bar and hydrated aglain 4b (20 mg, 0.039 mmol, 1 equiv) under 
argon, which was then dissolved in THF (2 mL). The resulting solution was then chilled 
to 0 °C, and tetrabutylammonium borohydride (50 mg, 0.195 mmol, 5 equiv) was added 
in one portion. The reaction was warmed gradually to rt and stirred for 12 h. The reaction 
was quenched with saturated ammonium chloride, and ethyl acetate (1 mL) and water 
(0.5 mL) were added. The layers were separated and the aqueous phase was then 
extracted with EtOAc (2 X 10 mL), washed with brine, and dried over sodium sulfate. 
The filtrate was concentrated in vacuo and purified by column chromatography to give 
the corresponding products (23 eluted at 5:95 EtOAc/CH2Cl2, 22 at 10:90 
EtOAc/CH2Cl2) were isolated in 98% yield, 5:1 dr. White solid;  Rf = 0.41 (1:9 
EtOAc/CH2Cl2); m.p. 200+ ºC, decomposition observed; IR νmax (film): 3476, 2952, 
1792, 1732, 1617, 1589, 1516, 1438, 1235, 1095, 737 cm-1; 1H NMR (500 MHz, CDCl3) 
δ 7.28 (d, J = 8.8 Hz, 2H), 7.02 (dd, J = 7.5, 7.2 Hz, 2H),  6.96 (brt, J = 7.2 Hz, 1H), 6.66 
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(d, J = 8.8 Hz, 2H), 6.23 (d, J = 2.2 Hz, 1H), 6.12 (d, J = 2.2 Hz, 1H), 5.88 (s, 1H), 4.82 
(d, J = 6.2 Hz, 1H), 4.10 (d, J = 9.0 Hz, 1H), 3.86 (s, 3H), 3.77 (s, 3H), 3.68 (s, 3H), 3.59 
(s, 3H), 3.33 (d, J = 9.0 Hz, 1H), 2.39 (d, J = 6.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
δ 171.3, 161.2, 159.4, 158.9, 154.0, 139.9, 129.31 (2C), 129.27, 128.7 (2C), 128.2 (2C), 
126.6, 113.3 (2C), 102.4, 94.4, 93.0, 87.4, 80.2, 73.7, 62.0, 56.0, 55.5, 55.2, 54.7, 51.9; 
HR-MS: m/z Calcd for [C28H28O8+H]+ 493.1862, found 493.1861 (-0.2 ppm). 
 
Benzyl (2R,3S,4S,10S)-5,10-dihydroxy-6,8-dimethoxy-2-(4-methoxyphenyl)-3-
phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[b]oxepine-4-carboxylate 27: A dry flask 
was charged with a stir bar, sodium triacetoxyborohydride (0.24 mmol, 6 equiv), acetic 
acid (13 µL, 0.24 mmol, 6 equiv.), and trifluorotoluene (1.5 mL) at rt under argon. The 
mixture was then sonicated briefly and stirred for 10 min. Aglain 29 (22 mg, 0.039 mmol, 
1.0 equiv) was then added in one portion under argon. The resulting mixture was then 
stirred for 18 h and was quenched with saturated ammonium chloride. The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 X 10 mL). The 
combined organic extracts were washed with saturated sodium bicarbonate, dried over 
sodium sulfate, and filtered. The filtrate was concentrated in vacuo and column 
chromatography was used to purify the compounds (27 eluted at 3:97 EtOAc/CH2Cl2, 
 
 80 
epi-27 at 8:92 EtOAc/CH2Cl2, 95%). Compound 27 was isolated as a white solid; Rf = 
0.70 (1:1 EtOAc/hexanes); m.p. 90-96 ºC; IR νmax (film): 3517, 3478, 3015, 1736, 
1616, 1588, 1519, 1464, 1341, 1257, 1217, 1202, 1179, 1129, 1094, 1036, 980, 948, 824, 
750 cm-1;  1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 8.5 Hz, 2H), 7.35-7.29 
(overlapping m, 1H), 7.33 (d, J = 7.0 Hz, 2H), 7.26-7.23 (ovrlp m, 4H), 7.06 (dd, J = 7.0, 
7.0 Hz, 2H), 7.02 (t, J = 7.0 Hz, 1H), 6.67 (d, J = 8.5 Hz, 2H), 6.10 (d, J = 2.0 Hz, 1H), 
6.01 (d, J =2.0 Hz, 1H), 5.72 (s, 1H), 5.07 (d, J = 12.8 Hz, 1H), 4.96 (d, J = 12.8 Hz, 1H), 
4.79 (s, 1H), 4.42 (d, J = 9.0 Hz, 1H), 3.89 (d, J = 9.0 Hz, 1H), 3.74 (s, 3H), 3.70 (s, 3H), 
3.58 (s, 3H), 3.42 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 171.8, 161.4, 158.9, 158.0, 
153.9, 141.6, 136.0, 130.3 (4C), 129.9, 128.7 (2C), 128.12, 128.10, 127.7 (2C), 126.3, 
113.0 (2C), 104.7, 94.5, 92.6, 89.2, 80.6, 79.3, 66.5, 65.4, 56.9, 55.8, 55.5, 55.2; HR-MS: 
m/z Calcd for [C34H32O8+Na]+ 591.1995, found 591.1981 (– 2.4 ppm). 10-Epi-27: 1H 
NMR (400 MHz, CDCl3) δ 7.36 (ovrlp m, 7H), 7.06-6.94 (ovrlp m, 3H), 6.91 (d, J = 7.0 
Hz, 2H), 6.66 (d, J = 8.8 Hz, 2H), 6.23 (d, J = 2.0 Hz, 1H), 6.04 (d, J = 2.0 Hz, 1H), 5.05 
(d, J = 12.8 Hz, 1H), 4.96 (d, J = 12.8 Hz, 1H), 4.83 (d, J =5.8 Hz, 1H), 4.14 (d, J = 9.0 






methanobenzo[b]oxepine-4-carboxylate 24: Aglain 19 was prepared from [3+2] 
photocycloaddition between 3-hydroxyflavone 20 and methyl cinnamate 6.27 A dry flask 
was charged with a stir bar, sodium triacetoxyborohydride (0.24 mmol, 6 equiv), acetic 
acid (13 µL, 0.24 mmol, 6 equiv.), and trifluorotoluene (1.5 mL) at rt under argon. The 
mixture was then sonicated briefly and stirred for 10 min. Aglain 19 (16 mg, 0.039 mmol, 
1.0 equiv) was then added in one portion under argon. The resulting mixture was then 
stirred for 18 h and was quenched with saturated ammonium chloride. The organic layer 
was separated, and the aqueous layer was extracted with CH2Cl2 (3 X 10 mL). The 
combined organic extracts were washed with saturated sodium bicarbonate, dried over 
sodium sulfate, and filtered. The filtrate was concentrated in vacuo and column 
chromatography was used to purify the compounds (24 eluted at 3:7 EtOAc/hexanes, 25 
at 1:1 EtOAc/hexanes, 90%, 8:1 dr). Compound 24 was isolated as a white solid; Rf = 
0.49 (1:1 EtOAc/hexanes); m.p. 220+ °C decomposition observed; IR νmax (film): 3458, 
3034, 1701, 1608, 1586, 1499, 1482, 1456, 1435, 1277, 1236, 1181, 1153, 1080, 1061, 
1034, 1014, 993, 961 cm-1; 1H NMR (400 MHz, (CD3)2SO) δ 7.45 (dd, J = 7.4, 1.4 Hz, 
2H), 7.31 (br d, J = 7.4 Hz, 1H), 7.24 (d, J = 7.4 Hz, 2H), 7.17-6.95 (ovrlp m, 8H), 6.88 
(dd, J = 7.4 Hz, 1H), 6.72 (d, J = 7.4 Hz, 1H), 6.46 (d, J = 4.2 Hz, 1H), 5.99 (s, 1H), 4.51 
(d, J =4.2 Hz, 1H), 4.27 (d, J = 8.6 Hz, 1H), 3.71 (d, J = 8.6 Hz, 1H), 3.44 (s, 3H); 13C 
NMR (100 MHz, (CD3)2SO) δ 171.7, 151.4, 142.0, 138.4, 129.9 (2C), 128.94 (2C), 
128.87, 127.7 (2C), 127.3, 127.0 (3C), 126.0, 124.7, 120.0, 114.9, 89.0, 79.3, 77.0, 64.0, 
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methanobenzo[b]oxepine-4-carboxylate 25: A dry flask was charged with a stir bar and 
aglain 19 (16 mg, 0.039 mmol, 1 equiv) under argon, which was then dissolved in THF (2 
mL). The resulting solution was then chilled to 0 °C, and tetrabutylammonium 
borohydride (50 mg, 0.195 mmol, 5 equiv) was added in one portion. The reaction was 
warmed gradually to rt and stirred for 12 h. The reaction was quenched with saturated 
ammonium chloride, and ethyl acetate (1 mL) and water (0.5 mL) were added. The layers 
were separated and the aqueous phase was then extracted with EtOAc (2 X 10 mL), 
washed with brine, and dried over sodium sulfate. The filtrate was concentrated in vacuo 
and purified by column chromatography to give the corresponding products (24 eluted at 
3:7 EtOAc/hexanes, 25 at 1:1 EtOAc/hexanes) were isolated in 73% yield, 7:1 dr. White 
solid; Rf = 0.27 (1:1 EtOAc/hexanes); m.p. 77 °C; IR νmax (film): 3452, 3060, 3033, 
2940, 1736, 1608, 1584, 1483, 1452, 1210, 905 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.38 
(ovrlp d, J = 7.2 Hz, 3H), 7.28 (ddd, J = 8.0, 8.0, 1.2 Hz, 1H), 7.17-6.95 (ovrlp m, 10H), 
4.93 (d, J = 8.2 Hz, 1H), 4.19 (d, J = 9.0 Hz, 1H), 3.65 (s, 1H), 3.57 (s, 3H), 3.47 (d, J = 
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9.0 Hz, 1H), 2.38 (d, J = 8.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 170.7, 151.7, 
139.6, 136.7, 130.1, 129.2 (2C), 128.2 (2C), 127.91 (2C), 127.85, 127.3 (2C), 126.8, 
126.0, 123.7, 121.5, 116.3, 88.2, 78.2, 73.9, 60.0, 54.5, 52.5; HR-MS: m/z Calcd for 
[C25H22O5+Na]+ 425.1365, found 425.1355 (− 2.3522 ppm). 
 
To a solution of aglain methyl ester (±)-23 (25 mg, 0.05 mmol, 1 equiv) in toluene (1.0 
mL), benzyl alcohol (520 µL, 5.0 mmol, 100 equiv) and Otera’s catalyst 
(C36H72N4O2S4Sn4, 12 mg, 0.01 mmol, 0.2 equiv) were added under argon at room 
temperature. The resulting slurry was then heated at 110 oC under house vacuum for 24 h. 
The resulting yellow solution was concentrated under high vacuum to remove excess 
benzyl alcohol and afford the crude product as an oil. The crude material was purified by 
flash chromatography using a gradient EtOAc/hexanes 20:80 to 60:40 affording the 
corresponding pure aglain 27 as a white solid (18 mg, 0.032 mmol, 64%) along with 
recovered starting aglain 23 (7 mg, 0.014 mmol, 28%). Spectroscopic data of compound 






carboxamide 3: To a solution of 4,4-dimethoxybutanamine 31 (637 mg, 4.78 mmol, 20 
equiv) in toluene (1.0 mL) under argon and at rt was added dropwise a solution of 
trimethylaluminum [2M] (2.4 mL, 4.79 mmol, 20 equiv). The resulting solution was 
heated at 40 oC for 1 h to preform the corresponding dimethylaluminum amide. Then a 
solution of aglain methyl ester (±)-23 (110 mg, 0.223 mmol, 1 equiv) in toluene (6.5 mL) 
was added via cannula, and the reaction mixture was heated at 70 oC for 12 h. The 
reaction mixture was quenched at 0 °C with saturated ammonium chloride (4 mL), stirred 
for 1 h, then acidified with 1 N HCl (1 mL). The mixture was extracted with EtOAc (3 X 
10 mL). The combined organic layers were washed with brine, dried over Na2SO4, and 
filtered. The solvent was removed in vacuo to afford a crude white yellow solid. 
Purification via flash chromatography using a gradient of EtOAc/hexanes 1:4 to 4:1 
afforded accordingly the corresponding pure amide (±)-3 (97  mg, 0.163 mmol, 64%). 
White solid; Rf = 0.22 (EtOAc/hexanes 4:1); m.p. 98 ºC; IR νmax (film): 3405, 2941, 
2837, 1661, 1617, 1589, 1517, 1467, 1439, 1252, 1214, 1201, 1183, 1148, 1129, 1075, 
830, 752 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 9.0 Hz, 2H), 7.22 (d, J = 7.2 
Hz, 2H), 7.03 (br dd, J = 7.2, 7.2 Hz, 2H), 6.97 (br t, J = 7.2 Hz, 1H), 6.67 (d, J = 9.0 Hz, 
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2H), 6.08 (d, J = 2.2 Hz, 1H), 6.06 (d, J = 2.2 Hz, 1H), 5.90 (s, 1H), 5.74 (br dd, J = 5.5, 
5.5 Hz), 4.75 (s, 1H), 4.48 (br d, J = 9.0 Hz, 1H), 4.30 (dd, J = 5.5, 5.5 Hz, 1H), 3.84 (s, 
3H), 3.72 (s, 3H), 3.70 (s, 3H), 3.53 (d, J = 9.0 Hz, 1H), 3.18 (ddd, J = 13.5, 7.5, 5.5 Hz, 
1H) 3.12 (ddd, J = 13.5, 6.5, 5.5 Hz, 1H),  1.56-1.51 (ovrlp m, 2H), 1.51-1.45 (ovrlp m, 
2H); 13C NMR (125 MHz, CDCl3) δ 169.8, 161.2, 158.8, 157.8, 154.0, 142.0, 130.3 (2C), 
130.2 (2C), 130.1, 128.0 (2C), 126.1, 113.0 (2C), 104.4, 104.3, 94.7, 92.5, 89.2, 81.0, 
79.6, 66.2, 56.1, 55.9, 55.4, 55.2, 53.15, 53.07, 39.5, 30.1, 24.8; HR-MS: m/z Calcd for 
[C33H39O9+H]+ 594.2703, found 594.2704 (+0.17 ppm). 
 
Procedure for the amidation of 27 to produce (±)-3 (2 steps): A dry flask was charged 
with 17 (70 mg, 0.124 mmol, 1.0 equiv) and a stir bar.  17 was then dissolved in a 
CHCl3/EtOH (1:3, 12 mL). 10% Pd on carbon (14 mg,  0.013 mmol, 0.1 equiv) was then 
added, and the mixture was stirred.  The reaction vessel was then purged with H2 gas 
using a balloon filled with H2 and a vacuum manifold.  The reaction was stirred under H2 
for 1 h, and then purged/charged with argon.  The Pd/C was filtered using a Celite plug, 
and the filtrate was concentrated in vacuo to produce the crude carboxylic acid (58 mg, 
100%) which was used in the next reaction without further purification. A flask was 
charged with the carboxylic acid (58 mg, 1.0 equiv, 0.124 mmol), HOBt•H2O (22 mg, 
0.146 mmol, 1.2 equiv), and a stir bar.  The contents were then dissolved in CH2Cl2 (3.5 
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mL) and cooled to 0 °C. EDCI (35 mg, 0.182 mmol, 1.5 equiv) was next added. A 
solution of 4,4-dimethoxybutanamine (49 mg, 0.365 mmol, 3.0 equiv.) in CH2Cl2 (1 mL) 
was added to the reaction vessel at 0 ºC under argon.  The reaction was then brought to rt 
and stirred for 16 h. Water (10 mL) and CH2Cl2 (10 mL) were added and the mixture was 
extracted with CH2Cl2 (3 X 10 mL).  Brine was used to aid separation of the layers.  The 
combined organic extracts were dried over sodium sulfate and purified via flash 
chromatography (product eluted with 8:2 EtOAc/hexanes, 51 mg, 71% yield). See above 
for spectroscopic data. 
 
Dimethyl (2R,3R)-1,4-dioxaspiro[4.5]decane-2,3-dicarboxylate: To a solution of L-
dimethyl tartrate (9.82 g, 55.1 mmol, 1.5 equiv) in 1,2-dichloroethane (150 mL) at -30 oC 
under inert atmosphere was added successively 1,1-dimethoxycyclohexane (5.3 g, 36.75 
mmol, 1.0 equiv) and BF3·Et2O (5.45 mL, 44.1 mmol, 1.2 equiv.) dropwise. The resulting 
mixture was then stirred for 3 h having the temperature raised from -30 oC to RT. The 
reaction was then cooled to 0 oC and carefully quenched with sat. aqueous NaHCO3 
solution. The organic layer was then separated and the aqueous phase was extracted with 
EtOAc (3 X 400 mL). The combined organic phases were washed with water (2 X 400 
mL) and brine (1 X 400 mL). The combined organic extracts were dried over Na2SO4, 
filtered, and concentrated in vacuo to afford a crude oil, which was further purified by 
flash chromatography (gradient of EtOAc/hexanes 2:98 to 15:85) affording pure the 
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dimethyl tartrate acetal as a colorless oil (8.07 g, 31.23 mmol, 85%) which was 
spectroscopically identical to a previously reported compound.9 
 
(R, R)-2,2-Cyclohexyl-α, α, α', α'-tetrakis(phenanthren-9-yl)-1,3-dioxolane-4,5-
dimethanol (+)-7. A solution of dimethyl (2R,3R)-1,4-dioxaspiro[4.5]decane-2,3-
dicarboxylate (1.00 g, 3.87 mmol, 1.0 equiv) in THF (10 mL) was added dropwise to a 
solution of (phenanthren-9-yl)magnesium bromide (19.4 mmol, 5 equiv (prepared from 
4.98 g of 9-bromophenanthrene and 0.46 g of Mg powder and catalytic amount of iodine 
in THF (70 mL) at rt)) at -20 oC under inert atmosphere. The reaction mixture was then 
stirred at rt for 12 h. The reaction was quenched at 0 oC by careful addition of ice and a 
saturated aqueous NH4Cl solution. The organic layer was separated and the aqueous layer 
was extracted with ether (3 X 50 mL). The combined organic extracts were dried over 
Na2SO4 and the solvent was removed in vacuo to afford a yellow oil. The TADDOL was 
purified via flash chromatography using EtOAc/hexanes (20:80). The white solid was 
then recrystallized from CH2Cl2/MeOH (10:90), affording pure TADDOL (+)-7 as a 
white powder (2.036 g, 58%). Rf = 0.35 (CH2Cl2/hexanes 1:1); [α]D20 = + 268o (c = 2.0, 
CHCl3); literature report9 [α]D20 = + 79o (c = 2.0, CHCl3); HR-MS: m/z Calcd for 
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[C66H50O4+Na]+ 929.3609, Found 929.3607 (+0.0 ppm). Other spectroscopic data for 
compound (+)-6 are identical to literature reports.9 
Enantioselective Photocycloaddition between 3-HF 5 and Methyl Cinnamate 6: 
 
Procedure for enantioselective photocycloaddition ((+)-13): A 16 x 100 mm Pyrex test 
tube was flame dried under vacuum and then charged with anhydrous 3-hydroxyflavone 5 
(dried overnight in vacuum oven) (100 mg, 0.305 mmol, 1.0 equiv), methyl cinnamate 6 
(247 mg, 1.52 mmol, 5 equiv), and TADDOL (+)-7 (276 mg, 0.305 mmol, 1.0 equiv) in 
anhydrous CH2Cl2 (0.05 M; 6 mL). After degassing with argon for 10 min, the mixture 
was mixed then irradiated at -78 oC in the Rayonet RPR-3100 (315 < λ < 400 nm) for 10 
h. The solution was concentrated in vacuo to afford a brown-yellow oil. Purification via 
flash chromatography using a gradient of hexanes/EtOAc (80:20 to 30:70) afforded 
cyclopenta[bc]benzopyran 4b, a light yellow foam, as a mixture of isomers (107 mg, 
0.210 mmol, 69%). This mixture of isomers was used without further purification and 
transformed into the desired reduced 10S-aglain 23 using sodium triacethoxyborohydride 
(see procedure for (±)-23). The four diastereomers were separated via flash 
chromatography using a gradient of hexanes/EtOAc (90:10 to 50:50) to afford the desired 
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reduced 10S aglain 23 (49 mg, 0.099 mmol, 47%) which was spectroscopically identical 
to the racemic compound (±)-23 (vide supra). Enantiopure crystals of 23 were obtained 
by slow evaporation from isopropanol (>96:04 er), then another recrystallization by slow 
evaporation from acetonitrile (>98.6:1.4 er). [α]D20 = + 136.5o (c = 1.0, CHCl3). 
 
Ester-amide exchange protocol to access aglain-amide (+)-3. (+)-23 (110 mg, 0.223 
mmol, 1 equiv) was used in the ester-amide exchange protocol (vide supra) to provide 
(+)-3 (85 mg, 0.143 mmol, 64%). []D20 = + 94.8° (c = 1.0, CHCl3); Other spectroscopic 
data of compound (+)-3 are identical to its racemate. 
 
Procedure to prepare (±)-ponapensin (1) (unoptimized) and other derivatives: A dry 
Pyrex tube was charged with aglain amide (±)-3 (50 mg, 0.085 mmol, 1.0 equiv.) and a 
stir bar under argon. (±)-3 was dissolved in EtOAc (9.0 mL) and chilled to 0 °C. Under 




mixture was then heated at 40 °C for 4 h. Triethylamine (7 µL, 0.045 mmol, 0.5 equiv) 
was added and stirred for 30 min. The mixture was concentrated and purified using 
preparative TLC (49:1 CHCl3/MeOH) using a TLC plate that was neutralized with a 
MeOH/triethylamine solution (99:1 MeOH/triethylamine). Fractions from the prep. TLC 
were further purified using reverse phase preparative HPLC (Gilson PLC2020 system, 
Waters SunFire™ Prep C18 OBD™ 5µm 19X50 mm column, 20.0 mL/min flow rate, 
30:70 MeCN/H2O to 80:20 MeCN/H2O gradient, 10 min). (±)-Ponapensin (1) (14 mg, 
30% yield), ethyl hemiaminal derivative (±)-32 (6 mg, 12% yield), and oxazinone (±)-33 




yl)methanone ((±)-32): White solid; Rf = 0.46 (4:1 EtOAc/hexanes); m.p. 195-200 °C; 
IR νmax (film): 3468, 2975, 1618, 1590, 1518, 1496, 1457, 1437, 1252, 1214, 1202, 
1181, 1148, 1130, 1096, 1080 cm-1; 1H NMR (400 MHz, CDCl3) δ (rotamers observed) 
7.42 (d, J = 9.0 Hz, 2H), 7.17 (d, J = 7.2 Hz, 2H), 7.00 (dd, J = 7.2, 7.0 Hz, 2H), 6.95 (t, J 
= 7.0 Hz, 1H), 6.68 (d, J = 9.0 Hz, 2H), 6.10 (d, J = 2.2 Hz, 1H), 6.04 (d, J = 2.2 Hz, 1H), 
5.69 (d, J = 4.0 Hz, 1H), 5.66 (s, 1H), 4.82 (s, 1H), 4.61 (d, J = 9.2 Hz, 1H), 4.22 (d, J = 
9.2 Hz, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 3.70 (s, 3H), 3.46-3.41 (m, 1H), 3.37-3.30 (m, 
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1H), 3.24 (s, 1H), 2.88 (dt, J = 14.0, 7.2 Hz, 1H), 2.73 (dt, J = 14.0, 7.2 Hz, 1H), 2.05-
1.93 (ovrlp m, 2H), 1.88-1.74 (ovrlp m, 2H), 0.76 (t, J = 7.2 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 169.1, 161.1, 158.8, 157.8, 153.8, 141.9, 130.5 (2C), 130.3, 130.1 (2C), 
127.9 (2C), 126.0, 113.1 (2C), 105.1, 94.5, 92.2, 89.2, 86.4, 81.7, 80.1, 63.3, 61.7, 57.1, 
56.0, 55.4, 55.2, 45.2, 32.9, 21.0, 15.0; HR-MS: m/z Calcd for [C33H37NO8+Na]+ 
598.2417, found 598.2416 (-0.17 ppm). Stereochemical assignment was determined by 
2D NOESY spectroscopy: H4/H13 nOe. Shielding of the 13-OEt was observed, which 




e]pyrrolo[2,1-b][1,3]oxazin-10(10aH)-one ((±)-33): White solid; Rf = 0.46 (4:1 
EtOAc/hexanes); IR νmax (film): 3530, 2962, 1614, 1261, 1091 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.37 (d, J = 8.8 Hz, 2H), 7.15 (d, J = 7.6 Hz, 2H), 7.06 (dd, J = 7.6, 7.2 
Hz, 2H), 7.00 (t, J = 7.2 Hz, 1H), 6.66 (d, J = 8.8 Hz, 2H), 6.04 (d, J = 2.4 Hz, 1H), 6.01 
(d, J = 2.4 Hz, 1H), 5.68 (dd, J = 6.4 Hz, 1H), 4.82 (s, 1H), 4.23 (d, J = 10.6 Hz, 1H), 
4.12 (d, J = 10.6 Hz, 1H), 3.75 (s, 3H), 3.714 (s, 3H), 3.708 (s, 3H), 3.57 (brdd, J = 10.8, 
9.2 Hz, 1H), 3.42 (ddd, J = 10.8, 6.8, 4.4 Hz, 1H), 2.85 (s, 1H), 2.44 (ddd, J = 14.0, 7.6, 
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6.4 Hz, 1H), 2.37 (ddd, J = 14.0, 7.6, 6.4 Hz, 1H), 2.13 (dddd, J = 13.4, 7.6, 7.2, 4.4 Hz, 
1H), 1.92 (brddd, J = 13.4, 9.2, 7.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 167.7, 
161.3, 158.9, 158.5, 154.5, 141.2, 130.4 (2C), 130.0 (3C), 128.1 (2C), 126.2, 112.9 (2C), 
105.5, 94.1, 93.3, 91.1, 90.7 (2C), 85.8, 60.0, 55.8, 55.4, 55.2, 51.2, 43.6, 31.5, 22.5; HR-
MS: m/z Calcd for [C31H31NO7+H]+ 530.2179, found 530.2164 (+2.8 ppm). 
 
Optimized procedure to prepare (+)-ponapensin (1): A dry flask was charged with 
aglain amide (+)-3 (53 mg, 0.090 mmol, 1.0 equiv) and a stir bar under argon.  (+)-3 was 
dissolved in THF (9.0 mL) and chilled to 0 °C.  Under argon, CSA (10.4 mg, 0.045 
mmol, 0.5 equiv) and MeOH (54 µL, 1.34 mmol, 15 equiv) were added, and the reaction 
was warmed up to rt, then heated at 40 °C for 2 h. Triethylamine (7 µL, 0.045 mmol, 0.5 
equiv) was added and stirred for 30 min. Water (2 mL) was added to the reaction, and the 
organic layer was separated and dried over sodium sulfate.  The organic extract was 
concentrated and purified using preparative TLC (49:1 CHCl3/MeOH) using a TLC plate 
that was neutralized with MeOH/triethylamine (99:1). Compound 1 was isolated (34 mg, 
0.062 mmol, 68%) as a white solid. The reaction of (±)-3 to  (±)-1 was reacted and 
purified in the exact same fashion and was crystallized via slow evaporation in benzene 
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(600 µL) and hexanes (100 µL).  White solid; Rf = 0.46 (1:4 hexanes/EtOAc); []D20 = + 
170° (c = 0.2, CHCl3); m.p. 235-240 ºC, decomposition observed; IR νmax (film): 3476, 
3011, 2935, 2840, 1619, 1591, 1517, 1436, 1251, 1215, 1148, 1128, 1081, 750 cm-1; 1H 
NMR (500 MHz, CD3OD) δ 7.40 (d, J = 9.0 Hz, 2H), 7.18 (br d, J = 7.0 Hz),  7.00-6.91 
(m, 3H), 6.61 (d, J = 9.0 Hz, 2H), 6.12 (d, J = 2.2 Hz, 1H), 6.03 (d, J = 2.2 Hz, 1H), 5.80 
(br d, J = 3.5 Hz, 1H), 4.62 (br s, 1H), 4.40 (br d, J = 9.5 Hz, 1H), 4.36 (d, J = 9.5 Hz, 
1H), 3.78 (s, 3H), 3.73 (s, 3H), 3.67 (s, 3H), 3.34 (m, 2H), 2.80 (s, 3H), 2.04-2.00 (m, 
1H), 1.94-1.88 (ovrlp m, 3H); 13C NMR (100 MHz, CDCl3) δ 172.4, 162.7, 160.0, 159.8, 
155.0, 143.1, 132.0, 131.7 (2C), 131.4 (2C), 128.6 (2C), 127.0, 113.4 (2C), 107.2, 95.2, 
92.8, 90.0, 89.6, 83.1, 80.9, 63.6, 58.5, 56.5, 55.8, 55.4, 54.3, 46.3, 32.7, 21.7; HR-MS: 




Table 2.3  Comparison of 1H and 13C Spectra for Natural and Synthetic Ponapensin (1) 







δ (ppm)  Appearance  δ (ppm)  Appearance  δ (ppm)  δ (ppm) 
7.40  d, J = 8.9 Hz, 2H  7.40  
d, J = 9.0 Hz, 
2H  172.4  172.4 
7.18  d, J = 6.8 Hz, 2H  7.18  
br d, J = 7.0 
Hz, 2H  162.7  162.7 
6.96  m, 3H  6.96  m, 3H  160.0  160.0 
6.61  d, J = 8.9 Hz, 2H  6.61  
d, J = 9.0 Hz, 
2H  159.8  159.8 
6.12  d, J =2.2 Hz, 1H  6.12  
d, J =2.2 Hz, 
1H  155.0  155.0 
6.03  d, J =2.2 Hz, 1H  6.03  
d, J =2.2 Hz, 
1H  143.1  143.1 
5.80  br d, J = 3.3 Hz, 1H  5.80  
br d, J = 3.5 
Hz, 1H  132.0  132.0 
4.62  s, 1H  4.62  br s, 1H  131.7 (2C)  
131.7 
(2C) 
4.40  d, J = 9.4 Hz, 1H  4.40  
br d, J = 9.5 





4.36  d, J = 9.4 Hz, 1H  4.36  






3.79  s, 3H  3.78  s, 3H  127.0  127.0 
3.73  s, 3H  3.73  s, 3H  113.4 (2C)  
113.4 
(2C) 
3.67  s, 3H  3.67  s, 3H  107.3  107.2 
3.34  m, 2H  3.34  m, 2H  95.2  95.2 
2.80  s, 3H  2.80  s, 3H  92.8  92.8 
2.02  m, 1H  2.02  m, 1H  90.0  90.0 
1.90  m, 2H  1.91  m, 2H  89.6  89.6 
1.88  m, 1H  1.89  m, 1H  83.1  83.1 
        80.9  80.9 
        63.6  63.6 
        58.5  58.5 
        56.5  56.5 
        55.8  55.8 
        55.5  55.4 
        54.3  54.3 
        46.3  46.3 
        32.7  32.7 




Procedure to Prepare elliptifoline (2): A dry flask was charged with aglain amide (+)-3 
(38 mg, 0.064 mmol, 1.0 equiv) and a stir bar under argon. (+)-3 was dissolved in THF 
(6.0 mL) and chilled to 0 °C.  Under argon, CSA (7.5 mg, 0.032 mmol, 0.5 equiv.) and 
tiglic amide 35 (32 mg, 0.32 mmol, 5 equiv) were added, and the reaction was warmed up 
to rt then heated at 40 °C for 6 h. Triethylamine (5 µL, 0.032 mmol, 0.5 equiv) was added 
and stirred for 30 min. Water (2 mL) was added to the reaction, and the organic layer was 
separated and dried over sodium sulfate.  The organic layer was concentrated and purified 
using preparative TLC (49:1 CHCl3/MeOH) using a TLC plate that was neutralized with 
a MeOH/triethylamine solution (99:1 MeOH/triethylamine). Elliptifoline 4 was isolated 
(32 mg, 0.051 mmol, 81%) as a white solid. The reaction of (±)-3 to  (±)-2 was reacted 
and purified in the exact same fashion and was crystallized via slow evaporation in 
CH2Cl2 (200 µL) and 2,2,4-trimethylpentane (100 µL).  White solid; Rf  =  0.24 (1:4 
hexanes/EtOAc); []D20 = + 172° (c = 0.2, CHCl3); m.p. 185 ºC; IR νmax (film): 3441, 
3018, 1621, 1517, 1215, 1149, 751 cm-1;  1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 9.0 
Hz, 2H), 7.11 (br dd, J = 6.5, 2.5 Hz, 1H), 6.91-6.88 (overlapping m, 3H), 6.67-6.58 (m, 
1H), 6.63 (d, J = 9.0 Hz, 2H), 6.14-6.01 (m, 1H), 6.10 (d, J = 2.0 Hz, 1H), 6.05 (d, J = 
2.0 Hz, 1H), 5.38 (d, J = 8.0 Hz, 1H), 4.78 (s, 1H), 4.46 (d, J = 9.0 Hz, 1H), 4.14 (d, J = 
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9.0 Hz, 1H), 3.81 (s, 3H), 3.72 (s, 3H), 3.68 (s, 3H), 3.66 (s, 1H), 3.60 (m, 1H), 3.21 
(ddd, J = 12.0, 9.8, 7.0 Hz, 1H), 2.07 (ddd, J  = 12.5, 12.5, 6.5 Hz, 1H), 2.00-1.89 (ovrlp 
m, 2H), 1.78-1.71 (m, 1H), 1.64 (dd, J = 7.0, 1.5 Hz, 3H), 1.48 (br s, 3H); 13C NMR (100 
MHz, CDCl3) δ 169.8, 167.7, 161.2, 158.7, 157.9, 153.8, 141.9, 132.0, 130.8, 130.41 
(2C), 130.37 (C1’), 130.2 (2C), 127.9 (2C), 125.7, 112.9 (2C), 105.2, 94.5, 92.2, 89.2, 
81.9, 80.00, 63.6, 62.6, 57.2, 56.1, 55.4, 55.2, 46.1, 34.6, 21.6, 14.0, 12.2; HR-MS: m/z 
Calcd for [C36H40N2O8+Na]+ 651.2682, found 651.2663 (-2.9 ppm). 
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Table 2.4  Comparison of 1H and 13C Spectra for Natural and Synthetic Elliptifoline (2) 
 






δ (ppm)  Appearance  δ (ppm)  Appearance  δ (ppm)  δ (ppm) 
7.41  m, 2H  7.40  d, J = 9.0 Hz, 2H  169.9  169.8 
7.11  m, 2H  7.11  m, 2H  167.9  167.7 
6.91  m, 1H  6.90  m, 1H  161.0  161.2 
6.89  m, 2H  6.89  m, 2H  158.4  158.7 
6.63  m, 1H  6.63  m, 1H  158.1  157.9 
6.60  m, 2H  6.63  d, J = 9.0 Hz, 2H  153.7  153.8 
6.09  m, 1H  6.10  d, J = 2.0 Hz, 1H  141.8  141.9 
6.06  m, 1H  6.05  d, J = 2.0 Hz, 1H  131.8  132.0 
6.02  m, 1H  6.08  m, 1H  130.7  130.4 
5.88  s, 1H  5.75  s, 1H  130.4  130.4 
5.57  d, J = 7.9 Hz, 1H  5.38  
d, J = 8.0 
Hz, 1H  130.2  130.2 
4.80  s, 1H  4.78  s, 1H  127.7  127.9 
4.62  s, 1H  3.66  s, 1H  125.6  125.7 
4.45  d, J = 9.2 Hz  4.46  
d, J = 9.0 
Hz, 1H  112.6  112.9 
4.15  d, J = 9.2 Hz  4.15  
d, J = 9.0 
Hz, 1H  105.4  105.2 
3.80  m, 3H  3.81  s, 3H  94.2  94.5 
3.71  m, 3H  3.72  s, 3H  91.9  92.2 
3.66  s, 3H  3.68  s, 3H  88.9  89.2 
3.58  m, 1H  3.60  m, 1H  81.9  81.9 
3.21  m, 1H  3.22  m, 1H  79.7  80.0 
2.02  m, 2H  2.08  m, 1H  63.7  63.6 
1.84  m, 2H  1.94  m, 2H  62.3  62.6 
    1.75  m, 1H  57.1  57.2 
1.63  d, J = 7.0, 3H  1.64  
dd, J = 7.0, 
1.5 Hz, 3H  56.0  56.1 
1.47  s, 3H  1.48  br s, 3H  55.2  55.4 
        55.0  55.2 
        46.1  46.1 
        34.5  34.6 
        21.4  21.6 
        13.9  14.0 
        12.0  12.2 
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Procedure to prepare (−)-methyl rocaglate (8) from enantioenriched 4b: 
Enantioenriched 4b was prepared using the following procedure: a 16 x 100 mm Pyrex 
test tube was flame dried under vacuum and then charged with anhydrous 3-HF 5 (dried 
overnight in vacuum oven) (100 mg, 1.0 equiv, 0.305 mmol), methyl cinnamate 6 (247 
mg, 5.0 equiv, 1.52 mmol), and TADDOL (+)-7 (276 mg, 0.305 mmol, 1.0 equiv) in 
anhydrous CH2Cl2 (0.05M; 6.0mL). After degassing with argon for 10 min, the mixture 
was stirred and irradiated at -78 oC in the Rayonet RPR-3100 (315 < λ < 400 nm) for 10 
h. The solution was concentrated in vacuo to afford a brown-yellow oil. Silica gel was 
washed successively with 80:20:03 hexanes/EtOAc/NEt3 (one column length) and 80:20 
hexanes/EtOAc (one column length) to neutralize acidity. Purification via flash 
chromatography using a gradient of hexanes/EtOAc (80:20 to 30:70) afforded 
cyclopenta[bc]benzopyran 4b, a light yellow foam, as a mixture of isomers (107 mg, 
0.210 mmol, 69%). This mixture of isomers was used without further purification in a 
base mediated ketol rearrangement to form a cyclopenta[bc]benzofuran keto-rocaglate 
using the following procedure:43 To a solution of 4b (107 mg, 0.210 mmol, 1 equiv) in 
MeOH (4 mL) under an inert atmosphere was added a solution of freshly prepared 
NaOMe in methanol (0.3 M, 1.8 mL, 0.540 mmol, 2.6 equiv) at rt. The resulting solution 
was stirred for 30 min at 60 °C. After removal of the MeOH under vacuum, the crude 
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reaction mixture was quenched with a sat. NH4Cl solution (10 mL) and HCl (1M, 5 mL) 
giving a yellowish, cloudy solution which was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were then washed with brine (10 mL), dried over sodium 
sulfate, filtered, and concentrated in vacuo to afford quantitatively a crude yellow oil 
(107 mg, 0.24 mmol) which was used without further purification in the next step:43 To a 
solution of trimethoxy-cyclopenta[b]benzofuran keto-rocaglate 10 (107 mg, 0.21 mmol, 
1.0 equiv) in CH3CN (6.0 mL) at 0 °C under inert atmosphere were added successively 
acetic acid (115 µL, 2.10 mmol, 10 equiv) and Me4NBH(OAc)3 (340 mg, 1.26 mmol, 6 
equiv). The resulting yellow solution was stirred for 12 h at 0 °C to rt before being 
quenched with a sat. NH4Cl solution (4 mL). The mixture was then extracted with EtOAc 
(3 x 5 mL) and the combined organic layers were washed with sat. NaHCO3 (20 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo. Note: removal of the generated 
AcOH by a basic wash (NaHCO3) prior to concentration avoided degradation of the 
crude material. The crude material was purified by flash chromatography (gradient of 
EtOAc/hexane, 10:90 → 40:60) to afford (–)-methyl rocaglate (8) (61 mg, 0.124 mmol, 





Kinetic Resolution of aglain (±)-4b: A dry flask was charged with a stir bar, (±)-4b (107 
mg, 0.218 mmol, 1 equiv) and CH2Cl2 (5 mL). In a separate flask, [RhCl2(Cp*)]2 (1.1 mg, 
0.00218 mmol, 1 mol%), (R,R)-N-Tosyl diphenylethylenediamine (1.6 mg, 0.00436 
mmol, 2 mol%), formic acid (0.008 mL, 0.059 mmol, 1.0 equiv), triethylamine (0.03 mL, 
0.059 mmol, 1.0 equiv), and CH2Cl2 (2 ml) were combined and stirred for 30 min. At this 
time, the entire contents of the separate flask were added to the reaction mixture, and the 
reaction was allowed to stir at room temp for 12 h. After this time, a saturated sodium 
bicarbonate solution was added (5 mL), and the reaction was diluted and extracted with 
CH2Cl2 (3 x 10 mL), then dried with anhydrous sodium sulfate, filtered, and concentrated 
in vacuo. The reduced product (–)-23 was purified via SiO2 gel column chromatography 
(2:3 EtOAc/hexanes) in 45% yield (46 mg, 0.0946 mmol) as a white solid. Aglain (+)-4b 
(6:4 EtOAc/hexanes) was also isolated in 42% yield (53 mg, 0.108 mmol) as a white 
solid.  The enantiopurity of (–)-23 was determined using analytical chiral HPLC (96% 
ee), and the ee of (+)-4b (single enantiomer) was determined by synthesizing (–)-methyl 




(+)-Aglaiastatin (36): To a flame-dried round bottom flask was added hydrate (+)-4b (46 
mg, 0.0946 mmol, 1 equiv) in methanol (3 mL) at rt under an argon atmosphere. To this 
solution was added sodium methoxide, 0.3 M (0.10 mL, 0.296 mmol, 3 equiv) and the 
reaction mixture was stirred for 30 min at 60 °C. The reaction was cooled to rt, then 
concentrated in vacuo. The reaction was then diluted in ethyl acetate (20 mL) then 
quenched with concentrated ammonium chloride (20 mL) then 1 N HCl (1 mL). The 
organic layer was separated and the aqueous was extracted with ethyl acetate (3 x 20 mL) 
then the combined organic fractions were dried with sodium sulfate, filtered, and 
concentrated in vacuo. The crude material (keto-rocaglate 10) was taken forward without 
purification. 
The crude mixture (10) was diluted in toluene (2 mL) and was heated to 110 °C. 
4,4-dimethoxybutanamine 31 (12 mg, 0.0946 mmol, 1.0 equiv) and 4-
dimethylaminopyridine (3 mg, 0.0236 mmol, 0.25 equiv) were added and the reaction 
was heated using microwave conditions (300 W) at 130 °C for 5 min. The crude reaction 
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mixture (acetal 38) was concentrated in vacuo then used in the next reaction without 
further purification. 
The crude material (38) was diluted in THF (1 mL) and cooled to 0 °C. At 0 °C 
was added a saturated ammonium chloride solution/1 N HCl aqueous solution (1 mL) 
dropwise. Precipitate formed immediately. After addition, the reaction was brought to rt, 
and stirred for 30 min. The reaction mixture was then extracted with ethyl acetate (3 x 10 
mL). The combined organic fractions were washed with brine, dried over sodium sulfate, 
then concentrated in vacuo. The crude material (hemiaminal 39) was taken without 
purification to the next step. 
The crude hemiaminal 39 was diluted in THF (3 mL) in a dry flask under argon. 
Ammonium acetate, dried with a vacuum dessicator for 4 h, (78 mg, 0.946 mmol, 10 
equiv) was added along with a stir bar under argon and the solution was heated and 
stirred at 60 °C for 12 h. The reaction was cooled to rt, then diluted with ethyl acetate (10 
mL) and water (5 mL). The organic phase was separated, and the aqueous layer was then 
extracted with ethyl acetate (3 x 10 mL). The combined organic extracts were washed 
with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. 1H NMR 
analysis revealed a 10:1 dr of the cyclization. The crude material was purified via SiO2 
gel column chromatography (4:6 → 1:0 EtOAc/hexanes, bright blue spot under short 
wave UV) to afford (+)-aglaiastatin (36) in 62% (31 mg, 0.0589 mmol). Aglaiastatin (36) 
was found to be unstable to air (oxidizes to aglaroxin C (37)). Rf = 0.2 (4:1 
EtOAc:hexanes); []D27 = + 86.1° (c = 0.2, CHCl3); m.p. 157  °C; IR νmax (film): 2953, 
2924, 2854, 1621, 1514, 1464, 1428, 1251, 1204, 1149, 1114 cm-1; 1H NMR (500 MHz, 
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CDCl3) δ 7.13 (d, J = 9.0 Hz, 2H), 7.10 (d, J = 7.5 Hz, 2H), 7.03 (dd, J  =  7.5, 7.5 Hz, 
2H), 6.96 (t, J = 7.5 Hz, 1H), 6.59 (d, J = 9.0 Hz, 2H), 6.28 (d, J = 2.0 Hz, 1H), 6.08 (d, J 
= 2.0 Hz), 5.24 (s, 1H), 5.23 (m, 1H), 4.60 (s, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.66 (s, 
3H), 3.62 (m, 1H), 3.50 (m, 2H), 2.46 (m, 2H), 2.01 (m, 3H), 1.88 (s, 1H); 13C NMR 
(125 MHz, CDCl3) δ 164.0, 162.5, 161.2, 158.5, 157.6, 157.5, 139.0, 128.6 (2C), 128.4 
(2C), 127.49 (2C), 127.47, 126.0, 112.5 (2C), 107.3, 106.3, 105.2, 92.9, 89.5, 88.3, 70.3, 
57.4, 55.9, 55.6, 55.1, 44.1, 32.5, 22.9; HR-MS: m/z Calcd for [C31H30N2O6+H]+  
527.2182, found 527.2159 (-4.4 ppm). 
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Table 2.5 Comparison of 1H and 13C Spectra for Natural and Synthetic Aglaiastatin (36) 
 
Position Natural Synthetic Natural Synthetic 
 δH (ppm) δH (ppm) 
δC 
(ppm) δC (ppm) 
1   157.2 157.5 
2   106.5 106.3 
3 4.60 (1H, s) 4.60 (1H, s) 57.3 57.4 
3a   105.1 105.2 
4a   161.1 161.2 
5 6.28 (1H, d, J = 2.0) 6.28 (1H, d, J = 2.0) 89.4 89.5 
6   164 164.0 
7 6.08 (1H, d, J = 2.0) 6.08 (1H, d, J = 2.0) 92.8 92.9 
8   157.5 157.6 
8a   107.2 107.3 
8b   88.2 88.3 
6-OCH3 3.83 (3H, s) 3.83 (3H, s) 55.5b 55.6 
8-OCH3 3.83 (3H, s) 3.84 (3H, s) 55.8b 55.9 
8b-OH 1.97 (1H, br s) 1.88 (1H, br s)   
1‘   127.2 127.47 
2‘,6‘ 7.13 (2H, d, J = 9.0) 7.13  2H, d, J = 9.0) 128.3 128.4 
3‘,5‘ 6.58 (2H, d, J = 9.0) 6.59 (2H, d, J = 9.0) 112.5 112.5 
4‘   158.5 158.5 
4‘-OCH3 3.66 (3H, s) 3.66 (3H, s) 55 55.1 
1‘‘   138.8 139.0 
2‘‘,6‘‘ 7.10 (2H, d, J = 7.4) 7.10 (2H, d, J = 7.5) 128.5 128.6 
3‘‘,5‘‘ 7.03 (2H, dd, J = 7.4, 7.4) 7.03 (2H, dd, J = 7.5, 7.5) 127.4 127.49 
4‘‘ 6.95 (1H, dd, J = 7.4, 7.4) 6.96 (1H, dd, J = 7.5, 7.5) 126 126.0 
1‘‘‘   162.3 162.5 
3‘‘‘ 3.48 (1H, m) 3.50 (1H, m) 44 44.1 
 3.62 (1H, m) 3.62 (1H, m)   
4‘‘‘ 1.94−2.06 (2H, m) 2.01 (2H, m) 22.8 22.9 
5‘‘‘ 1.97−2.06 (1H, m) 2.01 (1H, m) 32.5 32.5 
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 2.47 (1H, m) 2.46 (1H, m)   
5a‘‘‘ 5.23 (1H, m) 5.23 (1H, m) 70.3 70.3 







d]pyrrolo[1,2-a]pyrimidin-5-one 40: Hemiaminal 39 was prepared from aglain (±)-4b 
(40 mg, 0.0825 mmol, 1 equiv) following the first three steps outlined for (+)-aglaiastatin 
(36) (vide supra). The crude hemiaminal 39 was diluted in THF (2 mL) in a dry flask 
under argon. Ammonium formate, dried with a vacuum dessicator for 4 h, (76 mg, 1.21 
mmol, 15 equiv) was added along with a stir bar under argon. To the resulting mixture 
was added formic acid (0.005 mL, 0.08 mmol, 1 equiv) and the mixture was stirred at rt 
for 6 d. The reaction was cooled to 0 °C, then quenched with a saturated sodium 
bicarbonate solution. The mixture was diluted with ethyl acetate (10 mL) and water (5 
mL). The organic phase was separated, and the aqueous layer was then extracted with 
ethyl acetate (3 x 10 mL). The combined organic extracts were washed with brine, dried 
over sodium sulfate, filtered, and concentrated in vacuo. 1H NMR analysis revealed a 
1.2:1:1.2 ratio of products 36:40:41. The crude material was purified via SiO2 gel column 
chromatography (4:6 → 1:0 EtOAc/hexanes) to afford (±)-aglaiastatin (36) in 23% (10 
mg, 0.0190 mmol), (±)-40 18% (8 mg, 0.0152 mmol), and (±)-41 28% (12 mg, 0.0228 
mmol) as amorphous white solids. Epi-aglaiastatin 40: Rf = 0.16 (2:1 EtOAc:hexanes); 
IR νmax (film): 3395, 2954, 1621, 1513, 1454, 1427, 1250, 1148, 1113 cm-1; 1H NMR 
 
 107 
(500 MHz, CDCl3) δ 7.05 (d, J = 9.0 Hz, 2H), 7.03-6.99 (ovrlp m, 3H), 6.95 (br d, J = 8.0 
Hz, 2H), 6.55 (d, J = 9.0 Hz, 2H), 6.27 (d, J = 2.0 Hz, 1H), 6.07 (d, J = 2.0 Hz), 5.26 (s, 
1H), 5.06 (dd, J = 8.0, 5.0 Hz, 1H), 4.48 (s, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.66 (s, 3H), 
3.63 (ddd, J = 11.5, 7.5, 7.5 Hz, 1H), 3.40 (ddd, J = 11.5, 9.0, 4.0 Hz, 1H), 2.30-2.04 (m, 
4H); 13C NMR (125 MHz, CDCl3) δ 163.9, 162.9, 161.3, 158.6, 157.7, 157.2, 138.3, 
129.7 (2C), 128.9 (2C), 127.3 (2C), 127.0, 126.4, 112.3 (2C), 107.3, 106.2, 104.0, 92.8, 
89.6, 89.4, 72.5, 58.9, 55.90, 55.86, 55.2, 43.0, 33.0, 21.7; HR-MS: m/z Calcd for 




b][1,3]oxazin-5(6H)-one 41: Hemiaminal 39 was prepared from aglain (±)-4b (18 mg, 
0.0367 mmol, 1 equiv) following the first three steps outlined for (+)-aglaiastatin (36) 
(vide supra). The crude hemiaminal 39 was diluted in THF (2 mL) in a dry flask under 
argon. Magnesium sulfate (48 mg, 0.399 mmol, 11 equiv) was added along with a stir bar 
under argon. The mixture was stirred at 60 °C for 12 h. The reaction was cooled to rt, 
then filtered, and concentrated in vacuo. The crude material was purified via SiO2 gel 
column chromatography (4:6 → 7:3 EtOAc/hexanes) to afford (±)-41 in 42% (8 mg, 
0.0152 mmol) as an amorphous white solid. Oxazinone 41 was recrystallized from 
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EtOAc with slow diffusion of hexanes. Rf = 0.59 (EtOAc); IR νmax (film): 3509, 2955, 
1658, 1623, 1514, 1501, 1456, 1441, 1351, 1251, 1149, 1114, 1043 cm-1; 1H NMR (500 
MHz, CDCl3) δ 7.11-6.99 (ovrlp m, 7H), 6.57 (br d, J = 9.0 Hz, 2H), 6.25 (d, J = 2.0 Hz, 
1H), 6.06 (d, J = 2.0 Hz, 1H),  5.84 (ddd, J = 5.5, 4.0, 1.0 Hz, 1H), 4.59 (s, 1H), 3.82 (s, 
3H), 3.81(s, 3H), 3.72 (ddd, J = 12.5 Hz, 10.5 Hz, 6.5 Hz, 1 H), 3.66 (s, 3H), 3.42 (ddd, J 
= 12.5, 10.5, 6.5 Hz, 1H), 2.55 (s, 1H), 2.48 (ddd, J = 13.0, 7.0, 7.0 Hz, 1H), 2.44-2.37 
(m, 1H), 2.04 (ddd, J = 13.5, 7.0, 7.0 Hz, 1H),  1.96 (ddd, J = 13.0, 7.0 Hz, 7.0Hz); 13C 
NMR (125 MHz, CDCl3) δ 167.1, 164.0, 161.3, 160.8, 158.6, 158.1, 137.8, 128.68 (2C), 
128.66 (2C), 127.8 (2C), 126.9, 126.6, 112.53, 112.45 (2C), 106.3, 103.7, 92.8, 91.8, 
89.1, 88.0, 55.8, 55.7, 55.6, 55.1, 44.7, 31.8 22.4; HR-MS: m/z Calcd for 
[C31H30NO7+H]+  528.2022, found 528.2006 (-3.0 ppm). 
 
(−)-Aglaroxin C (37): To a dry 10 mL flask was added (+)-aglaiastatin (36) (7 mg, 
0.0133 mmol, 1 equiv), a stir bar, and CH2Cl2 under argon. DDQ (3.3 mg, 0.0146 mmol, 
1.1 equiv) was added in one portion under argon, and the reaction was stirred for 30 min 
at rt. Filtered with cotton, and purified using prep TLC (9:1 EtOAc/hexanes). Aglaroxin 
C (37) was isolated as an amorphous yellow solid in 66% yield (4.6 mg, 0.00877 mmol). 
Rf = 0.08 (EtOAc); []D27 = − 49.2° (c = 0.1, CHCl3) IR νmax (film): 3802, 3326, 2973, 
 
 109 
2927, 2854, 1677, 1616, 1579, 1261, 1149 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.08 ( d, 
J = 9.0 Hz, 2H), 7.06 (ovrlp m, 3H), 6.89 (m, 2H), 6.56 (d, J = 9.0 Hz, 2H), 6.20 (d, J = 
2.0 Hz, 1H), 6.05 (d, J = 2.0 Hz, 1H), 4.69 (s, 1H), 4.12 (ovrlp m, 2H), 3.84 (s, 3H), 3.79 
(s, 3H),   3.66 (s, 3H), 3.31 (s, 1H), 3.22 (m,  2H), 2.30 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ 166.9, 166.2, 163.6, 161.0, 159.2, 158.7, 158.2, 137.1, 129.4 (2C), 129.1 (2C), 
127.9 (2C), 127.2, 126.9, 121.8, 112.4 (2C), 107.4, 103.7, 92.8, 90.5, 89.2, 57.1, 55.81, 
55.75, 55.2, 46.9, 33.0, 19.7; HR-MS: m/z Calcd for [C31H28N2O6+Na]+  547.1845, found 
547.1860 (+2.7 ppm). 
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Table 2.6 Comparison of 1H and 13C spectra for natural and synthetic aglaroxin C (37) 
 
Position Natural Synthetic Natural Synthetic 
 δH (ppm) δH (ppm) 
δC 
(ppm) δC (ppm) 
1   159.0 159.2 
2   90.3 90.5 
3 4.69 (1H, s) 4.69 (1H, s) 56.9 57.1 
3a   103.6 103.7 
4a   160.8 161.0 
5 6.19 (1H, d, J = 2.0) 6.20 (1H, d, J = 2.0) 92.6 92.8 
6   163.4 163.6 
7 6.04 (1H, d, J = 2.0) 6.05 (1H, d, J = 2.0) 89.0 89.2 
8   158.0 158.2 
8a   107.2 107.4 
8b   121.4 121.8 
6-OCH3 3.78 (3H, s) 3.79 (3H, s) 55.5 55.75 
8-OCH3 3.83 (3H, s) 3.84 (3H, s) 55.6 55.81 
8b-OH 3.35 (1H, s) 3.31 (1H, s)   
1‘   127.0 127.2 
2‘,6‘ 7.08 (2H, d, J = 9.0) 7.08  (2H, d, J = 9.0) 128.9 129.1 
3‘,5‘ 6.55 (2H, d, J = 9.0) 6.56 (2H, d, J = 9.0) 112.2 112.4 
4‘   158.6 158.7 
4‘-OCH3 3.65 (3H, s) 3.66 (3H, s) 54.9 55.2 
1‘‘   136.9 137.1 
2‘‘,6‘‘ 7.06 (2H, m) 7.06 (2H, m) 129.2 129.4 
3‘‘,5‘‘ 6.89 (2H, m) 6.89 (2H, m) 127.6 127.9 
4‘‘ 7.06 (1H, m) 7.06 (1H, m) 126.7 126.9 
1‘‘‘   166.7 166.9 
2‘‘‘ 4.09 (2H, m) 4.12 (2H, m) 46.7 46.9 
3‘‘‘ 2.25 (2H, m) 2.30 (2H, m) 19.4 19.7 
4‘‘‘ 3.20 (2H, m) 3.22 (2H, m) 32.7 33.0 
5 ‘‘‘   166.0 166.2 
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Chiral HPLC Analyses 
Chiral HPLC Analysis of racemic methyl rocaglate (8): Regis Pirkle covalent 
(R,R) WHELK-O 1 column was used, with an isocratic mobile phase of 










Chiral HPLC Analysis of enantioenriched (−)-methyl rocaglate (8): Regis Pirkle 
covalent (R,R) WHELK-O 1 column was used, with an isocratic mobile phase of 
isopropanol/hexanes (20:80) with a flow rate of 1.0 mL/min for 45 min. 
  
 
After HPLC analysis of enantioenriched methyl rocaglate (8), the optical rotation 
was measured. [α]D20 = -32 ° (71.5% ee), consistent with previous literature reports for 











Chiral HPLC Analysis of enantiopure (−)-methyl rocaglate and (+)-methyl 
rocaglate (8): Regis Pirkle covalent (R,R) WHELK-O 1 column was used, with an 

















Analysis of Aglain (+)-23: SFC Chiralcel®OD-H column (temperature 35 oC) was used 
with isocratic elution of MeOH (NEt2 0.1% / Vol) : CO2 (08:92) with a flow rate of 1.5 

























Chiral HPLC Analysis of aglain 23: Chiralpak AD column was used, with an isocratic 






















Analysis of  (±)-3: SFC Chiralcel®OD-H column (temperature 35 oC) was used with an 
elution of MeOH (NEt2 0.1% / Vol) : CO2 with a flow of 2.5 mL/min at 100 bar (CO2 
pressure): isocratic 05:95 (3 min) then ramped from 05:95 to 20:80 over 43 min (rate: 
0.35). T1 = 25.7 min, T2 = 32.4 min. 
 
Analysis of enantioenriched (+)-3: SFC Chiralcel®OD-H column (temperature 35 oC) 
was used with an elution of MeOH (NEt2 0.1% / Vol) : CO2 with a flow rate of 2.5 
mL/min at 100 bar (CO2 pressure): isocratic 05:95 (3 min) then ramped from 05:95 to 
























X-ray crystallographic data for enantiopure (+)-23  
(Absolute and relative stereochemistry) 
Crystals of compound (+)-23 suitable for X-ray analysis were obtained by slow 
evaporation from isopropanol, then another recrystallization by slow evaporation from 
acetonitrile. Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC #833990). Copies of the data can be obtained free 
of charge on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: 
(+44)- 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk. 
 
 
Table 2.7 Crystal data and structure refinement for the absolute stereochemistry of the 
reduced aglain (+)-23. 




  C28H28O8 F(000) = 1040 
Mr = 492.50 Dx = 1.374 Mg m-3 
Orthorhombic, P212121 Cu Ka radiation, l = 1.54178 Å 
Hall symbol:  P 2ac 2ab Cell parameters from 9257 reflections 
a = 6.3478 (2) Å q = 13.7–131.9° 
b = 12.4544 (4) Å m = 0.84 mm-1 
c = 30.1079 (10) Å T = 100 K 
V = 2380.27 (13)  Å3 Block, colorless 




  Bruker Proteum-R  
diffractometer 
4168 independent reflections 
Radiation source: rotating anode 4141 reflections with I > 2s(I) 
graphite Rint = 0.033 
f & w scans qmax = 66.2°, qmin = 3.8° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1996) 
h = -7®7 
Tmin = 0.686, Tmax = 0.753 k = -14®14 
120163 measured reflections l = -35®35 
 
    
Refinement 
  Refinement on F2 Secondary atom site location: difference 
Fourier map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2s(F2)] = 0.024 H-atom parameters constrained 
wR(F2) = 0.061 w = 1/[s2(Fo2) + (0.0333P)2 + 0.5417P]   
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where P = (Fo2 + 2Fc2)/3 
S = 1.04 (D/s)max = 0.002 
4168 reflections Dñmax = 0.22 e Å-3 
367 parameters Dñmin = -0.17 e Å-3 
13 restraints Absolute structure:  Flack H D (1983), 
Acta Cryst. A39, 876-881 
Primary atom site location: structure-
invariant direct methods 
Flack parameter: -0.03 (11) 
 
 
      
Table 2.8 Fractional atomic coordinates and isotropic or equivalent isotropic 
displacement parameters (Å2) 
 x y z Uiso*/Ueq Occ. (<1) 
O2 0.63728 
(13) 





0.52418 (7) 0.37597 (3) 0.02269 
(18) 
 
H3 0.0785 0.5843 0.3784 0.034*  
O1 1.13444 
(13) 





0.83364 (7) 0.31928 (3) 0.0327 (2)  
O4 0.28545 
(14) 
0.72388 (7) 0.35232 (3) 0.02514 
(19) 
 
H4 0.3497 0.7816 0.3473 0.038*  
O7 0.28132 
(17) 
0.00827 (7) 0.37268 (3) 0.0366 (2)  
O8A 0.6000 (12) 0.7690 (9) 0.4474 (3) 0.0379 (15) 0.60 (3) 
O5 0.86467 
(16) 
0.69235 (8) 0.41110 (3) 0.0346 (2)  
C16 0.4986 (2) 0.35964 
(12) 
0.53217 (4) 0.0340 (3)  
H16 0.4800 0.3289 0.5608 0.041*  
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C17 0.6947 (3) 0.39232 
(15) 
0.51847 (5) 0.0464 (4)  
H17 0.8119 0.3850 0.5378 0.056*  
C11 0.59038 
(18) 
0.50155 (9) 0.40315 (4) 0.0169 (2)  
H11 0.7457 0.5023 0.3977 0.020*  
C18 0.7226 (2) 0.43616 
(12) 
0.47635 (4) 0.0324 (3)  





0.38010 (4) 0.0201 (2)  
H24 0.6999 0.2841 0.3896 0.024*  
C1 1.2536 (2) 0.72764 
(10) 
0.23044 (4) 0.0245 (3)  
H1C 1.2801 0.7649 0.2586 0.037*  
H1A 1.1741 0.7749 0.2105 0.037*  
H1B 1.3881 0.7085 0.2166 0.037*  
C7 0.87442 
(19) 
0.54562 (9) 0.28002 (4) 0.0182 (2)  
H7 0.9316 0.4789 0.2706 0.022*  
C9 0.31375 
(18) 
0.53313 (9) 0.34756 (4) 0.0188 (2)  
H9 0.2726 0.5249 0.3157 0.023*  
C10 0.48211 
(18) 
0.45127 (9) 0.36091 (4) 0.0166 (2)  
C12 0.51390 
(19) 
0.62024 (9) 0.40371 (4) 0.0188 (2)  
H12 0.3914 0.6256 0.4245 0.023*  
C13 0.55406 
(19) 
0.44888 (9) 0.44792 (4) 0.0179 (2)  
C15 0.3287 (2) 0.37175 
(11) 
0.50404 (4) 0.0279 (3)  
H15 0.1928 0.3491 0.5133 0.033*  
C22 0.3203 (2) 0.11561 0.36849 (4) 0.0239 (3)  
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(10) 
C21 0.1751 (2) 0.18818 
(10) 
0.35177 (4) 0.0248 (3)  
H21 0.0417 0.1637 0.3417 0.030*  
C6 0.70610 
(18) 
0.54864 (9) 0.30923 (4) 0.0168 (2)  
C23 0.5177 (2) 0.15195 
(10) 
0.38233 (4) 0.0225 (3)  
H23 0.6192 0.1025 0.3932 0.027*  
C3 0.8684 (2) 0.73938 
(10) 
0.27651 (4) 0.0211 (2)  
H3A 0.9226 0.8048 0.2650 0.025*  
C5 0.61287 
(19) 





0.26473 (4) 0.0188 (2)  
C19 0.41916 
(19) 
0.33482 (9) 0.36415 (3) 0.0176 (2)  
C8 0.43202 
(18) 
0.63886 (9) 0.35552 (4) 0.0194 (2)  
C25 0.6803 (2) 0.69747 
(10) 
0.41900 (4) 0.0224 (3)  
C20 0.2249 (2) 0.29713 
(10) 
0.34979 (4) 0.0218 (3)  
H20 0.1242 0.3464 0.3384 0.026*  
C4 0.6981 (2) 0.73928 
(10) 
0.30537 (4) 0.0215 (2)  
C14 0.3552 (2) 0.41686 
(10) 
0.46227 (4) 0.0244 (3)  
H14 0.2369 0.4260 0.4433 0.029*  
C28A 0.0882 (3) -0.03279 
(14) 
0.35960 (8) 0.0402 (6) 0.772 (4) 
H28B 0.0824 -0.1097 0.3665 0.060* 0.772 (4) 
H28A 0.0702 -0.0223 0.3276 0.060* 0.772 (4) 
H28C -0.0248 0.0046 0.3755 0.060* 0.772 (4) 
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C27A 0.6151 (3) 0.92590 
(12) 
0.28969 (6) 0.0284 (5) 0.809 (4) 
H27C 0.7575 0.9562 0.2904 0.043* 0.809 (4) 
H27B 0.5137 0.9803 0.2994 0.043* 0.809 (4) 
H27A 0.5810 0.9033 0.2594 0.043* 0.809 (4) 
C27B 0.7203 (15) 0.9325 (6) 0.3066 (3) 0.0284 (5) 0.191 (4) 
H27E 0.8609 0.9315 0.3201 0.043* 0.191 (4) 
H27F 0.6429 0.9956 0.3172 0.043* 0.191 (4) 
H27D 0.7336 0.9359 0.2742 0.043* 0.191 (4) 
C26A 0.7445 (11) 0.8444 (10) 0.4661 (4) 0.059 (2) 0.60 (3) 
H26B 0.8594 0.8057 0.4809 0.088* 0.60 (3) 
H26C 0.6710 0.8894 0.4879 0.088* 0.60 (3) 
H26A 0.8024 0.8897 0.4425 0.088* 0.60 (3) 
C28B 0.3506 (12) -0.0556 (5) 0.4031 (2) 0.0358 (18) 0.228 (4) 
H28E 0.2468 -0.1123 0.4085 0.054* 0.228 (4) 
H28F 0.3740 -0.0150 0.4306 0.054* 0.228 (4) 
H28D 0.4835 -0.0878 0.3933 0.054* 0.228 (4) 
O8B 0.588 (2) 0.7847 (10) 0.4360 (6) 0.043 (2) 0.40 (3) 
C26B 0.741 (2) 0.8716 (9) 0.4494 (8) 0.074 (3) 0.40 (3) 
H26E 0.8468 0.8416 0.4697 0.112* 0.40 (3) 
H26F 0.6649 0.9296 0.4644 0.112* 0.40 (3) 






X-ray crystallographic data for ponapensin (±)-1  
(Relative stereochemistry)  
 
Crystals of compound 1 suitable for X-ray analysis were obtained by slow evaporation 
from benzene/hexanes. Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC #833744). Copies of the data can be obtained free 
of charge on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: 











Table 2.9  Crystal data and structure refinement for compound 1. 
 
Identification code  1 
Empirical formula  C44 H47 N O8 
Formula weight  717.83 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
 126 
Space group  P-1 
Unit cell dimensions a = 11.6354(9) Å a= 71.620(4)°. 
 b = 12.6447(10) Å b= 69.603(4)°. 
 c = 15.6781(11) Å g = 63.746(4)°. 
Volume 1903.0(2) Å3 
Z 2 
Density (calculated) 1.253 Mg/m3 
Absorption coefficient 0.086 mm-1 
F(000) 764 
Crystal size 0.30 x 0.15 x 0.05 mm3 
Theta range for data collection 1.83 to 26.37°. 
Index ranges -14<=h<=14, -15<=k<=15, -19<=l<=19 
Reflections collected 31176 
Independent reflections 7763 [R(int) = 0.0324] 
Completeness to theta = 26.37° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9957 and 0.9748 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7763 / 66 / 574 
Goodness-of-fit on F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0435, wR2 = 0.1015 
R indices (all data) R1 = 0.0640, wR2 = 0.1135 
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Largest diff. peak and hole 0.269 and -0.231 e.Å-3 
 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 




 x y z U(eq) 
________________________________________________________________________
________   
O(1) 11264(1) -2264(1) -5237(1) 24(1) 
O(2) 14602(1) -3584(1) -4862(1) 27(1) 
O(3) 13601(1) -5304(1) -3710(1) 28(1) 
O(4) 10306(1) -3029(1) -2324(1) 33(1) 
O(5) 13686(1) -4033(1) -1225(1) 47(1) 
O(6) 11431(1) -5739(1) -2853(1) 35(1) 
O(7) 7915(1) -3872(1) -4343(1) 42(1) 
O(8) 13807(1) 1285(1) -7953(1) 39(1) 
N(1) 12054(1) -4177(1) -1714(1) 32(1) 
C(1) 12367(1) -2237(1) -5001(1) 22(1) 
C(2) 11866(2) -1989(1) -3979(1) 23(1) 
C(3) 12428(2) -3239(1) -3372(1) 23(1) 
C(4) 12712(1) -4117(1) -3988(1) 23(1) 
C(5) 11445(1) -4083(1) -4079(1) 24(1) 
C(6) 10801(1) -3162(1) -4711(1) 23(1) 
C(7) 9630(2) -3052(1) -4847(1) 28(1) 
C(8) 9074(2) -3885(2) -4302(1) 31(1) 
C(9) 9658(2) -4801(2) -3633(1) 32(1) 
C(10) 10813(2) -4880(1) -3522(1) 28(1) 
C(11) 11508(2) -3450(1) -2429(1) 25(1) 
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C(12) 13428(2) -4711(2) -1662(1) 37(1) 
C(13) 13502(2) -5893(2) -1005(2) 51(1) 
C(14) 12173(2) -5567(2) -290(2) 55(1) 
C(15) 11210(2) -4595(2) -843(1) 40(1) 
C(16) 12766(1) -1297(1) -5771(1) 23(1) 
C(17) 11959(2) -91(1) -5806(1) 27(1) 
C(18) 12255(2) 796(2) -6525(1) 30(1) 
C(19) 13400(2) 480(1) -7225(1) 29(1) 
C(20) 14204(2) -719(2) -7214(1) 34(1) 
C(21) 13888(2) -1597(2) -6500(1) 30(1) 
C(22) 12201(2) -1079(1) -3779(1) 26(1) 
C(23) 11219(2) -230(2) -3266(1) 34(1) 
C(24) 11517(2) 544(2) -2997(1) 45(1) 
C(25) 12800(2) 484(2) -3243(1) 44(1) 
C(26) 13786(2) -344(2) -3765(1) 40(1) 
C(27) 13489(2) -1117(2) -4034(1) 34(1) 
C(28) 13392(1) -3529(1) -4922(1) 22(1) 
C(29) 13723(2) -2908(2) -1775(2) 53(1) 
C(30) 10734(2) -6445(2) -2167(1) 48(1) 
C(31) 7257(2) -2933(2) -4998(2) 46(1) 
C(32) 13028(2) 2528(2) -7962(1) 45(1) 
C(1S) 8790(3) -747(2) 507(2) 76(1) 
C(2S) 7459(3) -259(2) 799(2) 70(1) 
C(3S) 6688(2) -300(2) 358(2) 73(1) 
C(4S) 7225(3) -839(3) -388(2) 75(1) 
C(5S) 8555(3) -1336(2) -699(2) 75(1) 
C(6S) 9352(2) -1291(2) -252(2) 78(1) 
C(7S) 12139(3) 7989(2) 1452(2) 81(1) 
C(8S) 12603(3) 7193(3) 882(2) 84(1) 
C(9S) 13095(2) 6004(3) 1217(2) 75(1) 
C(10S) 13113(2) 5601(2) 2125(2) 63(1) 
C(11S) 12644(2) 6389(2) 2695(2) 57(1) 




X-ray crystallographic data for Elliptifoline (±)-2  
(Relative stereochemistry)  
 
Crystals of compound 2 suitable for X-ray analysis were obtained by slow evaporation 
from CH2Cl2/isooctane. Crystallographic data has been deposited with the Cambridge 
Crystallographic Data Centre (CCDC #833988). Copies of the data can be obtained free 
of charge on application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: 
(+44)- 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk. 
 
 
Table 2.10 Crystal data and structure refinement for elliptifoline 2 
Identification code 833988 
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 Crystal data 
  C36H40N2O8·H20 V = 7317.1 (7)  Å3 
Mr = 646.72 Z = 8 
Orthorhombic, Pbcn Cu Ka radiation, l = 1.54178 Å 
a = 24.1823 (14) Å m = 0.69 mm-1 
b = 12.2311 (7) Å T = 100 K 
c = 24.7388 (13) Å 0.12 × 0.11 × 0.09 mm 
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
6426 independent reflections 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1996) 
5972 reflections with I > 2s(I) 
Tmin = 0.696, Tmax = 0.753 Rint = 0.051 
148848 measured reflections  
 
    
Refinement 
  R[F2 > 2s(F2)] = 0.061 0 restraints 
wR(F2) = 0.167 H atoms treated by a mixture of 
independent and constrained refinement 
S = 1.05 Dñmax = 1.00 e Å-3 
6426 reflections Dñmin = -0.42 e Å-3 
437 parameters  
 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
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 x y z Uiso*/Ueq  
O1 0.65939 (7) 0.76166 
(14) 
0.41089 (7) 0.0303 (4)  
O2 0.59242 (8) 0.04097 
(19) 
0.26062 (8) 0.0430 (5)  
O3 0.44870 (7) 0.12637 
(13) 
0.45243 (6) 0.0245 (4)  
O4 0.25832 (7) 0.40085 
(14) 
0.43582 (7) 0.0279 (4)  
O5 0.36672 (7) 0.13888 
(13) 
0.34146 (7) 0.0278 (4)  
O6 0.54565 (6) 0.35068 
(13) 
0.30354 (6) 0.0222 (4)  
H6 0.5403 0.3186 0.2740 0.027*  
O7 0.45475 (7) 0.21678 
(13) 
0.28945 (6) 0.0217 (4)  
H7 0.4310 0.1672 0.2927 0.026*  
N1 0.48591 (8) 0.01825 
(15) 
0.38838 (8) 0.0219 (4)  
O8 0.44981 (6) 0.46722 
(13) 
0.40169 (6) 0.0208 (3)  
C1 0.67899 
(11) 
0.7873 (2) 0.46375 
(11) 
0.0308 (6)  
H1A 0.6961 0.7223 0.4798 0.046*  
H1B 0.6480 0.8112 0.4863 0.046*  







0.0236 (5)  
C3 0.60572 
(11) 
0.6489 (2) 0.35552 
(10) 
0.0263 (5)  





0.34794 (9) 0.0237 (5)  
H4 0.5571 0.5457 0.3123 0.028*  
C5 0.54405 (9) 0.51130 
(18) 
0.39184 (9) 0.0204 (5)  
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C6 0.50307 (9) 0.41958 
(18) 
0.38483 (9) 0.0197 (5)  
C7 0.51335 (9) 0.31234 
(18) 
0.41983 (9) 0.0194 (5)  





0.38117 (9) 0.0199 (5)  
H8 0.5341 0.1934 0.3623 0.024*  
C9 0.47565 (9) 0.11710 
(19) 
0.41013 (9) 0.0206 (5)  
C10 0.51643 
(10) 
-0.0055 (2) 0.33838 (9) 0.0242 (5)  
H10 0.5048 0.0457 0.3090 0.029*  
N11 0.57580 (9) 0.00456 
(18) 
0.34846 (8) 0.0287 (5)  
H11 0.5894 -0.0100 0.3807 0.034*  
C12 0.60969 
(12) 
0.0364 (3) 0.30779 
(11) 
0.0377 (7)  
C13 0.66763 
(13) 
0.0689 (3) 0.32241 
(12) 
0.0414 (7)  
C14 0.69552 
(12) 
0.0121 (3) 0.35938 
(13) 
0.0468 (8)  
H14 0.6762 -0.0437 0.3782 0.056*  
C15 0.75343 
(17) 
0.0294 (4) 0.37304 
(18) 
0.0709 (11)  
H15A 0.7686 0.0879 0.3504 0.106*  
H15B 0.7742 -0.0382 0.3667 0.106*  
H15C 0.7565 0.0502 0.4112 0.106*  
C16 0.55831 (9) 0.54610 
(19) 
0.44344 (9) 0.0222 (5)  





0.45166 (9) 0.0223 (5)  
H17 0.6052 0.6532 0.4873 0.027*  





0.2884 (2) 0.41437 
(10) 
0.0255 (5)  
H19 0.6156 0.2948 0.3761 0.031*  
C20 0.66822 
(11) 
0.2696 (2) 0.43884 
(11) 
0.0305 (6)  
H20 0.7006 0.2634 0.4173 0.037*  
C21 0.67192 
(11) 
0.2598 (2) 0.49454 
(11) 
0.0300 (6)  
H21 0.7066 0.2454 0.5112 0.036*  
C22 0.62469 
(11) 
0.2711 (2) 0.52580 
(10) 
0.0277 (5)  





0.50147 (9) 0.0236 (5)  
H23 0.5417 0.2973 0.5232 0.028*  
C24 0.49777 
(12) 
-0.1221 (2) 0.32536 
(10) 
0.0313 (6)  
H24A 0.4626 -0.1219 0.3048 0.038*  
H24B 0.5262 -0.1614 0.3042 0.038*  
C25 0.49016 
(13) 
-0.1736 (2) 0.38089 
(11) 
0.0335 (6)  
H25A 0.4652 -0.2376 0.3791 0.040*  







0.0257 (5)  
H26A 0.4237 -0.0845 0.4123 0.031*  
H26B 0.4763 -0.0863 0.4524 0.031*  
C27 0.68963 
(15) 
0.1641 (3) 0.29232 
(14) 
0.0518 (8)  
H27A 0.6970 0.1429 0.2548 0.078*  
H27B 0.7240 0.1889 0.3093 0.078*  
H27C 0.6624 0.2234 0.2930 0.078*  
C28 0.46081 (9) 0.27235 
(18) 
0.33928 (9) 0.0192 (5)  
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C30 0.40652 (9) 0.30522 
(19) 
0.36592 (9) 0.0205 (5)  
C31 0.40403 (9) 0.40252 
(18) 





0.41827 (9) 0.0214 (5)  





0.41400 (9) 0.0224 (5)  
C34 0.25548 
(11) 
0.4966 (2) 0.46835 
(11) 
0.0309 (6)  
H34A 0.2639 0.5609 0.4462 0.046*  
H34B 0.2824 0.4912 0.4978 0.046*  
H34C 0.2182 0.5038 0.4835 0.046*  
C35 0.31018 
(10) 
0.2727 (2) 0.38846 
(10) 
0.0250 (5)  





0.36550 (9) 0.0222 (5)  
C37 0.32367 
(14) 
0.0602 (3) 0.34457 
(15) 
0.0543 (10)  
H37A 0.2896 0.0911 0.3294 0.081*  
H37B 0.3175 0.0401 0.3824 0.081*  
H37C 0.3342 -0.0050 0.3240 0.081*  
C38 0.49407 (9) 0.37621 
(18) 
0.32756 (9) 0.0199 (5)  
H38 0.4725 0.4290 0.3050 0.024*  
O1W 0.60059 (9) 0.00666 
(18) 
0.46674 (8) 0.0341 (4)  
H1WA 0.6010 (18) 0.072 (4) 0.4754 (18) 0.077 (14)*  





X-ray crystallographic data for (±)-41 
(Relative Stereochemistry) 
 
Crystals of compound 41 suitable for X-ray analysis were obtained by slow diffusion of 
hexanes from EtOAc. 
Table 2.11 Crystal data for oxazinone 41 
 C31H29NO7 V = 5024.1 (4)  Å3 
Mr = 527.55 Z = 8 
Triclinic, P¯1 F(000) = 2224 
a = 16.4623 (7) Å Dx = 1.395 Mg m-3 
b = 16.6870 (7) Å Cu Ka radiation, l = 1.54178 Å 
c = 21.9358 (10) Å m = 0.81 mm-1 
a = 72.571 (3)° T = 100 K 
b = 74.463 (2)° Prism, colorless 




 Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
qmax = 66.8°, qmin = 3.1° 
Tmin = 0.665, Tmax = 0.753 h = -18®19 
17631 measured reflections k = -18®19 
17631 independent reflections l = 0®26 
15808 reflections with I > 2s(I)  
 
Refinement 
 Refinement on F2 Primary atom site location: structure-
invariant direct methods 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2s(F2)] = 0.055 H-atom parameters constrained 
wR(F2) = 0.154  w = 1/[s2(Fo2) + (0.067P)2 + 2.886P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.03 (D/s)max = 0.001 
17631 reflections Dñmax = 0.56 e Å-3 
1432 parameters Dñmin = -0.38 e Å-3 
1392 restraints  
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 





0.92696 (7) 0.0279 (3)  
















0.95595 (7) 0.0277 (3)  








































0.43020 (8) 0.0317 (3)  





0.46433 (8) 0.0324 (3)  


























































































































































0.0276 (4)  

















































0.0324 (5)  
H19E -0.0697 0.5840 1.1522 0.039*  





















0.0316 (5)  





















0.0326 (5)  








0.0308 (5)  














0.0278 (4)  














0.0326 (5)  














0.0309 (5)  
H18E -0.0642 0.5440 1.0588 0.037*  







0.0283 (5)  







0.0286 (5)  





















0.0357 (5)  







0.0291 (5)  
C20B 0.06692 0.56107 1.10703 0.0305 (5)  
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(15) (16) (11) 
H20E 0.0915 0.5861 1.1299 0.037*  














0.0341 (5)  





















0.0369 (5)  
H20G -0.0025 0.5827 0.6251 0.044*  







0.0320 (5)  
H20I 0.7049 0.3796 0.9165 0.038*  




























0.0371 (5)  







0.0355 (5)  







0.0319 (5)  
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0.0337 (5)  







0.0314 (5)  




























0.0303 (5)  







0.0324 (5)  







0.0320 (5)  







0.0398 (6)  














0.0365 (5)  







0.0320 (5)  















0.0371 (5)  
H28D 0.0163 1.1965 0.9681 0.056*  
H28E 0.1172 1.1146 0.9773 0.056*  







0.0355 (5)  







0.0325 (5)  
H7C 0.0048 0.9979 0.2646 0.039*  
C28C 0.63071 
(18) 
0.5518 (2) 0.48145 
(13) 
0.0432 (6)  
H28G 0.6980 0.5142 0.4747 0.065*  
H28H 0.6017 0.5201 0.5194 0.065*  







0.0390 (6)  




0.0397 (6)  
H18G 0.1660 0.3894 0.5416 0.048*  














0.0327 (5)  







0.0335 (5)  







0.0421 (6)  
H14C -0.1098 0.7507 0.3031 0.051*  
C19A 0.61537 0.47750 0.85079 0.0339 (5)  
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(16) (17) (12) 
H19I 0.6219 0.5230 0.8110 0.041*  







0.0390 (5)  
H19G 0.0976 0.4306 0.6544 0.047*  







0.0376 (5)  
H3C 0.2666 0.9371 0.1690 0.045*  




0.0442 (6)  
H31D 0.2828 0.8489 1.0493 0.066*  
H31E 0.2909 0.7559 1.1015 0.066*  







0.0353 (5)  
H18I 0.4793 0.5743 0.8743 0.042*  







0.0411 (6)  
H7D 0.2639 0.2511 0.6478 0.049*  











0.0384 (5)  







0.0381 (5)  







0.0336 (5)  




0.0410 (6)  
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0.0362 (5)  







0.0343 (5)  
H31J 0.9470 0.6600 0.7262 0.051*  
H31K 1.0033 0.5924 0.7845 0.051*  







0.0365 (5)  







0.0363 (5)  
C31C 0.31045 
(19) 
0.7390 (2) 0.57884 
(13) 
0.0444 (6)  
H31G 0.3459 0.7760 0.5572 0.067*  
H31H 0.3503 0.6800 0.6035 0.067*  







0.0415 (6)  
H20A -0.1039 0.1938 0.4237 0.050* 0.703 (8) 
H20B -0.0569 0.2527 0.3665 0.050* 0.703 (8) 
H20C -0.1036 0.2406 0.4112 0.050* 0.297 (8) 







0.0361 (5)  







0.0391 (5)  















0.0378 (5)  







0.0349 (5)  





















0.0369 (5)  




























0.0412 (6)  














0.0360 (5)  







0.0352 (5)  







0.0407 (6)  















0.0409 (6)  
C13B 0.25435 
(17) 
0.4885 (2) 0.72378 
(13) 
0.0416 (6)  







0.0431 (6)  







0.0426 (6)  
H13C -0.0670 0.7781 0.1916 0.051*  
C27D 0.39088 
(19) 
0.2660 (2) 0.25485 
(12) 







0.0400 (6)  
H9D 0.3341 0.0045 0.4840 0.048*  




0.0451 (6)  
H13D 0.2187 0.0228 0.7510 0.054*  




0.0444 (6)  
H14D 0.0951 0.0730 0.6954 0.053*  




0.0433 (6)  
H31A 0.1319 0.4670 0.2326 0.065*  
H31B 0.1680 0.5028 0.2755 0.065*  
H31C 0.0615 0.5192 0.2888 0.065*  
C4D 0.42779 
(19) 
0.1637 (2) 0.50480 
(14) 
0.0474 (6)  







0.0424 (6)  
H1CA 0.1853 1.0545 0.0912 0.064*  
H1CB 0.2043 1.0943 0.1413 0.064*  
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0.0415 (6)  
H11D 0.3973 -0.0152 0.5842 0.050*  
C26D 0.42214 
(18) 
0.1914 (2) 0.30492 
(13) 
0.0437 (6)  
H26D 0.4840 0.1446 0.3017 0.052*  
C3D 0.4588 (2) 0.1776 (2) 0.55194 
(16) 
0.0527 (7)  
H3D 0.5219 0.1674 0.5464 0.063*  
C18D 0.0473 (2) 0.0287 (2) 0.40200 
(17) 
0.0550 (8)  
H18A 0.0068 -0.0001 0.4319 0.066* 0.703 (8) 
H18B 0.0982 -0.0170 0.3775 0.066* 0.703 (8) 
H18C 0.0507 -0.0335 0.4250 0.066* 0.297 (8) 
H18D 0.0808 0.0258 0.3573 0.066* 0.297 (8) 
C1A 0.6712 (2) 1.0153 (2) 1.13357 
(17) 
0.0562 (8)  
H1AA 0.6947 1.0495 1.0940 0.084*  
H1AB 0.6838 1.0253 1.1712 0.084*  
H1AC 0.6040 1.0373 1.1362 0.084*  
C1B 0.5919 (2) 0.5901 (2) 0.64986 
(15) 
0.0515 (7)  
H1BA 0.6413 0.5956 0.6145 0.077*  
H1BB 0.5790 0.5392 0.6480 0.077*  
H1BC 0.6119 0.5774 0.6913 0.077*  
C28D 0.5332 (2) 0.2057 (2) 0.18639 
(14) 
0.0515 (7)  
H28A 0.5621 0.2181 0.1414 0.077*  
H28B 0.5250 0.1486 0.1950 0.077*  
H28C 0.5733 0.1986 0.2154 0.077*  
C28A 0.6407 (2) 1.0484 (2) 0.67552 
(14) 
0.0549 (8)  
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H28J 0.6505 1.0826 0.6314 0.082*  
H28K 0.6303 1.0855 0.7064 0.082*  
H28L 0.5863 1.0359 0.6813 0.082*  
C1D 0.3812 (3) 0.2201 (3) 0.71478 
(19) 
0.0741 (11)  
H1DA 0.3271 0.2802 0.7116 0.111*  
H1DB 0.4179 0.2150 0.7454 0.111*  
H1DC 0.3601 0.1704 0.7299 0.111*  
C19D -0.0089 (3) 0.1182 (3) 0.3562 (2) 0.0447 (12) 0.703 (8) 
H19A 0.0316 0.1317 0.3159 0.054* 0.703 (8) 
H19B -0.0604 0.1131 0.3449 0.054* 0.703 (8) 
C19E -0.0589 (6) 0.1057 (6) 0.4028 (4) 0.042 (3) 0.297 (8) 
H19C -0.0861 0.1092 0.3664 0.051* 0.297 (8) 
H19D -0.0984 0.0940 0.4441 0.051* 0.297 (8) 
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Studies Toward Catalytic, Enantioselective [3+2] Photocycloaddition 
Between 3-Hydroxyflavones and Cinnamic Derivatives 
 
3.1 ESIPT [3+2] Photocycloadditions 
 This chapter describes studies toward development of a catalytic, enantioselective 
[3+2] photocycloaddition between 3-hydroxyflavones (3-HFs) and cinnamic derivatives. 
Before discussing the experiments conducted, it is important to discuss what is known 
about the racemic reaction. We have learned through studies by Dr. Stéphane P. Roche of 
the Porco laboratory that excited state intramolecular proton transfer is necessary for 
photocycloaddition between 3-HF 1 and methyl cinnamate 2.45 This hypothesis is 
supported by the experiment shown in Scheme 3.1. Photocycloaddition between 3-
methoxyflavone (3-MF) 3 and methyl cinnamate 2 does not take place, whereas 3-HF 1 
and methyl cinnamate 2 react to provide cycloadduct 4. It is important to note that the 
fluorescence spectra of 3-HF 1 and 3-MF 3 differ significantly. Using a mixture of 
chloroform/trifluoroethanol (7:3 ratio), it was found that 3-MF 3 emits 450 nm 
fluorescence when excited at 360 nm, while 3-HF 1 emits fluorescence of 520 nm and a 
small 450 nm shoulder when excited at 360 nm. 
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Excited state intramolecular proton transfer (ESIPT) is a phenomenon observed 
for 3-hydroxyflavones (3-HFs) and was reported in detail by Kasha and coworkers.28,81 
After 3-HF 5 is excited (290-350 nm), a large Stokes-shift (i.e. bathochromic shift of 
fluorescence) is observed (523 nm, green light) which provides evidence of an excited 
state tautomer (Figure 3.1). Through the course of their fluorescence studies, Kasha and 
coworkers found that solvent played a critical role in the fluorescence emission spectra 
for 3-HF 5. Nonpolar, hydrocarbon solvents such as anhydrous methylcyclohexane 
(MCH) solely emitted tautomer fluorescence at 523 nm (77 K, solid state, 290-350 nm 
excitation).81b As water was titrated in, the authors noticed that a blue-shifted 
fluorescence shoulder was forming, a perturbation they hypothesized to result from the 
monohydrate form A (Figure 3.2) that is capable of excited state double proton transfer. 
When the ratio of water:solvent approached 1:1, the authors observed the normal 
emission fluorescence band appear (~420 nm, blue light), which has a typical Stokes shift 
corresponding to the normal excited form of 3-HF 5 (S1) (Figure 3.1). They proposed 
that the polyhydrate form of 3-HF 5, B (Figure 3.2), was responsible for the observance 
of the S1 fluorescence. 
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 Using crystalline matrices of solvent (octane) and 3-HF 5 at 10 K (referred to as a 
Shpol’skii matrix), Gooijer and coworkers estimated the rates of ESIPT and back proton 
transfer to be 49 fs and 210 fs, respectively.82 Excited tautomer S’1 has an estimated 
lifetime on the order of nanoseconds, and Chou and coworkers elucidated the existence of 
a long lived triplet tautomer species, T’1 (lifetime = ~ 14 µs, Figure 3.1).83 Practical 
applications of 3-HF 5 and its ESIPT include probes for metal chelation which inhibits 
ESIPT from occurring.84 
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 As mentioned in Chapter 2, use of ESIPT in in synthesis is highly 
underdeveloped. In the context of ESIPT [3+2] photocycloadditions of 3-HFs, Porco and 
coworkers showed that a variety of dipolarophiles could react with the excited tautomer 
of 3-HF 1 (cf. Scheme 1.15).45 Cinnamates tended to work better than cinnamides. 
Stilbene also worked in the reaction, which was proposed to be possibly mediated 
through the excited triplet tautomer of 3-HF 1 (T’1) or through a photoinduced electron 
transfer (PET) mechanism.85 Also noteworthy was the observation that electron poor 
dipolarophiles had enhanced endo selectivity due to donor-acceptor π interactions, while 
electron rich dipolarophiles had diminished endo selectivity due to repulsion of electron 
rich π systems (Figure 3.3).45 
Perhaps more intriguing than the dipolarophiles that are useable were the 
dipolarophiles that did not work in the photocycloaddition. Figure 3.4 shows a selected 
list of dipolarophiles that were evaluated in the photocycloaddition but did not provide 
isolable quantities of cycloadducts.45 Bulky dipolarophiles such as tri-substituted alkenes 
6a and 6b did not provide a cycloaddition product with 3-HF 1, nor did bulkier 
phenylthioester 6c. o-Bromo substituted cinnamate 6d did not provide a cycloadduct, 
possibly because the bromide is pushing the phenyl group out of plane with the alkene of 
















































endo/exo ratio 1:2  
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the cinnamate, perturbing the electronic conjugation of the system. Bulky, electron rich 
dipolarophiles such as 6e and 6f did not react, most likely because their bulkiness 
prohibited cycloaddition. Methyl styrene 6g did not provide clean photocycloaddition 
products, as the authors observed a complex mixture of regioisomers and diastereomers 
forming from [3+2] cycloaddition with 1. Interestingly, methyl butenoate 6h did not 
react, demonstrating the importance of the phenyl group for reactivity. It is important to 
note that trans- and cis-dimethyl fumarate 7a/7b provided the trans-[3+2] 
photocycloaddition product 8 with 3-HF 5 (Scheme 3.2), suggesting that a stepwise 
mechanism is involved.80 What is perhaps most surprising is the observation that 
cinnamaldehyde 6l and cinnamic acid 6m do not undergo photocycloaddition with 3-HF 
5 when irradiated despite being similar sterically and electronically to methyl cinnamate 
2. 
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 In addition, we have also observed the same phenomena using ketones. Ketone 6j 
was reported to not react with 3-HF 1, and in the course of our studies, we did not 
observe [3+2] photocycloaddition with acyl imidazole 986 (Scheme 3.3). Addition of 
Lewis acids such as Sc(OTf)3 did not facilitate photocycloaddition. In addition, iminium 
catalysis methods with cinnamaldehyde and catalytic amounts of proline-derived 
catalysts did not provide cycloadducts. It seems the electronics of esters, amides, 
thioesters, and benzenoids are necessary for [3+2] photocycloaddition to take place with 
3-HF 1. 
 
 Since cycloaddition appeared to be occurring through a stepwise mechanism (cf. 
Scheme 3.2), it was previously proposed that the triplet tautomer (T’1) was the reactive 
species of the cycloaddition.80 To contradict this, a Stern-Volmer plot was made, which 
Scheme 3.2 Cycloaddition between 3-HF 5 and cis/trans Dimethyl Fumarate 






















































showed the addition of methyl cinnamate 2 quenched the 520 nm fluorescence of 3-HF 1, 
suggesting direct interaction between the singlet tautomer (S’1) of 1 and methyl 
cinnamate 2.45 Note that this experiment does not preclude the reaction from taking place 
in the triplet state. Exciplex formation between S’1 of 3-HF 1 and methyl cinnamate 2 
may be occurring, which may then undergo intersystem crossing (ISC) and react in the 
triplet state via a stepwise mechanism (Figure 3.5). This proposed mechanism accounts 
for the fluorescence quenching of 1 with dipolarophiles and the stepwise cyclization. 
Bulkier dipolarophiles do not react as well possibly because their bulkiness inhibits 
orbital interaction with 3-HF 1’*, thus slowing down the rate of exciplex formation. If the 
exciplex does not form fast enough, excited tautomer 1’* will relax to the ground state 
without undergoing cycloaddition. 
 
3.2 Catalytic, Enantioselective Photochemical Reactions 
 Catalytic (i.e. using substoichiometric amounts of additive), enantioselective 
photochemistry is a burgeoning field of organic synthesis. Recently, there have been 
groundbreaking examples of catalytic, enantioselective photochemistry reported in the 
literature. In 2005, Bach and coworkers reported the first catalytic, enantioselective 
photochemical cyclization using a chiral benzophenone catalyst and lactam with a 

































tethered pyrrolidine, catalyzed through PET cyclization.87 More recently, Bach and 
coworkers reported the use of chiral xanthone catalyst 11 that was selectively irradiated 
by the 360 nm light source, which transferred its triplet energy to lactam 12 (λmax = 315 
nm, with no absorbance at 366 nm) (Scheme 3.4). 88  Rapid [2+2] intramolecular 
cyclization inside the chiral environment was necessary in order to form regioisomers 13 
and 14 in 94% ee; otherwise, 12* could dissociate from chiral catalyst 11 and cyclize in a 
chiral, racemic fashion. 
 
 Bathochromic shifts of a chromophore’s absorbance is another strategy employed 
in catalytic, enantioselective photochemistry. Bach and coworkers recently disclosed this 
strategy in the intramolecular [2+2] cyclizations of tethered homoallylic alkene lactam 15 
(Scheme 3.5).89 Chiral Lewis acid 16 could sufficiently bind substrate 15 and red-shift its 
λabs sufficiently so that excitation with 366 nm promoted [2+2] cyclization, leading to the 
formation of 17 in 88% ee. 
Scheme 3.4 Catalytic, Enantioselective Photochemistry Through Selective 
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 Lastly, Sivaguru and coworkers have disclosed an account of catalytic, 
enantioselective [2+2] photocycloadditions of alkenyl coumarins to afford cycloadducts 
in 96% ee with 10 mol% catalyst loading (Figure 3.6).90 This report is unique because 
the authors propose that catalyst 18 is donating neither its triplet nor singlet energy to the 
coumarin substrate 19 which is supported by fluorescence data (singlet energy) and 
phosphorescence (triplet energy) measurements. The singlet and triplet energies of 
coumarin 19 are higher than that of catalyst 18, which precludes direct energy transfer 
from catalyst to substrate. Since coumarin substrate 19 quenches the fluorescence of 
thiourea 18, the authors propose exciplex formation between 18* and 19 is responsible 
for the observed catalysis. They also propose that the reaction is most likely proceeding 
in the triplet state, as oxygenated solvent reduces the conversion of the reaction. It is also 
worth pointing out that coumarin 19 absorbs minimally at 360 nm, which helps limit the 
background racemic reaction.91 
Scheme 3.5 Catalytic, Enantioselective [2+2] Cycloaddition via Bathochromic 
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3.3 Screening of Substoichiometric Additives: Ureas and Thioureas 
 
 We first started our catalytic, enantioselective studies examining ureas and 
thioureas through a collaboration with the Jacobsen lab at Harvard University. We 
hypothesized that chiral (thio)ureas could stabilize the SOMO of 3-HF excited tautomer 
1’* through hydrogen bonding to the oxidopyrylium, thus bringing it closer in energy to 
the HOMO of methyl cinnamate 2 and catalyzing the reaction (Figure 3.7). Several urea 
and thiourea additives were examined, and through control experiments, we found that 





















































some of these additives (20a-i) were not stable to UV irradiation (λ > 350 nm) at 0 ºC 
(Scheme 3.6). We propose that an interrupted Norrish type II reaction 92  may be 
occurring, where the triplet thiourea 20a* abstracts a hydrogen from the neighboring t-Bu 
group. This nascent radical can then abstract a proton from the benzylic position of the 
amide, forming a benzylic radical, which then fragments to afford imine 21a. Purification 
with silica gel hydrolyzes the imine to form naphthaldehyde 21b, which was isolated in 
12% yield. With this knowledge, we tested the stable thioureas to see if the urea/thioureas 
could induce enantioselectivity in the [3+2] photocycloaddition between 3-HF 1 and 
methyl cinnamate 2 (Scheme 3.7). 
 168 
 
Scheme 3.6 Catalyst Instability and Isolated Naphthaldehyde Biproduct 21b 
catalyst degradation
hν,  λ > 350 nm
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 Catalysts 24a-f performed modestly at 0 ºC (3 equiv of methyl cinnamate), with 
the highest observed ee being 22% induced by catalyst 24f. Interestingly, the unstable 
catalyst 20a provided a 12% yield of (±)-methyl rocaglate (25). Encouraged by these 
results, we screened other additives substoichiometrically at -78 ºC (5 equiv methyl 
cinnamate), in which case we may observe better catalyst stability. Scheme 3.8 shows 
chiral thioureas used in [3+2] photocycloaddition between 3-HF 1 and methyl cinnamate 
2 at -78 ºC. From this round of screening, lower ees were observed, possibly due to use of 
5 equiv of methyl cinnamate 2 which amplified the racemic background reaction. The 
highest ee was induced by urea 26d which provided (–)-27 in 14% ee after reduction of 
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(–)-4. A similar squaramide catalyst provided chiral, racemic 4 (cf. Scheme 3.1), which 
was measured on the reduced product 27.  
 
  
3.4  Chiral Trifluoroethanols and TADDOLs 
 
  
Having explored a range of chiral (thio)urea photocatalysts, we considered 
exploring TADDOLs and other additives in substoichiometric amount that may catalyze 
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Figure 3.8 Pirkle’s Alcohol 28 as an NMR Additive to Determine Enantiomeric 




















the enantioselective [3+2] photocycloaddition through SOMO stabilization and excited 
state double proton transfer. Since trifluoroethanol was able to significantly improve the 
yield of the racemic photocycloaddition between 3-HF 1 and methyl cinnamate 2, we 
hypothesized that chiral trifluoroethanols (TFEs) could mediate catalytic, 
enantioselective [3+2] photocycloaddition via excited state double proton transfer (cf. 
Figure 3.2).81b Pirkle’s alcohol (–)-28 has been previously used as an additive in NMR 
analysis to determine enantiomeric ratios of γ-lactones through formation of 
diastereomeric complexes (Figure 3.8).93 We first tested Pirkle’s alcohol (−)-28 in our 
photocycloaddition as a substoichiometric additive and found that this catalyst provides 
(+)-27 in 40% ee using 1 equiv of methyl cinnamate to limit the background reaction 
(Scheme 3.9). Encouraged by this result, we synthesized two analogs: 1-pyrenyl and 9-
phenanthrenyl derivatives (–)-29 and (–)-30 (Scheme 3.10). Friedel–Crafts alkylation of 
pyrene 31 provided ketone 32 in modest yield.94 CBS reduction95 of pyrenyl ketone 32 
provided pyrene (–)-29 in excellent yield and ee. 
 




























 Starting from 9-bromophenanthrene 33, ketone 34 was prepared from Grignard 
addition to the corresponding Weinreb amide 35. CBS reduction then provided (–)-30 in 
excellent yield and ee. 
 
Scheme 3.10 Syntheses of Chiral TFEs (–)-29 and (–)-30 
TFAA,
Me2S•BF3,













catechol borane (1.5 equiv)
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 173 
 With the new chiral trifluoroethanols in hand, we tried them in enantioselective 
[3+2] photocycloaddition between 3-HF 1 and methyl cinnamate 2 (Scheme 3.11). 
Interestingly, we found phenanthrenyl TFE (–)-30 to give the same ee as Pirkle’s alcohol 
(–)-28, and the 1-pyrenyl TFE (−)-29 provided aglain (+)-27 in 19% ee. 
 To determine how Pirkle’s alcohol (–)-28 binds to 3-HF 1 in the ground state, we 
attempted a 2-D NOESY spectrum of 1 and (–)-28. We observed an intermolecular nOe 
between H2’ of 3-HF 1 and H8 of (–)-28 (Figure 3.9).96 Two possible conformations of 
3-HF 1 and (–)-28 that could exhibit this observed correlation and lead to formation of 
(+)-4 through cycloaddition between 1 and methyl cinnamate 2 include assembly A: 
double hydrogen bonded structure; and assembly B: H-bonding to the phenol of 3-HF 1. 
Interestingly, these proposed assemblies lack π−π* interactions between 3-HF 1 and (−)-
28. Assemblies C and D lead to formation of the less favored (−)-4 through 
photocyloaddition with 2, but retain close contact between H2’ and H8. Assembly D 
exhibits π−π* interactions between 1 and (−)-28 while assembly C does not. Attempts to 
co-crystallize 28 or 30 with 3-HF 1 were unsuccessful; in all cases, 3-HF 1 would 
crystallize without the chiral TFEs. 
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 In parallel studies of other additives that may promote catalysis through excited 
state double proton transfer (cf. Figure 3.2), tetrakis pentafluorophenyl TADDOL (+)-36 
provided inconsistent ee’s in the photocycloaddition (35-70% ee, 40% ee average) when 
used in substoichiometric amounts (Scheme 3.12). This type of TADDOL has been 
termed TEFDDOL (α,α,α’,α’-tetrakis(perfluoroaryl)-2,2-dimethyl-1,3-dioxolane-4,5-
dimethanol) in the literature97 and has a higher pKa than expected because the o-fluoride 
H-bonds with the hydroxyls instead of the hydroxyls H-bonding with each other as is 
normally the case.29 This conformation can be observed in the solid state as X-ray crystal 
analysis of (+)-36 (recrystallized from petroleum ether) illustrates this F-H bond. To 
compare, 9-phenanthrenyl TADDOL (+)-37 provides (+)-27 in 36% ee with 20 mol% 
loading. We also attempted to co-crystallize TADDOL (+)-36 with 3-HF 1, and we 
observed crystallization of 3-HF 1 as a chiral helix98 with 93% ee using Cu Kα radiation. 






































































3.5 TADDOL’s Role in Enantioselective Photocycloaddition 
 With TADDOLs and chiral TFEs being used to modestly induce 
enantioselectivity in catalytic amounts, we wanted to explore their role in 
enantioselective [3+2] photocycloadditions. In collaboration with Prof. David Coker, Dr. 
Michael Bellucci, and Prof. Marco Masia (Boston University), we considered whether 9-
phenanthrenyl TADDOL 37 was imparting asymmetry by first binding to 3-HF 1 or 
methyl cinnamate in the ground state. Through his research, Dr. Bellucci proposed that 
TADDOL (+)-37 may be complexing to methyl cinnamate 2 in the ground state, in which 
the resulting assembly is attacked by the excited tautomer of 3-HF 1’* to provide (+)-4 in 
high diastereo- and enantioselectivity (Figure 3.10).99 To test this hypothesis, stilbene 38 
and methyl cinnamate 2 were used as dipolarophiles with stoichiometric quantities of 




































33%, 3:1 dr (cycloaddition)
36% ee
24%, 5:1 dr (cycloaddition)
40% ee  
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TADDOL (+)-37 (Table 3.13). In collaboration with Mr. Wenyu Wang (graduate 
student, Boston University), we populated Table 3.13: I observed cycloadditions with 
varying equivalences of methyl cinnamate 2 and stoichiometric (+)-37, and Mr. Wang 
observed cycloadditions involving varying equivalences of stilbene 38 with 
stoichiometric (+)-37. We found that methyl cinnamate 2 and stilbene 38 show similar 
enantioselectivity profiles. Interestingly, as the equivalents of 2 and 38 are reduced, the 
ee of the observed cycloadduct decreases. This may be due to excited flavone tautomer 
1’* dissociating from TADDOL (+)-37 before cyclizing with methyl cinnamate 2/stilbene 
38. Lowering the equivalence of methyl cinnamate 2 when employing a stoichiometric 
amount of host complex should have this effect according to studies and proposals 
outlined by Bach and coworkers.88 In previous experiments, using 20 mol% of the host 
molecule (e.g. Schemes 3.9, 3.11, and 3.12) leaves 80 mol% of 3-HF 1’* unbound and 
exposed to racemic cycloaddition. In those cases, use of less dipolarophile is more 
optimal for enantioselectivity. Although the yields and corresponding ee’s track well for 
methyl cinnamate 2 and stilbene 38, it should be known that at the time of this writing, 























hν ( 315 < λ < 400 nm)



















entry equiv of 1 dipolarophile & equiv product & yield ee (%) 
1 1 2, 5 equiv 27, 34% 78 
2 1  2, 2 equiv 27, 15% 66 
3 1  2, 1 equiv 27, 6% 48 
4 2  2, 1 equiv 27, 3% 60 
5 1 38, 5 equiv 39, 27% 82 
6 1 38, 2 equiv 39, 15% 61 
7 1 38, 1 equiv 39, 9% 49 
8 2 38, 1 equiv 39, 6% 41 
 





















Tautomer 1’* approaches from the top face of methyl cinnamate. 
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3.6 Bathochromic Shift as a Possible Mode of Catalysis 
 While TADDOLs and chiral TFEs were being evaluated, other hypothesized 
modes of catalysis were considered, including catalysis through a bathochromic shift of 
the 3-HF 1’s absorbance. It is known that the excitation wavelength of 3-HFs such as 
quercetin, can be red-shifted through metal chelation (e.g. Ca(II),Co(II), Cu(II), Yb(III)) 
to the 3-OH and 4-CO.100 Additionally, metals including Fe(II), Mn(II), Ni(II), and Zn(II) 
have been shown to bind to the parent 3-HF 5, red-shift its absorbance, and catalyze the 
[3+2] reaction of 3-HF 5 with molecular oxygen.101 If the metal has a chiral ligand 
bound, 3-HF 1 can be selectively excited inside the chiral environment with visible light, 
thus eliminating the racemic background reaction. 
 
 The absorption spectra of 3-HF 1 chelated with Yb(III) is shown in Figure 3.11. 
Without the metal, 3-HF 1 absorbs light with a λmax = 350 nm. Once Yb(III) is 
introduced, the excitation is red-shifted into the visible region. With this knowledge, 
[3+2] photocycloaddition of 1 and methyl cinnamate were examined using catalytic 
Yb(OTf)3, triethylamine, and various visible light sources (violet LEDs (425 nm), blue 
Figure 3.11 Absorption Spectra of 3-HF 1 Chelated with Yb 
 
Blue: 3-HF 1 without Yb(III); red: 3-HF 1, Yb(OTf)3 (1:1); green: 3-HF 1, Et3N, 
Yb(OTf)3 (1:1:1) 
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LEDs (475 nm), and white light). Unfortunately, all trials with Yb(OTf)3 and other metals 
that bind 3-HFs were unsuccessful in generating isolable yields of aglain 4 (Figure 3.12). 
From this data, it can be proposed that tautomerization of 3-HF 1 to 1’* is being blocked 
by the Lewis acid chelating to the 3-OH and 4-CO. We also tried Lewis acids (e.g. 
catalytic Yb(OTf)3) in conjunction with Brønsted acids (e.g. 2,2,2-trifluoroethanol, acetic 
acid, benzoic acid, and (S)-(+)-1,1′-Binaphthyl-2,2′-diyl hydrogenphosphate) to red-shift 
the absorption of 3-HF 1 and promote tautomerization through synergistic catalysis.102 
Unfortunately, these trials did not provide isolable cycloadduct 4. From the previously 
published studies45 and since Lewis acid chelation did not effect catalysis, it is apparent 
that tautomerization of 1 to 1’* is necessary for photocycloaddition to take place. 
 
3.7 Summary and Outlook 
 In summary, we have found substoichiometric additives that can promote [3+2] 
photocycloaddition of 3-HF 1 and methyl cinnamate 2 with enantioselectivities up to 
40% ee with 20 mol% loading of catalyst. Chiral TFEs and TADDOLs may be 
interacting with the 3-HF 1 through an excited state double proton transfer mechanism. 
Most likely, enantioselectivity is induced through host-guest complexation in the ground 
state, which explains why substoichiometric amounts of additives, in the case of 























TADDOLs (+)-36 and (+)-37, do not induce high ees as is the case when used 
stoichiometrically. 
 Future work should be done analyzing absorption and fluorescence profiles of 3-
HF 1 and catalyst candidates. Through continued collaboration with the Coker group 
(Boston University), we have proposed that Brønsted acids should have a similar effect as 
Lewis acids in red-shifting the absorption of 3-HF 1. Indeed, we have shown this to be 
true experimentally by examining absorption spectra of 3-HF 1 in the presence of chiral 
Brønsted acids (Figure 3.13). Pirkle’s alcohol 28 and TADDOLs (36 and 37) indeed red-
shift the absorption of 1 into or near the visible region. Furthermore, fluorescence spectra 
should be obtained to detect the slight blue-shift in fluorescence that was proposed to be 
due to excited state double proton transfer.81b Indeed, this hypsochromic shift of the 
fluorescence was previously observed when analyzing the effects of 2,2,2-
trifluoroethanol on fluorescence.45 The proposed analysis could be further expedited 

























1 (0.03 M) ; 28 (6 mM) ; 36 (6 mM) ; 37 (6 mM) ; 1 (0.03 M) and 28 (6 mM) ; 1 (0.03 M) 
and 36 (6 mM) ; 1 (0.03 M) and 37 (6 mM) . 
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3.8 Experimental Section 
General Information: 1H NMR spectra were recorded at 300, 400, or 500 MHz at 
ambient temperature with CDCl3, CD3OD, DMSO-d6 or benzene-d6 (Cambridge Isotope 
Laboratories, Inc.) as solvents. Data for 1H NMR are reported as follows: chemical shift, 
integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet) and coupling constants in Hz. 13C NMR spectra were 
recorded at 75.0, 100.0, or 125 MHz at ambient temperature with the same solvents 
unless otherwise stated. Chemical shifts are reported in parts per million relative to the 
deuterated solvents. All 13C NMR spectra were recorded with complete proton 
decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
Chemical Instrumentation Center using a Waters Q-TOF API-US mass spectrometer. 
Melting points were recorded on a Mel-Temp apparatus (Laboratory Devices). Analytical 
LC-MS was performed on a Waters Acquity UPLC (Ultra Performance Liquid 
Chromatography (Waters MassLynx Version 4.1) with a Binary solvent manager, SQ 
mass spectrometer, Water 2996 PDA (PhotoDiode Array) detector, and ELSD 
(Evaporative Light Scattering Detector). An Acquity UPLC BEH C18 1.7 m column 
was used for analytical UPLC-MS. Optical rotations were recorded on an AUTOPOL III 
digital polarimeter at 589 nm, and specific rotations are given [α]D20 (concentration in 
grams/100 mL solvent). SFC analysis of enantioenriched compounds was performed on a 
Berger SFC (Waters) System with a diode array detector using a SFC Chiralcel®OD-H 
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(Chiral Technologies Inc., 100 × 4.6 mm I.D., 5µm) column. Absorption Spectra were 
taken using a Cary 100 UV/vis spectrophotometer. 
Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-
F plates. Flash chromatography was performed using 200-400 mesh silica gel (Scientific 
Absorbents, Inc.). Yields refer to chromatographically and spectroscopically pure 
materials, unless otherwise stated. HPLC grade tetrahydrofuran, methylene chloride, 
diethyl ether, toluene, acetonitrile, and benzene were purchased from Fisher and VWR 
and were purified and dried by passing through a PURE SOLV® solvent purification 
system (Innovative Technology, Inc.). Other ACS grade solvents for chromatography 
were purchased from Clean Harbors.  
Select photochemistry experiments were performed using a Rayonet RPR-100 
photochemical reactor equipped with RPR-3500 irradiation lamps (UVA 315-400 nm). 
Photochemical reactions were performed in a photobox using a Hanovia 450 W medium 
pressure mercury lamp housed in a quartz immersion well, cooled with a Thermo Neslab-
ULT 80 system circulator. Pyrex test tubes (16 x 100 mm) were mounted on a support 
approximately 5.0 cm from the immersion well lamp. A uranium filter (hν > 350 nm) was 
obtained from James Glass (Hanover, MA). All other reactions were carried out in oven-




General procedure for [3+2] photocycloaddition of 3-HF 1 and methyl cinnamate 
with substoichiometric additives: A dry Pyrex test tube was charged with oven dried 3-
HF 1 (20 mg, 0.061 mmol, 1.0 equiv), methyl cinnamate (10 mg, 0.061 mmol, 1.0 equiv) 
and CH2Cl2 (2 mL). The was evacuated and then charged with argon (3 times). The 
resulting mixture was then degassed under argon by sonication with a brief period of 
sparging with argon. The degassed mixture was sealed, and cooled to -78 °C using a dry 
ice/isopropanol bath (acetone absorbs UV light). The mixture was then irradiated 
(Rayonet, λ > 315 nm) at -78 oC for 10 h. Crude 1H NMR analysis generally revealed 
ketone 4 to be the predominant forming from the reaction (1H NMR (500 MHz, CDCl3) δ 
7.26 (d, J = 9.2 Hz, 2H), 7.03 (br dd, J = 7.5, 6.5 Hz, 2H), 7.00 (t, J = 7.5 Hz, 1H), 6.85 
(d, J = 6.5 Hz, 2H), 6.64 (d, J = 9.2 Hz, 2H), 6.19 (d, J = 2.5 Hz, 1H), 6.13 (d, J = 2.5 Hz, 
1H), 5.80 (s, 1H), 4.50 (d, J = 9.0 Hz, 1H), 3.85 (s, 3H), 3.77 (s, 3H), 3.67 (s, 3H), 3.64 
(s, 3H), 3.59 (d, J = 9.0 Hz, 1H)). 
The crude material was concentrated under vacuum and the resulting oil was 
directly chromatographed on SiO2. Purification via flash chromatography using a 
gradient of hexanes/EtOAc (2:8 → 7:3) afforded cyclopenta[bc]benzopyrans 4 as mixture 























4 (1 equiv), 2,2,2-trifluorotoluene (0.04 M solution) and a stir bar. The resulting mixture 
was cooled to 0 °C. Acetic acid (6 equiv) and NaBH(OAc)3 were added sequentially, and 
the reaction was warmed to rt and stirred overnight for 12 h. The reaction was quenched 
with a saturated ammonium chloride solution, and extracted with CH2Cl2 (3 X 10 mL). 
The combined organic layers were dried over sodium sulfate, filtered, and concentrated. 
The crude product was then purified with column chromatography using a gradient of 
CH2Cl2/EtOAc (99:1 → 5:95) to provide  27 as a white foam. Rf = 0.88 (1:9 
EtOAc/CH2Cl2); [a]20D = + 136.5o (c = 1.0, CHCl3) m.p. 206-209 ºC; IR νmax (film): 
3427, 2952, 1729, 1617, 1516, 1456, 1250, 1214, 1186, 1148, 1120, 1079, 831, 752 cm-1;  
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 9.0 Hz, 2H), 7.23 (d, J = 6.8, 2H), 7.05 (dd, J 
= 6.8, 6.8 Hz, 2H), 7.01 (brt, J = 6.8 Hz, 1H), 6.67 (d, J = 9.0 Hz, 2H), 6.09 (d, J = 2.4 
Hz, 1H), 6.07 (d, J = 2.4 Hz, 1H), 5.63 (s, 1H), 4.78 (s, 1H), 4.37 (d, J = 9.2 Hz, 1H), 
3.85 (s, 3H), 3.79 (d, J = 9.2 Hz, 1H), 3.73 (s, 3H), 3.70 (s, 3H), 3.60 (s, 3H), 3.35 (s, 
1H); 13C NMR (125 MHz, CDCl3) δ 172.3, 161.3, 158.8, 157.9, 153.8, 141.6, 130.3 
(2C), 130.2 (2C), 129.9, 128.1 (2C), 126.3, 113.0 (2C), 104.7, 94.4, 92.5, 89.1, 80.5, 
79.2, 65.2, 56.8, 56.0, 55.4, 55.2, 51.8; HR-MS: m/z Calcd for [C28H28O8+Na]+ 































Procedure to prepare methyl rocaglate (25) from aglain 4: To a solution of aglain 4 
(107 mg, 0.210 mmol, 1 equiv) in MeOH (4 mL) under an inert atmosphere was added a 
solution of freshly prepared NaOMe in methanol (0.3 M, 1.8 mL, 0.540 mmol, 2.6 equiv) 
at rt. The resulting solution was stirred for 30 min at 60 °C. After removal of the MeOH 
under vacuum, the crude reaction mixture was quenched with a sat. NH4Cl solution (10 
mL) and HCl (1M, 5 mL) giving a yellowish, cloudy solution which was extracted with 
EtOAc (3 x 10 mL). The combined organic layers were then washed with brine (10 mL), 
dried over sodium sulfate, filtered, and concentrated in vacuo to afford quantitatively a 
crude yellow oil (107 mg, 0.24 mmol) which was used without further purification in the 
next step:45 To a solution of trimethoxy-cyclopenta[b]benzofuran keto-rocaglate (107 mg, 
0.21 mmol, 1.0 equiv) in CH3CN (6.0 mL) at 0 °C under inert atmosphere were added 
successively acetic acid (115 µL, 2.10 mmol, 10 equiv) and Me4NBH(OAc)3 (340 mg, 
1.26 mmol, 6 equiv). The resulting yellow solution was stirred for 12 h at 0 °C to rt 
before being quenched with a sat. NH4Cl solution (4 mL). The mixture was then 
extracted with EtOAc (3 x 5 mL) and the combined organic layers were washed with sat. 
NaHCO3 (20 mL), dried over Na2SO4, filtered, and concentrated in vacuo. Note: removal 
of the generated AcOH by a basic wash (NaHCO3) prior to concentration avoided 
degradation of the crude material. The crude material was purified by flash 
chromatography (gradient of EtOAc/hexane, 10:90 → 40:60) to afford methyl rocaglate 
(25) (61 mg, 0.124 mmol, 52% over two steps) and its diastereomer (19 mg, 0.039 mmol, 
(16% over two steps)). 
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2,2,2-trifluoro-1-(pyren-1-yl)ethan-1-one 32: At -78 °C a solution of trifluoroacetic 
anhydride (4.24 ml, 30 mmol, 3 equiv) in methylene chloride (4 ml) was added to a 
solution of boron trifluoride methyl sulfide complex (Me2S·BF3, 3.16 ml, 30 mmol, 3 
equiv) in methylene chloride (20 ml) under argon. After 10 min of stirring, a solution of 
pyrene 31 (2.02 g, 10 mmol, 1 equiv) in methylene chloride (6 ml) is added to the 
mixture. The resulting solution was stirred for an additional 15 min, and the mixture was 
allowed to warm to room temperature and stirred for 24 h. After careful quenching with a 
saturated sodium bicarbonate solution, the mixture was extracted with methylene chloride 
(3 X 50 mL), dried over sodium sulfate, filtered, and concentrated. The mixture was 
purified by column chromatography (hexanes/EtOAc 99:1). Ketone 32 (2.98 g, 65%) was 













catechol borane (1.5 equiv)















(R)-2,2,2-Trifluoro-1-(pyren-1-yl)ethan-1-ol (−)-29: To a stirred solution of 32 (100 
mg, 0.335 mmol, 1 equiv) and (S)-CBS catalyst (0.034 mmol, 0.10 equiv) in toluene at -
78 °C was added a solution of catechol borane (1 M, 0.5 mL, 0.50 mmol, 1.5 equiv) 
dropwise over 20 min.95 The reaction was stirred at -78 °C for 12 h. The reaction was 
quenched with water, and washed with sodium hydroxide (1 N) to remove catechol. The 
organic layer was then acidified and extracted with EtOAc (3 X 15 mL). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and 
concentrated. The resulting crude residue was purified using column chromatography 
(PhMe) to provide (−)-29 as an off white solid (92 mg, 0.306 mmol, 91%) as a white 
solid. [α]27D = −23.8° (literature: [α]20D = −20.6°). All other spectroscopic properties 
were found to be identical to those previously reported.94 Enantiopurity was determined 
by chiral HPLC analysis. (±)-29 was prepared via sodium borohydride reduction as 
previously reported.94  
 
(R)-2,2,2-Trifluoro-1-(phenanthren-9-yl)ethan-1-ol  (−)-30: To a round bottom flask 
was added ground magnesium turnings (removes the oxide coating) (104 mg, 4.28 mmol, 
1.10 equiv), catalytic iodine, and a stir bar. The flask and its contents were then flame 
dried under high vacuum. After cooling, argon was charged and THF (4 mL) was added 
Br
33



















catechol borane (1.5 equiv)








under argon. A solution of 9-bromophenanthrene 33 (1.00 g, 3.89 mmol, 1.00 equiv) in 
THF (2 mL) was added dropwise via cannula. The contents were then heated at 50 °C 
and stirred for 4 h, until all or most of the magnesium was gone. The resulting dark 
mixture was then cooled to -20 °C, and 2,2,2-trifluoro-N-methoxy-N-methylacetamide 35 
(0.470 mL, 3.89 mmol, 1.00 equiv) was added dropwise. The reaction was stirred at this 
temperature for 1 h then warmed up to rt and stirred for an additional 4 h. The flask was 
then cooled to 0 °C, and the reaction was quenched with a saturated ammonium chloride 
solution. The mixture was extracted with EtOAc (3 X 50 mL) and the combined organic 
extracts were washed with brine. After drying over sodium sulfate, the organic phase was 
filtered and concentrated to provide 34 as a crude yellow solid (999 mg, 94%) which was 
taken forward to the next step without further purification. To a stirred solution of 34 
(100 mg, 0.335 mmol, 1 equiv) and (S)-CBS catalyst (0.034 mmol, 0.10 equiv) in toluene 
at -78 °C was added a solution of catechol borane (1 M, 0.5 mL, 0.50 mmol, 1.5 equiv) 
dropwise over 20 min.95 The reaction was stirred at -78 °C for 12 h. The reaction was 
quenched with water, and washed with sodium hydroxide (1 N) to remove catechol. The 
organic layer was then acidified and extracted with EtOAc (3 X 15 mL). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and 
concentrated. The resulting crude residue was purified using column chromatography 
(PhMe) to provide (−)-30 as an off white solid (92 mg, 0.306 mmol, 91%) as a white 
solid. [α]27D = −34.6° (literature: [α]20D = −37.0°).103 All other spectroscopic properties 
were found to be identical to those previously reported.103 Enantiopurity was determined 
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by chiral HPLC analysis. (±)-30 was prepared via sodium borohydride reduction using 
procedures reported by Virgili and coworkers.94 
 
((2R,3R)-1,4-dioxaspiro[4.5]decane-2,3-diyl)bis(bis(perfluorophenyl)methanol) (+)-
36: To a solution of bromopentafluorobenzene 40 (1.00 mL, 8.02 mmol, 4 equiv) in ether 
(30 mL) under argon at -78 oC was added n-BuLi (2.0 M in hexane, 4.0 mL, 8.0 mmol, 
4.0 equiv). After the reaction mixture was stirred from -78 oC to -20 oC for 40 min, a 
solution of ketal-L-tartrate 41 (518 mg, 2.0 mmol, 1 equiv) in ether (20 mL) was added 
dropwise using addition funnel (Caution: reaction mixture internal temperature should 
not exceed 0 oC). The reaction mixture was then stirred from -20 oC to 0 °C for 4 h. The 
reaction was quenched by careful addition of ice and a saturated NH4Cl solution at 0 oC. 
The organic layer was separated and the aqueous layer extracted with ether (3 X 50 mL). 
The combined organic layers were dried over Na2SO4, the solvent was removed in vacuo 
to afford a yellow oil. Purification via flash chromatography (2:8 EtOAc/hexanes) 
affording (+)-36 as a white foam. Recrystallization from petroleum ether provided (+)-36 
as a pure white solid (600 mg, 34%). Spectroscopic data were found to be identical to 























(R, R)-2,2-Cyclohexyl-α, α, α', α'-tetrakis(phenanthren-9-yl)-1,3-dioxolane-4,5-
dimethanol (+)-37. A solution of dimethyl (2R,3R)-1,4-dioxaspiro[4.5]decane-2,3-
dicarboxylate 41 (1.00 g, 3.87 mmol, 1.0 equiv) in THF (10 mL) was added dropwise to a 
solution of (phenanthren-9-yl)magnesium bromide 42 (19.4 mmol, 5 equiv (prepared 
from 4.98 g of 9-bromophenanthrene 33 and 0.46 g of Mg powder and catalytic amount 
of iodine in THF (70 mL) at rt)) at -20 oC under inert atmosphere. The reaction mixture 
was then stirred at rt for 12 h. The reaction was quenched at 0 oC by careful addition of 
ice and a saturated aqueous NH4Cl solution. The organic layer was separated and the 
aqueous layer was extracted with ether (3 X 50 mL). The combined organic extracts were 
dried over Na2SO4 and the solvent was removed in vacuo to afford a yellow oil. The 
TADDOL was purified via flash chromatography using EtOAc/hexanes (20:80). The 
white solid was then recrystallized from CH2Cl2/MeOH (10:90), affording pure 
TADDOL (+)-37 as a white powder (2.036 g, 58%). Spectroscopic data for compound 














Chiral HPLC Analyses 
 
Chiral HPLC Analysis of methyl rocaglate (25): Regis Pirkle covalent (R,R) 
WHELK-O 1 column was used, with an isocratic mobile phase of isopropanol/hexanes 

















Chiral HPLC Analysis of aglain 27: Chiralpak AD column was used, with an isocratic 






















Chiral HPLC Analysis of TFE 29: Chiralcel OD column was used, with an isocratic 













Chiral HPLC Analysis of TFE 30: Chiralcel OD column was used, with an isocratic 









X-ray Structure of (+)-36 
 Crystals of (+)-36 were obtained from slow evaporation of petroleum ether. 
 
   
Table 3.2 Crystal data for (+)-36 
  C34H14F20O4 F(000) = 1720 
Mr = 866.45 Dx = 1.840 Mg m-3 
Orthorhombic, P212121 Cu Ka radiation, l = 1.54178 Å 
Hall symbol:  P 2ac 2ab Cell parameters from 9986 reflections 
a = 12.6546 (5) Å q = 4.1–65.9° 
b = 12.9361 (5) Å m = 1.82 mm-1 
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c = 19.1080 (8) Å T = 134 K 
V = 3128.0 (2)  Å3 Block, colorless 
Z = 4 0.13 × 0.09 × 0.04 mm 
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
5317 independent reflections 
Radiation source: rotating anode 5217 reflections with I > 2s(I) 
multilayer Rint = 0.029 
f & w scans qmax = 66.4°, qmin = 4.1° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -14®14 
Tmin = 0.702, Tmax = 0.753 k = -15®13 
22262 measured reflections l = -20®22 
 
    
Refinement 
  Refinement on F2 Secondary atom site location: difference 
Fourier map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2s(F2)] = 0.021 H-atom parameters constrained 
wR(F2) = 0.054 w = 1/[s2(Fo2) + (0.028P)2 + 0.6237P]   
where P = (Fo2 + 2Fc2)/3 
S = 1.04 (D/s)max = 0.001 
5317 reflections Dñmax = 0.16 e Å-3 
525 parameters Dñmin = -0.16 e Å-3 
0 restraints Absolute structure:  Flack H D (1983), 
Acta Cryst. A39, 876-881 
Primary atom site location: structure-
invariant direct methods 
Flack parameter: 0.03 (5) 
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Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq  
F20 0.19968 (9) 0.89538 (9) 0.42921 (5) 0.0414 (3)  
F26 0.36807 (7) 0.71313 (9) 0.47199 (5) 0.0372 (2)  
F14 -0.40994 (7) 0.82070 (9) 0.66112 (5) 0.0385 (2)  
F13 -0.29189 (7) 0.66704 (8) 0.71787 (5) 0.0351 (2)  
F16 -0.10503 (7) 1.02345 (7) 0.63708 (5) 0.02736 
(19) 
 
F15 -0.31204 (7) 0.99666 (8) 0.61549 (5) 0.0356 (2)  
F18 0.03847 (7) 0.71708 (6) 0.61321 (4) 0.02364 
(18) 
 
F22 0.14163 (8) 1.06784 (7) 0.63977 (5) 0.0348 (2)  
F21 0.21302 (9) 1.06784 (8) 0.51050 (6) 0.0435 (3)  
F19 0.11251 (7) 0.72014 (8) 0.48284 (5) 0.0330 (2)  
F25 0.28261 (7) 0.55316 (8) 0.54247 (5) 0.0317 (2)  
F24 0.23960 (7) 0.56669 (7) 0.67766 (5) 0.0302 (2)  
F27 0.41264 (7) 0.89283 (8) 0.54045 (5) 0.0347 (2)  
F28 0.36932 (7) 0.91125 (7) 0.67628 (5) 0.02724 
(19) 
 
F34 0.36614 (7) 0.96259 (7) 0.81690 (5) 0.0317 (2)  
F33 0.54480 (8) 0.98343 (9) 0.88332 (6) 0.0467 (3)  
F32 0.67922 (8) 0.81988 
(10) 
0.90042 (6) 0.0491 (3)  
F31 0.62388 (8) 0.63139 (9) 0.84911 (6) 0.0400 (3)  
F30 0.44547 (7) 0.60827 (7) 0.77708 (5) 0.0314 (2)  
F12 -0.08741 (7) 0.68843 (6) 0.73676 (5) 0.02584 
(19) 
 
O3 0.03692 (8) 0.98263 (8) 0.74169 (5) 0.0225 (2)  
H3 0.0186 1.0308 0.7148 0.034*  
O4 0.24552 (8) 0.66542 (8) 0.79187 (5) 0.0229 (2)  
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H4 0.2312 0.6750 0.8343 0.034*  
O2 0.19590 (8) 0.84796 (9) 0.85182 (5) 0.0260 (2)  






























0.75538 (7) 0.0189 (3)  





0.77748 (8) 0.0204 (3)  




















































































































0.93644 (8) 0.0283 (3)  
H5A 0.1313 0.7868 0.9742 0.034*  





0.96538 (9) 0.0357 (4)  
H6A -0.0791 0.7365 0.9287 0.043*  
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0.98922 (9) 0.0379 (4)  
H1A -0.0240 0.8917 1.0294 0.045*  





0.93005 (9) 0.0319 (4)  
H2A -0.1081 0.9283 0.8923 0.038*  





0.90049 (8) 0.0240 (3)  
H3A 0.0558 0.9980 0.8603 0.029*  
H3B 0.1026 0.9759 0.9367 0.029*  
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Syntheses of Rocaglate Derivatives and Analogs 
 
4.1  Synthesis of a Rocaglate β-Lactone 
 As previously mentioned in Chapter 1, rocaglamides and rocaglates are 
cyclopenta[b]benzofuran natural products isolated from the genus Aglaia that have been 
shown to be potent anticancer agents. Figure 4.1 shows two natural products, silvestrol 
(1)7 and methyl rocaglate (2),3,4 that have secondary hydroxyls syn-facial and β-
substituted to the ester moiety. Accordingly, we considered that the novel β-lactone 
structure 3 may be derived from methyl rocaglate (2) (Figure 4.2).105 
 
 β-Lactones are an important class of enzyme inhibitors that have found broad 
utility as both chemical probes106 and drugs.107 There are numerous bioactive β-lactones 
found in nature, several of which are widely used in biomedical research, including 
omuralide (lactacystin-β-lactone, 4)105b and lipstatin108 (or lipostatin, 5, Figure 4.2). 
Furthermore, these chemotypes have appeared in the clinical agents salinosporamide A 
Figure 4.1 Rocaglate Natural Products with Secondary Hydroxyls syn-Facial and 























(Marizomib or NPI-0052, 6), a Phase I clinical candidate for cancer, 109  and 
tetrahydrolipstatin (THL or Orlistat) which is currently an approved treatment for 
obesity.110 The mechanism of biological action of β-lactones is typically through covalent 
acylation of a functional nucleophilic residue in the active sites of enzymes to produce 
stable and inactive acyl-enzyme adducts.111 Because these chemotypes show a wide range 
of activities across the serine hydrolase class,112 we wondered if β-lactones derived from 
rocaglates would display a unique pharmacology and present new opportunities for probe 
development for serine hydrolases and other proteolytic enzymes. 
 
 (±)-Methyl rocaglate (2) was synthesized from ESIPT [3+2] photocycloaddition 
of 3-hydroxyflavone 7 and methyl cinnamate 8 (Scheme 4.1). The resulting aglain 9 was 
rearranged to a keto-rocaglate intermediate and subsequently reduced providing (±)-
methyl rocaglate (2). We next evaluated the synthesis of the target rocaglate β-lactone 
structure. Using BOP-Cl/triethylamine,113 we observed the transformation of rocagloic 
acid5 (derived from (±)-methyl rocaglate (2)) to β-lactone (±)-3 (Scheme 4.1). 



































Interestingly, the chemical shifts for H1 and H2 (δ = 5.41 and 4.55 ppm, respectively) 
were found to be further downfield from their respective shifts observed for methyl 
rocaglate (2) (5.01 and 3.88 ppm, respectively) due to deshielding by the β-lactone. The 
coupling constants for H13 are lower than the respective coupling constants observed 
for 2 due to ring strain of the β-lactone. IR analysis (C=O stretch, 1830 cm-1)105a and 
high-resolution mass spectrometry supported the proposed structure of β-lactone 3 which 
was later unambiguously confirmed by X-ray crystal structure analysis (Figure 4.3). 
 

































































4.2 Unexpected Photochemical Di-epimerization 
 With β-lactone 3 in hand, we next studied its reactivity. We first evaluated 
thermolysis of β-lactone (±)-3 to facilitate extrusion of carbon dioxide and observed 
formation of alkene (±)-12 using microwave conditions (Scheme 4.2).114,35 Additionally, 
we explored photochemical methods to extrude carbon dioxide.105c,115 When exposed to 
UV light (>280 nm), β-lactone (±)-3 underwent an unexpected rearrangement to form the 
corresponding di-epi-β-lactone (±)-13 (Scheme 4.3). The relative configuration of isomer 
13 was unambiguously confirmed through X-ray crystal structure analysis (cf. Figure 
4.4). The reaction did not go to complete conversion and irradiation for more than four 
hours led to decomposition. We considered whether 13 was thermodynamically more 
stable; indeed, computational analyses of 3 and 13 showed that β-lactone 13 was 7.0 
kcal/mol lower in energy.68 Single point energies were computed for the X-ray structures 
of 3 and 13 in the gas phase using the B3LYP/6-31G* level of theory. This is mostly 








likely due to the release of strain from caged structure 3 to the staircase structure of 
















Hydrogens omitted for clarity. 






O O hν (λ > 280 nm)
CDCl3, rt, 1 h
67% conversion,
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4.3 Mechanistic Investigations 
 
Further experiments were performed to probe the mechanism of the di-
epimerization process. We considered whether β-lactone 3 could isomerize to 13 in the 
presence of Brnsted acid. However, 3 did not undergo the observed rearrangement when 
subjected to catalytic amounts of camphorsulfonic acid or p-TsOH without irradiation 
with UV light.116 Furthermore, we did not observe a reaction when aqueous HCl was 
added. Previously, Ullman and Wan studied the photosolvolysis of benzylic alcohols in 
methanol.117 We considered that 3 may be undergoing a similar transformation as 
outlined in Figure 4.5(A). A benzylic cation intermediate may be formed from excitation 
of 3 which can then form an ortho-quinone methide cation.118 The electron rich para-
methoxyphenyl moiety of 3 may stabilize the ortho-quinone methide cation for di-
epimerization. Attack by water then gives the di-epimerized product 13. To test this 
hypothesis, 4’-bromo β-lactone 14 (synthesized by Mr. Steve Stone, undergraduate, 
Boston University) and 6,8,4’-tridesmethoxy β-lactone 15 were synthesized from methyl 
Figure 4.5 Possible Mechanisms of the Photochemical Di-epimerization via (A) 


































































rocaglate analogs 1641 and 1727, respectively (Scheme 4.4). When β-lactones 14 and 15 
were subjected to UV light in CDCl3, no reaction was observed after four hours. From 
this data, we hypothesize that an electron rich phenyl ring at C3 is necessary for the 
photochemical di-epimerization to take place and supports the mechanism proposed in 
Figure 4.5(A). 
 
To further test this mechanistic hypothesis, we conducted photochemical 
solvolysis experiments (Scheme 4.5). However, treatment of 3 with methanol (in the 
presence of heat from the lamp) ring-opened the β-lactone to form methyl rocaglate (2) 
which further reacted to form multiple products.  Use of the mildly acidic solvent 
1,1,1,3,3,3-hexafluoroisopropanol (HFIP) (Table 4.1, entry 1) did not afford 
isomerization product 13. If the reaction is indeed proceeding through 


















R1 = OMe, R2 = Br: (±)-16
R1 = R2 = H: (±)-17
R1 = OMe, R2 = Br: (±)-14,  30%, 2 steps
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photodehydroxylation, acidic/hydrogen bonding solvents such as HFIP should facilitate 
the reaction outlined in Figure 4.5(A).117d Irradiation of ()-rocaglaol (20)9 (Scheme 4.5) 
with and without solvent additives also led to complex mixtures that we were unable to 
separate and characterize. 
 

















































 We also considered an alternative mechanism in which photoexcited 3 could 
undergo photoinduced electron transfer (PET)85,119 from the benzofuran ring oxygen to 
the β-lactone carbonyl (Figure 4.5(B)). Examination of the X-ray structure of 3 (cf. 
Figure 4.3) indicates that the cyclopenta[b]benzofuran oxygen of 3 is 2.9 Å from the β-
lactone carbonyl carbon. The resulting radical ion pair may then undergo C3a-C8b bond 
cleavage, C3a inversion, and subsequent cyclization/electron transfer. By screening 
different solvents, we found that the reaction does not proceed when irradiated in toluene 
(Table 4.1, entry 3). However, addition of benzophenone (1 equiv) resulted in a 69% 
yield of (±)-13 (Table 4.1, entry 4). Other sensitizing additives such as 1,4-
dicyanonaphthalene and Michler’s ketone did not afford rearranged 13 (λ > 280 nm, 
toluene used as solvent).119c Selective irradiation of benzophenone also sensitized the 
Table 4.1 Evidence for a PET Mechanism Involved in the Transformation of 




















entry λ (nm) additivea solvent yield (%)b 
1 >280 − HFIP −c 
2 >280 − CDCl3 40 
3 >280 − PhCH3 − 
4 >280 Ph2CO PhCH3 69 
5 315−400 − CDCl3 − 
6 315−400 Ph2CO CDCl3 81 




transformation when using lower energy light (Table 4.1, entries 5 and 6).  When the 
electron-accepting sensitizer benzophenone is used, we propose that electron transfer 
from 3 to triplet-excited benzophenone occurs, thereby generating a radical cation 
rocaglate species that can undergo di-epimerization (Figure 4.6). Although we cannot 
rule out the benzylic cation mechanism (Figure 4.5(A)), the reaction is most likely 
proceeding via a PET mechanism (Figure 4.5(B)) since we achieved the highest yields of 
13 employing benzophenone as sensitizer. 
 
4.4 Activity-Based Protein Profiling of 3 and Analogs 
 With β-lactone (±)-3 and analogs in hand, we next assessed their activity across 
the serine hydrolase class using competitive activity-based protein profiling (ABPP) 
through collaboration with Prof. Benjamin Cravatt (Scripps Research Institute). Serine 
hydrolases are important proteins involved in the proliferative, invasive, and migratory 
properties of tumors.120 Their roles include growth factor activation, extracellular matrix 













































degradation, and angiogenesis. Serine hydrolase protein levels are elevated in cancer cell 
lines and tumors, but the function of these increased levels remains unknown. Activity-
based protein profiling (ABPP) is a method used in chemical biology that elucidates the 
functional state of enzymes including serine hydrolases directly in complex samples such 
as tumor specimens. Fluorophosphonate (FP) biotinylated probes 22121 (Figure 4.7) react 
with serine residues through nucleophilic attack on the electrophilic FP, and the biotin 
moiety permits avidin binding and molecular identification by a mass-spectrometry 
(MS)-based method such as Multidimensional Protein Identification Technology 
(MudPIT).122 ABPP probes selectively label active enzymes, which can be used to 
observe changes in enzyme activities that occur in the cell, independent of alterations in 
transcript or protein abundance. Importantly, ABPP can detect changes in the activity of 
an enzyme that was not previously known to have that activity. This approach has 
identified tumor-associated activities with roles in cell invasion, migration, and 
intravasation123 (the invasion of cancer cells through the basal membrane into the blood 
or lymphatic system). 
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Cravatt and coworkers have treated proteomes derived from human cancer cell 
lines (PC3 and LNCaP) and mouse tissues (brain, liver and testes) with (±)-3 (1.0 µM or 
25 µM) or DMSO for 30 minutes followed by the serine hydrolase-directed activity-
based probe fluorophosphonate-rhodamine (FP-Rh) 22 (cf. Figure 4.7). FP-Rh-labeled 
proteomes were then resolved by SDS-PAGE and imaged using a fluorescent gel scanner.  
This analysis identified multiple serine hydrolase targets of (±)-3, some of which were 
prominently inhibited at 1.0 µM. Notably, these targets were not inhibited by (±)-methyl 
rocaglate (2) and were less sensitive to inhibition by the diastereomeric β-lactone (±)-13, 
analogs ()-14 and ()-15, or THL. 
 Prof. Cravatt and coworkers next applied a quantitative mass spectrometry (MS)-
based platform ABPP-SILAC124 to identify the targets of (±)-3. This analysis identified 
~40 serine hydrolases in PC3 proteomes, four of which were inhibited >75% at 1.0 µM of 
(±)-3: α,β-hydrolase domain-containing 10 (ABHD10), cathepsin A (CTSA), serine 































carboxypeptidase 1 (SCPEP1) and acyl-CoA thioesterases 1/2 (ACOT1/2).  Notably, 
these targets were dose-dependently inhibited by (±)-3 but not by (±)-methyl rocaglate 2. 
Interestingly, CTSA or cathepsin A, one of the primary targets of (±)-3, is also 
known to be inhibited by other β-lactones including omuralide (lactacystin-β-lactone, 4) 
and salinosporamide A (6).112b,125 CTSA has been shown to hydrolyze a variety of 
bioactive peptide hormones, suggesting cathepsin A outside the lysosomes plays a role in 
regulation of bioactive peptide functions.126 Inhibitors for ABHD10 have only recently 
been discovered in competitive ABPP studies of aza-β-lactams.127 That ABHD10 is also 
sensitive to β-lactones128 suggests that strained cyclic esters and amides are particularly 
well-suited for ABHD10 inhibition. ABHD10 has been shown to be responsible for 
deglucuronidation of mycophenolic acid acyl-glucuronide in the liver;129 however, its 
relevance in cancer is not clear. SCPEP1 is a poorly characterized secreted 
carboxypeptidase that appears to be involved in vascular remodeling.130 While lacking 
selective small-molecule inhibitors, SCPEP1 has recently been shown to be targeted by 
the β-lactones omuralide and vibralactone.128 We are not aware of any reported inhibitors 
for ACOT1 or 2.  These enzymes appear to be important for lipid homeostasis through 
the hydrolysis of acyl-CoA species; 131  however, the biological consequences of 
disrupting ACOT1/2 activity is unknown, warranting the pursuit of pharmacological 
inhibitors. 
Having identified several serine hydrolase targets of (±)-3, we next wondered if 
its pure enantiomers would exhibit distinct potency and specificity profiles.  Both 
enantiomers of 3 were accessed via hydrolysis of (±)-methyl rocaglate (2), menthyl ester 
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formation/separation (rocaglates 23 and 24), and subsequent hydrolysis/BOP-Cl coupling 
(Scheme 4.6).47 Testing both enantiomers by competitive ABPP revealed that (–)-3 more 
potently inhibited ABHD10 and ACOT1/2 than the enantiomer (+)-3. 
 
The activity displayed by 3 for poorly characterized enzymes that lack selective 
inhibitors (or even leads), suggests that this agent, as well as derivatives thereof, could 
serve as valuable chemical probes.  To achieve this goal, however, 3 would need to 
exhibit inhibitory activity in situ. Accordingly, the Cravatt lab treated PC3 cells with 
DMSO or increasing concentrations of (–)-3, and, after two hours, the cells were 
harvested, lysed, and treated with FP-Rh 22 for gel-based ABPP. From this analysis, 
greater than 90% blockage of ABHD10 activity at 100 nM with greater than 10-fold 
selectivity over ACOT1/2, which was also inhibited at higher in situ concentrations of (
)-3 was observed. These data demonstrate that (–)-3 is highly active as a serine hydrolase 
inhibitor in cells. 




































































4.5 Biotinylated Derivatives to Determine the Molecular Target of 
Rocaglates 
 In collaboration with Dr. Luke Whitesell (Whitehead Institute), we proposed to 
synthesize and test biotinylated rocaglate derivatives 25 and 26 to test the hypothesis that 
rocaglates inhibit translation through direct, noncovalent interaction with eIF4A, an RNA 
helicase39 (Figure 4.8). Having two distinct derivatives (each with a pendant biotin 
moiety linked on opposite ends of the molecule) could elucidate which end of the 
rocaglate scaffold is binding to its protein target (e.g. eIF4A). A pendant biotin moiety 
was not installed on the 4’ position of the molecule since previous studies have shown 
this position to be critical for activity.41,43,52 Biotin has a strong affinity for the protein 
avidin, which can be immobilized and used to determine molecular targets for 
biotinylated analogs.132 During the course of these studies, Rizzacasa and coworkers 
synthesized biotinylated silvestrol analog 27, and indeed found that this compound 
selectively binds with eIF4A from mouse embryo fibroblasts (Figure 4.9).133 It is also 
important to point out that Rizzacasa and coworkers did not pull down prohibitins I and II 
(PHBs) from the cell lysates, which are the targets that Désaubry and coworkers 
identified as the main targets of rocaglamides.134 PHBs I and II are scaffolding proteins 
that interact with each other and with Ras and c-Raf. Moreover, PHBs are localized in 
different organelles and areas of the cell. In mitochondria, PHBs regulate respiration and 
protein metabolism. In the nucleus, PHBs interact with various proteins to regulate 
transcription and DNA synthesis. When PHBs are localized in the cytoplasm, they 
regulate signaling proteins including c-Raf, Akt, and MLK2.135 Désaubry and coworkers 
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report that binding of rocaglamides to PHBs prevents interaction between PHBII and 
CRaf. This inhibits CRaf activation and subsequently CRaf-MEK-ERK signaling that is 
upstream of the eIF4F complex. 
 
 Synthesis of the C2 linker 25 commenced with EDCI coupling of (±)-rocagloic 
acid 28 and azide 29 providing 30 in 32% (Scheme 4.7). Azide 29 was synthesized by 
Dr. Christina Rodrigo of the Porco laboratory from alkyl halide 31 and 
hydroxycarbamate 32. Huisgen 1,3-dipolar cycloaddition136 proceeded in 37% yield after 
filtering through silica/celite and purification via reverse phase chromatography. 
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Biotinylated 25 was isolated as a 1:1 mixture with diastereomer 33 as a consequence of 
using racemic rocagloic acid (28) with enantiopure biotin 34.  
 
 The 6-O biotinylated rocaglate 26 was prepared from the previously synthesized 
compound 3531 through coupling with chloride 36 (Scheme 4.8). Saponification and 
amide coupling with methoxyamine 38 provided hydroxamate 39 in 54% yield. Huisgen 
[3+2] between azide 39 and alkyne 34 formed 26 and diastereomer 40 in 34% yield. 

















































































L-ascorbic acid (1 equiv)
























 With the two biotinylated derivatives in hand, Dr. Luke Whitesell (Whitehead 
Institute) tested these compounds for translation inhibition and found the C2 linked 25/33 
mixture to be more active than the 6-O linked 26/40 mixture. Prof. Jerry Pelletier and 
coworkers (McGill University) also observed that the C2-linked biotinylated mixture 
25/33 to be more potent in their Cap-dependent and IRES-dependent in vitro translation 
assays.45 When these biotinylated derivatives were applied in the streptavidin pull down 
assay, 26/40 pulled down eIF4G and tubulin and 25/33 did not pull down any proteins 
involved in the eIF4F complex. The eukaryotic translation initiation factor eIF4G plays 
an important role in translation initiation serving as a scaffolding protein binding several 
other initiation factors in the eIF4F complex, other proteins as well as RNA.39,40, 137 



















































L-ascorbic acid (1 equiv)





























































Furthermore, recent work has shown that eIF4G contains a low affinity binding domain 
close to the entrance of the ATP binding domain of eIF4A, suggesting that eIF4G also 
binds to ATP and further enhances eIF4A activity.137 We planned to synthesize the 
enantiopure rocagloic acid 28 and phenol 35 to make single diastereomers of the 
rocaglate biotin derivatives, but after Rizzacasa and coworkers’ publication133 the 
significance of the study was diminished. The binding of eIF4G with 6-O linked 26/40 
may represent the mechanism of translation inhibition of hydroxamate rocaglates as 
eIF4G binds to the RNA helicase eIF4A, which may prevent the eIF4F assembly from 
fully forming. However, the higher potency of C2-linked 25/33 and its lack of targets 
being pulled down creates more questions than answers that may be addressed by 
simplifying the diastereomeric mixture. 
4.6 Summary 
 In summary, the synthesis, unexpected light-driven di-epimerization, and 
biological evaluation of a novel rocaglate-derived β-lactone and β-lactone analogs have 
been achieved. In addition to in vitro inhibition of the serine hydrolases ABHD10 and 
ACOT1/2, the most potent β-lactone enantiomer was found to inhibit ABHD10 in PC3 
cells, suggesting that derivatives of this β-lactone may serve as valuable chemical probes. 
The mechanism of the photochemical di-epimerization was investigated and may be 
occurring through photoinduced electron transfer (PET). 
Two biotinylated rocaglate derivatives have been synthesized and evaluated in a 
streptavidin pull down assay to determine the molecular target of rocaglates. eIF4G and 
tubulin were pulled down by one of the biotinylated analogs, but eIF4A was not pulled 
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down by any of the biotinylated analogs. The study may show that eIF4G is a relevant 
target of hydroxamate rocaglamides, but this study is currently inconclusive. Overall, the 
studies presented in this writing underscore how valuable rocaglamides and analogs are 
as potential therapeutics and means to advance the field of organic synthesis. 
4.7 Experimental Section  
General Information: 1H NMR spectra were recorded at 300, 400, or 500 MHz at 
ambient temperature with CDCl3, CD3OD, DMSO-d6 or benzene-d6 (Cambridge Isotope 
Laboratories, Inc.) as solvents. Data for 1H NMR are reported as follows: chemical shift, 
integration, multiplicity (br = broad, ovrlp = overlapping, s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet) and coupling constants in Hz. 13C NMR spectra were 
recorded at 75.0, 100.0, or 125 MHz at ambient temperature with the same solvents 
unless otherwise stated. Chemical shifts are reported in parts per million relative to the 
deuterated solvents. All 13C NMR spectra were recorded with complete proton 
decoupling. Infrared spectra were recorded on a Nicolet Nexus 670 FT-IR 
spectrophotometer. High-resolution mass spectra were obtained in the Boston University 
Chemical Instrumentation Center using a Waters Q-TOF API-US mass spectrometer. 
Melting points were recorded on a Mel-Temp apparatus (Laboratory Devices). Analytical 
LC-MS was performed on a Waters Acquity UPLC (Ultra Performance Liquid 
Chromatography (Waters MassLynx Version 4.1) with a Binary solvent manager, SQ 
mass spectrometer, Water 2996 PDA (PhotoDiode Array) detector, and ELSD 
(Evaporative Light Scattering Detector). An Acquity UPLC BEH C18 1.7 m column 
was used for analytical UPLC-MS. Optical rotations were recorded on an AUTOPOL III 
 232 
digital polarimeter at 589 nm, and specific rotations are given [α]D20 (concentration in 
grams/100 mL solvent). Chiral HPLC analysis of enantioenriched compounds was 
performed using a Waters 1525 Binary HPLC Pump with a Waters 2487 diode array 
detector. Preparative HPLC was performed on a Gilson PLC2020 using a Waters 
SunFire™ Prep C18 OBD™ 5µm 19X50 mm column. 
Analytical thin layer chromatography was performed using 0.25 mm silica gel 60-
F plates. Flash chromatography was performed using 200-400 mesh silica gel (Scientific 
Absorbents, Inc.). Yields refer to chromatographically and spectroscopically pure 
materials, unless otherwise stated. HPLC grade tetrahydrofuran, methylene chloride, 
diethyl ether, toluene, acetonitrile, and benzene were purchased from Fisher and VWR 
and were purified and dried by passing through a PURE SOLV® solvent purification 
system (Innovative Technology, Inc.). Other ACS grade solvents for chromatography 
were purchased from Clean Harbors.  
Photochemistry experiments were performed using a Rayonet RPR-100 
photochemical reactor equipped with RPR-3500 irradiation lamps (UVA 315-400 nm). 
Other photochemical reactions were performed in enclosed box using a Hanovia 450 W 
medium pressure mercury lamp housed in a quartz immersion well, cooled with a 
Thermo Neslab-ULT 80 system circulator. Pyrex test tubes (16 x 100 mm) were mounted 
on a support approximately 5.0 cm from the immersion well lamp. All other reactions 






one 3: To a 50 mL flask charged with a stir bar was added methyl rocaglate (2)45 (82 mg, 
0.16 mmol, 1.0 equiv) and THF (6.0 mL). To the stirring solution was added a solution of 
LiOH (20.0 mg, 0.83 mmol, 5.0 equiv) in water (4.0 mL). The resulting yellow solution 
was then heated at 60 °C for 5 h. The reaction was then cooled to rt, and diethyl ether (5 
mL) and hydrochloric acid (1 N) were added. Hydrochloric acid (1 N) was added until 
the water layer reached a pH of ~ 2 (3 mL). The organic phase was then separated and the 
aqueous layer was then further extracted with diethyl ether (3 X 10 mL). The combined 
organic layers were washed with brine, dried over soldium sulfate, filtered and 
concentrated in vacuo to afford rocagloic acid (27) as a yellow foam (79 mg, 
quantitative). The crude product was used in the next step without further purification. A 
dry 10 mL flask was charged with rocagloic acid (79 mg, 0.16 mmol, 1.0 equiv) from the 
previous step, a stir bar, and dichloromethane under argon. The resulting solution was 
then cooled to 0 °C. Triethylamine (69 µL, 0.50 mmol, 3.0 equiv) and bis(2-oxo-3-
oxazolidinyl)phosphinic chloride (BOP-Cl, 55 mg, 0.22 mmol, 1.3 equiv) were 




















65%, 2 steps  
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mL) and CH2Cl2 (4 mL) were added and the organic phase was separated. The aqueous 
layer was then further extracted with CH2Cl2 (3 X 10 mL). The combined organic layers 
were washed with dried over sodium sulfate, filtered and concentrated in vacuo to afford 
a yellow foam. Please note that without the aqueous workup (i.e. directly loading the 
concentrated reaction mixture on silica) we observed a significantly diminished yield of 3 
after chromatography. The crude yellow solid was purified by column chromatography 
(elutes at 35:65 EtOAc/hexanes) to afford β-lactone 3 as a white solid (49 mg, 0.11 
mmol, 65%). The product was crystallized via slow evaporation from toluene. Rf = 0.48 
(1:1 EtOAc/hexanes); m.p. 184-185 ºC; IR νmax (film): 3438, 2939, 2839, 1830, 1600, 
1514, 1454, 1252, 1218, 1182, 1147, 1128, 1037, 819, 735 cm-1; 1H NMR (400 MHz, 
CDCl3) d 7.15-7.14 (ovrlp m, 3H), 7.03 (d, J = 8.8 Hz, 2H), 6.98-6.95 (m, 2H), 6.64 (d, J 
= 8.8 Hz, 2H), 6.24 (d, J = 2.0 Hz, 1H), 6.09 (d, J = 2.0 Hz, 1H), 5.41 (d, J = 5.0 Hz, 1H), 
4.55 (dd, J = 5.6, 5.0 Hz, 1H), 4.10 (d, J = 5.6 Hz, 1H), 3.82 (s, 3H), 3.81 (s, 3H), 3.70 (s, 
3H), 2.64 (s, 1H); 13C NMR (100 MHz, CD3Cl) d 169.3, 164.2, 160.0, 159.0, 157.7, 
137.1, 128.8 (2C), 128.7 (2C), 128.2 (2C), 127.3, 126.6, 112.9 (2C), 108.1, 106.8, 93.1, 
89.8, 89.7, 83.0, 60.3, 55.8, 55.7, 55.2, 54.8; HR-MS: m/z Calcd for [C27H24O7+H]+ 
461.1600, found 461.1597 (-0.65 ppm). 
 
(±)-(3S,3aR,8bR)-6,8-Dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-3,3a-dihydro-8bH-



















0.024 mmol, 1 equiv), a stir bar, and N,N-dimethylacetamide (0.5 mL). The mixture was 
then heated at 180 °C for 10 min. Water was then added (2 mL) and the mixture was 
extracted with EtOAc (3 X 5 mL). The combined organic extracts were then washed with 
a 1:4 mixture of brine/water (3 X 5 mL), washed with brine, and dried over sodium 
sulfate. The extracts were then filtered and concentrated in vacuo to afford a yellow 
foam. The crude solid was then purified by column chromatography (3:7 EtOAc/hexanes) 
to afford a white solid (9 mg, 0.022 mmol, 90%). Rf = 0.16 (25:75 EtOAc/hexanes); m.p. 
130−133 ºC; IR νmax (film): 3463, 2956, 1614, 1600, 1514, 1499, 1453, 1247, 1219, 
1201, 1147, 1111, 1031, 814 cm-1; 1H NMR (400 MHz, CDCl3) d 7.18 (d, J = 8.8 Hz, 
2H), 7.12−7.01 (ovrlp m, 5H), 6.60 (d, J = 8.8 Hz, 2H), 6.55 (dd, J = 6.2, 2.6 Hz, 1H), 
6.30 (dd, J = 6.2, 2.0 Hz, 1H), 6.28 (d, J = 2.0 Hz, 1H), 6.09 (d, J = 2.0 Hz, 1H), 4.37 
(dd, J = 2.6, 2.0 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.67 (s, 3H), 1.90 (s, 1H); 13C NMR 
(125 MHz, CD3Cl) d 163.5, 160.3, 158.6, 157.3, 139.2, 135.5 133.8, 128.6 (2C), 128.1 
(2C), 127.9 (2C), 127.6, 126.5, 112.6 (2C), 109.7, 106.8, 92.5, 92.1, 89.1, 62.0, 55.8, 






one 13: Procedure (A): To an NMR tube was added a solution of 3 (10 mg, 0.022 mmol, 
1 equiv) in CDCl3 (1.0 mL). The solution was then degassed with argon for 2 min and 
sealed. The sample was then irradiated using the Hanovia lamp set up (vide supra) at rt 
for 1 h and the reaction was monitored using 1H NMR. Please note that an NMR tube was 
used not only for reaction monitoring, but also for a higher conversion due to the better 
surface area/volume ratio than that of a test tube.  The reaction mixture was concentrated 
and purified via preparative TLC (3:7 EtOAc/hexanes, two migrations) to afford β-
lactone 13 as a white solid (4 mg, 0.0087 mmol, 40%). β-Lactone 3 was recovered (2 mg, 
0.0043 mmol, 20%). Procedure (B):To a test tube was added β-lactone 3 (11 mg, 0.024 
mmol), benzophenone (4 mg, 0.024 mmol, 1 equiv) and CDCl3 (1.0 mL). After degassing 
for 2 min with N2, the solution was then irradiated in the Rayonet photoreactor for 2.5 h 






O O hν (λ > 280 nm)
CDCl3, rt, 1 h
67% conversion,
40% isolated yield









hν (315 < λ < 400 nm)








preparative TLC (3:7 EtOAc/hexanes, two migrations) to afford β-lactone 13 as a white 
solid (9 mg, 0.020 mmol, 81%). Compound 13 was crystallized by vapor diffusion using 
benzene/hexanes. Rf = 0.52 (1:1 EtOAc/hexanes); m.p. 125 ºC; IR νmax (film): 3466, 
2939, 2839, 1827, 1597, 1514, 1201, 1150 cm-1; 1H NMR (400 MHz, CDCl3) d 7.50 (d, J 
= 8.8 Hz, 2H), 7.12 (br t, J = 7.0 Hz, 1H), 6.97 (d, J  = 8.8 Hz, 2H), 6.73 (br dd, J = 7.0, 
7.0 Hz, 2H), 6.03 (d, J = 2.0 Hz, 1H), 5.72 (d, J = 4.6 Hz, 1H), 5.40 (d, J = 2.0 Hz, 1H), 
4.49 (br d, J = 2.0 Hz, 1H), 4.34 (dd, J = 4.6, 2.0 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.61 
(s, 3H), 2.19 (s, 1H); 13C NMR (100 MHz, CD3Cl) d 169.8, 164.7, 162.0, 159.9, 157.9, 
137.9, 129.3, 128.6 (2C), 128.3 (2C), 127.7 (2C), 127.0, 114.0 (2C), 104.7, 102.1, 92.7, 
88.2, 88.0 (2C), 77.5, 59.3, 55.7, 55.4, 53.2; HR-MS: m/z Calcd for [C27H24O7-H2O]+ 
443.1495, found 443.1490 (-1.1 ppm). 
(±)-(2aR,3S,3aR,8bS,8cR)-8b-hydroxy-3,3a-diphenyl-3,3a,8b,8c-
tetrahydrooxeto[2',3':3,4]cyclopenta[1,2-b]benzofuran-2(2aH)-one 15: β-Lactone 15 
was prepared using the same procedure for β-lactone 3 starting from known methyl 
rocaglate derivative 1727 (60.0 mg, 0.154 mmol). Compound 15 was purified using 
column chromatography (elutes with 25:75 EtOAc/hexanes) and was isolated as a white 
solid (32.0 mg, 0.0864 mmol, 56%).  Rf = 0.23 (25:75 EtOAc/hexanes); m.p. 














56%, 2 steps  
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1204, 1113, 1020, 931, 803, 753, 698 cm-1; 1H NMR (400 MHz, CDCl3) d 7.42-7.34 
(ovrlp m, 2H), 7.18-7.02 (ovrlp m, 10H), 6.96-6.92 (m, 2H), 6.95-6.93 (m, 2H), 5.46 (d, J 
= 5.6 Hz, 1H), 4.62 (dd, J = 5.6, 5.6 Hz, 1H), 4.16 (d, J = 5.6 Hz, 1H), 2.02 (s, 1H); 13C 
NMR (100 MHz, CD3Cl) d 168.6, 157.9, 136.8, 133.9, 131.5, 128.7 (2C), 128.3 (2C), 
128.1, 128.0 (2C), 127.9, 127.5, 127.2 (2C), 125.8, 122.5, 111.7, 107.0, 90.0, 82.6, 60.4, 




one 3: Menthyl ester 23 was prepared from (±)-methyl rocaglate (2) using previously 
reported methods.47 A round bottom flask was charged with menthyl ester 23 (12.0 mg, 
0.0194 mmol, 1.0 equiv), DMSO (0.7 mL), and a stir bar under argon. A 2.8 N aqueous 
solution of NaOH (60 µL, 0.168 mmol, 8.7 equiv) was then added at rt. The resulting 
mixture was heated at 60 °C for 3 h. The reaction was cooled to room temperature, 
acidified to pH ~ 1 using 1N HCl, and extracted with ethyl ether (3 x 10 mL). The 
combined organic extracts were washed with 1N HCl (4 x 5 mL). The organic phase was 
dried with sodium sulfate and concentrated. ()-Rocagloic acid (28) was purified by 
column chromatography (MeOH/CH2Cl2 2.5:97.5, then flushed with EtOAc/MeOH 9:1) 

























()-rocagloic acid (28) using the same procedure to prepare ()-3 from ()-rocagloic 
acid (28). Enantiopurity was determined using analytical chiral HPLC (> 97% ee). [
]D26 = − 218.2° (c = 0.1, CHCl3); other spectroscopic data for compound (−)-3 were 
found to be identical to its racemate (see above). 
 (+)-(2aR,3S,3aR,8bS,8cR)-8b-Hydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-
phenyl-3,3a,8b,8c-tetrahydrooxeto[2',3':3,4]cyclopenta[1,2-b]benzofuran-2(2aH)-
one 5: Menthyl ester 24 was prepared from (±)-methyl rocaglate (2) using previously 
reported methods.47 A round bottom flask was charged with menthyl ester 24 (33.0 mg, 
0.0535 mmol, 1.0 equiv), DMSO (2.0 mL), and a stir bar under argon. A 2.8 N aqueous 
solution of NaOH (152 µL, 0.426 mmol, 8.0 equiv) was then added at rt. The resulting 
mixture was heated at 60 °C for 3 h. The reaction was cooled to room temperature, 
acidified to pH ~ 1 using 1N HCl, and extracted with ethyl ether (3 x 10 mL). The 
combined organic extracts were washed with 1N HCl (4 x 5 mL). The organic phase was 
dried with sodium sulfate and concentrated. (+)-Rocagloic acid (28) was purified by 
column chromatography (MeOH/CH2Cl2 2.5:97.5, then flushed with EtOAc/MeOH 9:1) 
to provide a white solid (14.0 mg, 0.0293 mmol, 55%). (+)-β-Lactone 3 was prepared 
from (+)-rocagloic acid (28) using the same procedure to prepare ()-3 from ()-

























ee). []D26 = +218.2° (c = 0.1, CHCl3); other spectroscopic data of compound (+)-3 are 




cyclopenta[b]benzofuran-2-carboxamide 30: To a flask was added azide 29 (58.0 mg, 
0.191 mmol, 3 equiv), a solution of rocagloic acid (28) (23 mg, 0.0481 mmol, 1 equiv) in 
DMF (1 mL). EDCI (13.2 mg, 0.0690 mmol, 1.5 equiv), HOBt hydrate (9.16 mg, 0.0598 
mmol, 1.2 equiv) and triethylamne (26.8 µL, 0.191 mmol, 3 equiv) and stirred at rt for 12 
h. HCl aq. solution was added (1N, 1 mL), extracted with ethyl acetate (3 X 10 mL). The 
organic extracts were washed with a 10% brine/water solution (3 X 10 mL) to remove as 
much DMF as possible, then washed with brine. The organic extract was dried over 
sodium sulfate, filtered, and concentrated. Purification with prep TLC (5:95 
MeOH/CH2Cl2) provided 30 as a white solid (10 mg, 32%). Rf = 0.4 (5:95 
MeOH/CH2Cl2); 1H NMR (400 MHz, (CD3)2CO) δ 7.14 (d, J  = 8.4 Hz, 2H), 7.03 (ovrlp 
m, 5H), 6.62 (d, J = 8.4 Hz, 2H), 6.26 (d, J =2.0 Hz, 1H), 6.16 (d, J = 2.0 Hz, 1H), 4.80 
































3.62 (ovrlp m, 10H) 3.39 (ovrlp m, 2H), 2.78 (s, 1H). LR-MS: m/z Calcd for 









phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-2-carboxamide 33: To an 
HPLC vial was added 30 (4.5 mg, 0.0069 mmol, 1 equiv), t-BuOH (500 µL), water (250 
µL) and a stir bar. Biotinylated alkyne 34 (4.1 mg, 0.00776 mmol, 1.5 equiv) was then 










O N( )3 N N
CuSO4 (50 mol%)
L-ascorbic acid (1 equiv)















































sodium L-ascorbate (1.4 mg, 0.00692 mmol, 1 equiv), and TBTA ligand (1.8 mg, 
0.00346 mmol, 50 mol%) were added. The resulting mixture was stirred for 24 h. Filtered 
through celite/silica plug (7:3 EtOAc/MeOH) then purified 25/33 as a white solid using 
prep HPLC (3 mg, 37%). 1H NMR (400 MHz, (CD3OD) δ 7.88 (s, 1H), 7.34 (m, 2H), 
7.12 (d, J = 8.8 Hz, 2H), 7.01 (ovrlp m, 3H), 6.92 (d, J = 6.5 Hz, 2H), 6.62 (d, J = 8.8 Hz, 
2H), 6.28 (d, J = 2.0 Hz, 1H), 6.17 (d, J = 2.0 Hz, 1H), 5.53 (m, 1H), 4.78 (d, J = 2.0 Hz, 
1H), 6.17 (d, J = 2.0 Hz, 1H), 5.53 (m, 1H), 4.78 (d, J = 6.5 Hz, 1H), 4.51 (dd, J = 10.5, 5 
hz, 2H), 4.45 (m, 1H), 4.40 (m, 2H), 4.27 (m, 2H), 3.84 (m, 3H), 3.83 (s, 3H), 3.81 (s, 
3H), 3.71 (m, 3H), 3.66 (s, 3H), 3.59 (s, 3H), 3.58 (ovrlp m, 8H), 3.51 (ovrlp m, 4H), 
3.30 (dd, J = 10.5 Hz, 5.5 Hz), 3.18 (m, 2H), 2.90 (dd, J = 13.0, 5.0 Hz, 2H), 2.68 (d, J = 
13.0 Hz, 2H), 2.44 (dd, J = 12.0, 6.0 Hz, 2H), 2.20 (dd, J = 14.5 Hz, 7.0 Hz, 2H), 1.62 
(ovrlp m, 5H), 1.42 (m, 2H). LR-MS: m/z Calcd for [C57H78N8O17S+H]+ 1179.5284, 




2-carboxylate 37: Phenol 35 was prepared according to previous literature reports.31,32 
































carbonate (3.2 mg, 0.023 mmol, 1.1 equiv), azide 36 (6 mg, 0.021 mmol, 1 equiv), DMF 
(300 µL), and a stir bar. The reaction was sealed and heated to 100 °C for 12 h. The 
reaction was cooled and concentrated with high vacuum and purified by prep TLC (1:1 
hexanes/EtOAc)to provide 37 as a white solid (7.0 mg, 57%). 1H NMR (400 MHz, 
(CDCl3) δ 7.10 (d, J  = 8.8 Hz, 2H), 7.05 (ovrlp m, 3H), 6.87 (m, 2H), 6.67 (d, J = 8.8 
Hz, 1H), 6.28 (d, J = 2.0 Hz, 1H), 6.18 (d, J = 2.0 Hz, 1 H), 5.02 (d, J = 6.4 Hz, 1H), 4.17 
(ovrlp m, 2H), 3.89 (ovrlp m, 3H), 3.87 (s, 3H), 3.77 (m, 2H), 3.71 (s, 3H), 3.71 (m, 1H), 




carboxamide 39: To an HPLC vial was added 37 (7 mg, 0.012 mmol, 1 equiv), 1,4-
dioxane (100 µL), LiOH (2.8 mg, 0.118 mmol, 10 equiv), water (1 drop), and a stir bar. 
The reaction was stirred and heated to 60 °C for 12 h. The mixture was diluted with 1:9 
MeOH/CH2Cl2 and filtered through silica gel. The filtrate was concentrated and the 
carboxylic acid was used in the next reaction without further purification. To an HPLC 
vial was added methoxylamine hydrochloride 38 (6 mg, 0.0718 mmol, 6 equiv), EDCI 
































54%, 2 steps  
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stir bar. To the mixture was added the carboxylic acid generated from saponification of 
37 (0.012 mmol, 1 equiv) in methylene chloride (0.3 mL) and triethylamine (10 µL, 
0.0719 mmol, 6 equiv). The resulting mixture was stirred at rt for 2 d, then quenched with 
1 N HCl (0.1 mL). The mixture was concentrated, and purified with prep TLC (4:96 
MeOH/CH2Cl2) to provide 39 as a white solid (4 mg, 54%). 1H NMR (400 MHz, 
(CDCl3) δ 8.53 (s, 1H), 7.12 (d, J = 8.6 Hz, 2H), 7.07 (ovrlp m, 3H), 6.96 (m, 2H), 6.66 
(d, J = 8.6 Hz, 2H), 6.28 (d, J = 2.0 Hz, 1H), 6.19 (d, J = 2.0 Hz, 1H), 4.96 (m, 1H), 4.18 
(dd, J = 10.0, 4.8 Hz, 2H), 4.15 (m, 1 H), 3.89 (ovrlp m, 3H), 3.88 (s, 3H), 3.78 (m, 1 H), 
3.77 (dd, J = 10.0, 4.8 Hz, 2H), 3.71 (s, 3H), 3.54 (br s, 3H), 3.44 (dd, J =10.0 Hz, 4.8 

















































L-ascorbic acid (1 equiv)



































2,3,3a,8b-tetrahydro-1H-cyclopenta[b]benzofuran-2-carboxamide 40: To an HPLC 
vial was added 39 (2.0 mg, 0.0033 mmol, 1 equiv), t-BuOH (200 µL), water (100 µL) 
and a stir bar. Biotinylated alkyne 34 (1.6 mg, 0.00776 mmol, 1.5 equiv) was then added 
and stirred. Copper sulfate pentahydrate (0.5 mg, 0.0017 mmol, 50 mol%) and sodium L-
ascorbate (0.7 mg, 0.0033 mmol, 1 equiv), and TBTA ligand (0.8 mg, 0.0015 mmol, 50 
mol%) were added. The resulting mixture was stirred for 24 h. Filtered through 
celite/silica plug (7:3 EtOAc/MeOH) then purified 26/40 as a white solid using prep 
HPLC (1.2 mg, 34%). LR-MS: m/z Calcd for [C55H74N8O16S+H]+ 1135.5021, found 
1136 (+438.5 ppm). 
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Analysis of (−)-3 and (+)-3: Chiral HPLC analysis of ()-3: Regis Pirkle covalent (R,R) 
WHELK-O 1 column was used, with an isocratic mobile phase of isopropanol/hexanes 





































X-ray Crystallographic Data 
X-ray crystallographic data for (±)-3 
 
 
Crystals of compound (±)-3 suitable for X-ray analysis were obtained by slow 
evaporation from toluene. Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC # 943262). Copies of the data can be obtained free 
of charge through application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK 
(fax: (+44)- 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Table 4.2 Crystal data and structure refinement for β-lactone 3. 
Identification code 3 
Crystal data 
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  C27H24O7 V = 2225.7 (2)  Å3 
Mr = 460.46 Z = 4 
Monoclinic, P21/n Cu Kα radiation, λ = 1.54178 Å 
a = 13.0969 (8) Å µ = 0.82 mm-1 
b = 10.2768 (7) Å T = 100 K 
c = 17.7108 (11) Å 0.3 × 0.1 × 0.03 mm 
β = 110.980 (3)°  
 
    
Data collection 
  Bruker Proteum-R  
diffractometer 
3761 independent reflections 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
3242 reflections with I > 2s(I) 
Tmin = 0.691, Tmax = 0.753 Rint = 0.052 
23432 measured reflections  
 
    
Refinement 
  R[F2 > 2σ(F2)] = 0.048 0 restraints 
wR(F2) = 0.123 H atoms treated by a mixture of 
 251 
independent and constrained refinement 
S = 1.14 Δ〉max = 0.31 e Å-3 
3761 reflections Δ〉min = -0.22 e Å-3 
313 parameters  
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 


































0.88130 (9) 0.0252 (3)  
H6 0.370 (2) 0.248 (3) 0.8742 (16) 0.038*  





0.9449 (2) 0.97883 
(14) 
0.0330 (5)  
H1A 0.2993 0.9627 0.9288 0.050*  
H1B 0.4027 1.0251 0.9981 0.050*  
H1C 0.3338 0.9124 1.0201 0.050*  
C2 0.38618 
(17) 
0.7300 (2) 0.93617 
(12) 
0.0238 (5)  
C3 0.27690 
(17) 
0.6999 (2) 0.92154 
(12) 
0.0233 (5)  
H3 0.2271 0.7612 0.9291 0.028*  
C4 0.24630 
(16) 
0.5742 (2) 0.89514 
(11) 
0.0213 (4)  
C5 0.15559 
(17) 
0.3824 (2) 0.88577 
(12) 
0.0229 (5)  
C6 0.17561 
(16) 
0.3474 (2) 0.97355 
(12) 
0.0225 (5)  
C7 0.22874 
(18) 
0.2338 (2) 1.01083 
(13) 
0.0267 (5)  
H7 0.2518 0.1726 0.9801 0.032*  
C8 0.24849 0.2087 (2) 1.09164 0.0308 (5)  
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(18) (14) 
H8 0.2873 0.1325 1.1162 0.037*  
C9 0.21173 
(18) 
0.2947 (2) 1.13715 
(13) 
0.0310 (5)  
C10 0.1889 (2) 0.3419 (3) 1.26197 
(16) 
0.0514 (8)  
H10A 0.2180 0.4303 1.2647 0.077*  
H10B 0.2081 0.3070 1.3168 0.077*  
H10C 0.1091 0.3439 1.2355 0.077*  
C11 0.05132 
(17) 
0.3250 (2) 0.82092 
(12) 
0.0263 (5)  
H11 -0.0136 0.3773 0.8197 0.032*  
C12 0.07092 
(18) 
0.3452 (2) 0.74117 
(13) 
0.0282 (5)  
H12 0.0336 0.2794 0.6987 0.034*  
C13 0.19450 
(18) 
0.3547 (2) 0.76042 
(13) 
0.0261 (5)  
H13 0.2245 0.2874 0.7332 0.031*  
C14 0.06962 
(19) 
0.4825 (3) 0.70820 
(13) 
0.0327 (5)  





0.4834 (2) 0.88265 
(11) 
0.0207 (4)  
C17 0.42213 
(16) 
0.5170 (2) 0.89473 
(11) 
0.0212 (4)  
C18 0.59190 
(17) 
0.4541 (2) 0.88465 
(13) 
0.0286 (5)  
H18A 0.5913 0.5261 0.8482 0.043*  
H18B 0.6267 0.3779 0.8708 0.043*  
H18C 0.6329 0.4799 0.9406 0.043*  
C19 0.45886 
(17) 
0.6408 (2) 0.92346 
(12) 
0.0228 (5)  
H19 0.5329 0.6645 0.9344 0.027*  
C20 0.03269 
(17) 
0.1840 (2) 0.83627 
(13) 
0.0279 (5)  
C21 0.08037 
(18) 
0.0824 (2) 0.80873 
(13) 
0.0288 (5)  
H21 0.1255 0.1012 0.7784 0.035*  
C22 0.06290 
(19) 
-0.0460 (2) 0.82499 
(14) 
0.0340 (6)  
H22 0.0952 -0.1143 0.8051 0.041*  
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C23 -0.0011 (2) -0.0749 (3) 0.86973 
(15) 
0.0422 (6)  
H23 -0.0126 -0.1628 0.8811 0.051*  
C24 -0.0484 (2) 0.0249 (3) 0.89801 
(17) 
0.0469 (7)  
H24 -0.0923 0.0055 0.9291 0.056*  
C25 -0.03207 
(19) 
0.1530 (3) 0.88127 
(15) 
0.0379 (6)  
H25 -0.0655 0.2208 0.9007 0.046*  
C26 0.15567 
(19) 
0.4055 (3) 1.10066 
(14) 
0.0328 (5)  
H26 0.1287 0.4639 1.1307 0.039*  
C27 0.13885 
(17) 
0.4315 (2) 1.01994 
(13) 
0.0281 (5)  




X-ray crystallographic data for (±)-13 
Crystals of compound (±)-13 suitable for X-ray analysis were obtained by vapor diffusion 
from benzene/hexanes. Crystallographic data have been deposited with the Cambridge 
Crystallographic Data Centre (CCDC # 943263). Copies of the data can be obtained free 
of charge through application to the CCDC, 12 Union Road, Cambridge CB21EZ, UK 
(fax: (+44)- 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk). 
 
Table 4.3 Crystal data and structure refinement for β-lactone  13. 
Identification code 13 
Crystal data 
  C27H24O7 F(000) = 968 
Mr = 460.46 Dx = 1.378 Mg m-3 
Monoclinic, P21/c Cu Kα radiation, λ = 1.54178 Å 
Hall symbol:  -P 2ybc Cell parameters from 9922 reflections 
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a = 9.8122 (2) Å θ = 4.5–66.5° 
b = 22.2466 (5) Å µ = 0.82 mm-1 
c = 10.2293 (2) Å T = 100 K 
β = 96.410 (1)° Fragment, colorless 
V = 2218.98 (8)  Å3 0.13 × 0.12 × 0.05 mm 
Z = 4  
 
Data collection 
  Bruker Proteum-R  
diffractometer 
3856 independent reflections 
Radiation source: rotating anode 3657 reflections with I > 2σ(I) 
multilayer Rint = 0.043 
ω & φ scans θmax = 66.5°, θmin = 4.5° 
Absorption correction: multi-scan  
SADABS (Sheldrick, 1997) 
h = -11→11 
Tmin = 0.717, Tmax = 0.753 k = -26→26 
82996 measured reflections l = -12→12 
 
Refinement 
  Refinement on F2 Primary atom site location: structure-
invariant direct methods 
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Least-squares matrix: full Secondary atom site location: difference 
Fourier map 
R[F2 > 2σ(F2)] = 0.035 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.090 H atoms treated by a mixture of 
independent and constrained refinement 
S = 1.05 w = 1/[σ2(Fo2) + (0.0397P)2 + 1.2596P]   
where P = (Fo2 + 2Fc2)/3 
3856 reflections (Δ/σ)max = 0.001 
313 parameters Δ〉max = 0.31 e Å-3 
0 restraints Δ〉min = -0.19 e Å-3 
 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement 
parameters (Å2) 
 x y z Uiso*/Ueq 
O1 -0.27620 (10) 0.76182 (5) 0.57089 (11) 0.0291 (2) 
O2 0.11927 (9) 0.63543 (4) 0.54357 (9) 0.0185 (2) 
O3 0.69823 (11) 0.54323 (5) 0.78244 (11) 0.0337 (3) 
O4 0.34782 (10) 0.74124 (4) 0.51269 (10) 0.0239 (2) 
H4 0.426 (2) 0.7327 (8) 0.4868 (18) 0.036* 
O5 0.42013 (10) 0.69939 (5) 0.27409 (10) 0.0264 (2) 
 259 
O6 0.46134 (11) 0.61648 (5) 0.15070 (11) 0.0327 (3) 
O7 0.11270 (11) 0.82930 (4) 0.37440 (10) 0.0270 (2) 
C1 -0.33431 (15) 0.72076 (7) 0.65666 (16) 0.0306 (3) 
H1A -0.3548 0.6826 0.6107 0.046* 
H1B -0.4190 0.7378 0.6834 0.046* 
H1C -0.2689 0.7137 0.7348 0.046* 
C2 -0.15005 (14) 0.74767 (6) 0.53580 (14) 0.0228 (3) 
C3 -0.08570 (14) 0.69292 (6) 0.56362 (13) 0.0200 (3) 
H3 -0.1272 0.6617 0.6088 0.024* 
C4 0.04296 (13) 0.68651 (6) 0.52130 (12) 0.0180 (3) 
C5 0.23444 (13) 0.63931 (6) 0.46545 (13) 0.0177 (3) 
C6 0.35819 (13) 0.61362 (6) 0.54968 (13) 0.0184 (3) 
C7 0.46666 (14) 0.58547 (6) 0.49665 (14) 0.0224 (3) 
H7 0.4639 0.5815 0.4039 0.027* 
C8 0.57839 (15) 0.56323 (6) 0.57700 (15) 0.0252 (3) 
H8 0.6518 0.5448 0.5388 0.030* 
C9 0.58399 (14) 0.56768 (6) 0.71253 (14) 0.0242 (3) 
C10 0.69930 (18) 0.53957 (9) 0.92184 (17) 0.0417 (4) 
H10A 0.6901 0.5800 0.9579 0.063* 
H10B 0.7859 0.5217 0.9603 0.063* 
H10C 0.6226 0.5145 0.9430 0.063* 
 260 
C11 0.36799 (14) 0.61960 (6) 0.68601 (14) 0.0209 (3) 
H11 0.2973 0.6401 0.7242 0.025* 
C12 0.47819 (14) 0.59642 (6) 0.76791 (14) 0.0239 (3) 
H12 0.4812 0.6002 0.8607 0.029* 
C13 0.10776 (14) 0.73034 (6) 0.45574 (13) 0.0196 (3) 
C14 0.24702 (14) 0.70884 (6) 0.43075 (13) 0.0198 (3) 
C15 0.27253 (14) 0.71124 (6) 0.28775 (14) 0.0219 (3) 
H15 0.2329 0.7471 0.2383 0.026* 
C16 0.38555 (15) 0.64817 (7) 0.20261 (14) 0.0247 (3) 
C17 0.23484 (14) 0.65082 (6) 0.22251 (13) 0.0216 (3) 
H17 0.1697 0.6528 0.1401 0.026* 
C18 0.19398 (14) 0.60678 (6) 0.32908 (13) 0.0190 (3) 
H18 0.2517 0.5698 0.3267 0.023* 
C19 0.04449 (14) 0.58796 (6) 0.30718 (12) 0.0187 (3) 
C20 -0.05966 (14) 0.62704 (6) 0.25680 (13) 0.0205 (3) 
H20 -0.0369 0.6667 0.2322 0.025* 
C21 -0.19596 (15) 0.60896 (6) 0.24212 (14) 0.0234 (3) 
H21 -0.2656 0.6361 0.2073 0.028* 
C22 -0.23058 (15) 0.55124 (6) 0.27841 (14) 0.0241 (3) 
H22 -0.3237 0.5387 0.2686 0.029* 
C23 -0.12823 (15) 0.51215 (6) 0.32902 (14) 0.0242 (3) 
 261 
H23 -0.1515 0.4728 0.3551 0.029* 
C24 0.00822 (14) 0.53005 (6) 0.34198 (13) 0.0216 (3) 
H24 0.0776 0.5025 0.3750 0.026* 
C25 0.04133 (15) 0.78576 (6) 0.43163 (13) 0.0216 (3) 
C26 0.05541 (18) 0.88866 (6) 0.36907 (16) 0.0331 (4) 
H26A -0.0296 0.8890 0.3089 0.050* 
H26B 0.1211 0.9169 0.3375 0.050* 
H26C 0.0356 0.9007 0.4572 0.050* 
C27 -0.08828 (15) 0.79374 (6) 0.46977 (14) 0.0241 (3) 
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